Composition and method for neuropathy

Engineered LGIC receptors and gene therapy vectors address the ineffectiveness of current treatments for chronic pain and neurological disorders by modulating neuronal activity, offering a safer and more effective treatment with enhanced drug response.

JP2024160218APending Publication Date: 2024-11-13CODA BIOTHERAPEUTICS INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
JP2024105712
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2018-04-19
Filing Date
2024-06-28
Publication Date
2024-11-13

AI Technical Summary

Technical Problem

Current treatments for chronic pain and neurological disorders are often ineffective, invasive, and come with significant side effects, while gene therapy methods have not been widely used for these conditions.

Method used

Development of engineered ligand-gated ion channel (LGIC) receptors and gene therapy vectors to modulate neuronal activity, using engineered receptors with specific amino acid mutations to alter ligand binding and signaling, allowing for targeted treatment of neurological disorders.

Benefits of technology

The engineered receptors provide a safer, more effective, and cost-effective treatment option for neurological disorders by enhancing the response to known drugs, increasing their clinical applicability and reducing side effects.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024160218000001_ABST
    Figure 2024160218000001_ABST
Patent Text Reader

Abstract

To provide a gene therapy for treating neuropathy.SOLUTION: There is provided a composition and a method for adjusting activity of cells by using an engineered receptor, a polynucleotide encoding an engineered receptor, and a gene therapy vector including a polynucleotide encoding an engineered receptor. The composition and method find out a particular application in adjusting activity of a neuron in treatment of disease or research of a neural circuit, for example. The engineered receptor is a chimeric ligand-gated ion channel (LGIC) receptor, and includes (a) a ligand binding domain derived from a first wild-type Cys loop LGIC receptor, (b) a Cys loop domain from a second wild-type Cys loop LGIC receptor, and (c) an ion hole domain derived from the second wild-type Cys loop LGIC receptor.SELECTED DRAWING: Figure 1
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] CROSS-REFERENCE TO RELATED APPLICATIONS Pursuant to 35 U.S.C. §119(e), this application claims priority to the filing dates of U.S. Provisional Patent Application No. 62 / 590,911, filed November 27, 2017, and U.S. Provisional Patent Application No. 62 / 659,911, filed April 19, 2018, the entire disclosures of which are incorporated herein by reference.

[0002] Description of electronically submitted text files The sequence listing associated with this application is provided in text format in lieu of a hard copy and is incorporated herein by reference. The name of the text file containing the sequence listing is SWCH_012_04WO_ST25.txt. This text file is 178kb, was created on November 27, 2018, and is submitted electronically via EFS-Web.

[0003] The present disclosure relates to engineered receptors and the use of engineered receptors and small molecule ligands to modulate cellular activity and treat disease. [Background technology]

[0004] Intractable neurological diseases are often associated with abnormally functioning neurons. Attempts to develop therapies to treat these conditions are hampered by the lack of traceable target proteins associated with the disease. For example, unrelieved chronic pain is a significant health problem in the United States and worldwide. A report from the Institute of Medicine estimates that 116 million Americans suffer from pain for weeks to years, resulting in annual costs of over $560 million. Chronic pain patients lack adequate long-term therapies, resulting in significant costs to society and individuals. Pain is often disabling and even in the absence of disability, it profoundly impacts quality of life. Even when the context of treatment delivery is optimal, such as attentive and well-trained physicians, immediate access to opioids, use of adjuvant analgesics, availability of patient-controlled analgesics, and evidence-based use of procedures such as nerve blocks and IT pumps, pain treatment frequently fails.

[0005] The most commonly used therapy for chronic pain is the application of opioid analgesics and nonsteroidal anti-inflammatory drugs, but these drugs can lead to addiction and cause side effects such as drug dependency, tolerance, respiratory depression, sedation, cognitive impairment, hallucinations, and other systemic side effects. Despite the widespread use of pharmaceutical drugs, the success rate of their effectiveness in pain relief is much lower. A large randomized study with various pharmaceutical drugs could only find one in two to three patients who achieved at least 50% pain relief (Finnerup et al., 2005). A follow-up study with the most developed pharmacological treatments found the same results and showed no improvement in the effectiveness of pharmaceutical drugs for pain (Finnerup et al., Pain, 150(3):573-81, 2010).

[0006] More invasive options for treating pain include nerve blocks and electrical stimulation. Nerve blocks involve local anesthetic injections, usually into the spinal cord, to interrupt pain signals to the brain, with effects lasting only a few weeks to months. In most cases, nerve blocks are not a recommended treatment method (Mailis and Taenzer, Pain Res Manag.17(3):150-158, 2012). Electrical stimulation involves delivering an electrical current to interrupt pain signals. It can be more effective than nerve blocks, but there are risks associated with the electrical lead itself, such as displacement, infection, breakage, or battery depletion. One review found that 40% of patients treated with electrical stimulation for neurological disorders experienced one or more of these problems associated with the device (Wolter, 2014).

[0007] The most invasive and least preferred method for managing pain is the complete surgical removal of the nerve or its parts causing pain. This option is only recommended if the patient has exhausted the previously mentioned and other less invasive treatments and found them ineffective. Radiofrequency nerve ablation uses heat to destroy the problem nerve and provides longer pain relief than nerve blocks. However, one study found no difference between control and treatment groups in partial radiofrequency lesions of the DRG for chronic lumbar radicular pain (Geurts et al., 2003). Other operative methods for surgically removing painful nerves have similar drawbacks and can cause serious long-term side effects, including sensory and motor impairments, or cause pain elsewhere.

[0008] Methods for treating neurological disorders must be safe, efficient, and cost-effective. Gene therapy can provide a non-invasive treatment option for a variety of neurological disorders, including pain management. However, to date, gene therapy methods have not been widely utilized to treat neurological disorders. The present disclosure addresses these needs. [Brief description of the drawings]

[0009] The present disclosure is best understood from the following detailed description when read in conjunction with the accompanying drawings. The patent or application file contains at least one drawing executed in color. Copies of this patent or patent application publication with the color drawing(s) will be provided by the Office upon request and payment of the necessary fee. It is emphasized that, according to common practice, the various features of the drawings are not to scale. Conversely, the dimensions of the various features have been arbitrarily expanded or reduced for clarity. Included in the drawings are the following figures:

[0010] [Figure 1] FIG. 1 shows a schematic diagram of an exemplary engineered chimeric LGIC receptor. [Diagram 2] FIG. 1 shows a schematic diagram of the protocol for the development and characterization of the engineered LGIC receptor and its variants of the present disclosure. [Diagram 3] Examples of dose-response curves of several functional CHRNA7 / GLRA1 chimeric receptors to their natural ligand, acetylcholine, are shown. These receptors show inward currents in response to various doses of the ligand acetylcholine when applied for 1 s. Voltage clamp recordings were performed in HEK293T cells transiently expressing the channel and corresponded to summed conduction currents from up to 20 cells patched simultaneously using the automated patch clamp system IonFlux (Fluxion Biosciences) in ensemble mode. [Figure 4A-4F]Ligand-dependent response profiles of wild-type alpha-7 nAChR and various engineered chimeric LGIC receptors to acetylcholine and non-natural ligands TC-6987, AZD-0328, and fascinicline / RG3487 are shown. Receptors were transiently expressed in HEK293T cells, and currents were measured on an automated patch clamp system (Fluxion Biosciences) after 1 second of drug addition. Figure 4A shows results with wild-type alpha-7 nAChR. Figure 4B shows results with SEQ ID NO: 16. Figure 4C shows results with SEQ ID NO: 35. Figure 4D shows results with SEQ ID NO: 33. Figure 4E shows results with SEQ ID NO: 41. Figure 4F shows results with SEQ ID NO: 37. Filled box: protein sequence from human wild-type alpha7-nAChR. Striped box: protein sequence from human alpha1 glycine receptor. Dose is indicated above each recording, scale bar=1. Currents in Figure 4A were measured in single cell mode, with traces representing the conductance from one cell per recording, while currents in Figures 4B-F were measured in ensemble mode, with traces representing the sum of the conductance from up to 20 cells sampled per recording, with the recordings that passed through the QC shown in grey and the composite intermediate trace in black. [Figure 5A-5F]Ligand-dependent response profiles of wild-type α7-nAChR and various engineered chimeric LGIC receptors expressed in Xenopus oocytes to acetylcholine, and non-natural ligands ABT-126, TC-6987, AZD-0328, and fascinicline / RG3487 are shown. Figures 5A-5B show the response profiles of wild-type α7-nAChR to acetylcholine, nicotine, and ABT-126 (Figure 5A), and TC-6987, AZD-0328, and fascinicline / RG3487 (Figure 5B). Figures 5C-5D show the response profiles of SEQ ID NO:33 to acetylcholine, nicotine, and ABT-126 (Figure 5C), and TC-6987, AZD-0328, and fascinicline / RG3487 (Figure 5D). Figures 5E-5F show the response profiles of SEQ ID NO:41 to acetylcholine, nicotine, and ABT-126 (Figure 5E), as well as TC-6987, AZD-0328, and fascinicline / RG3487 (Figure 5F). Currents were measured on a manual patch clamp system after 5-10 s application of increasing doses of compound, as listed at the top of each panel. Left panels, exemplary currents in oocytes expressing the indicated receptors. The EC50 for each ligand estimated from the concentration-response curves shown on the right is marked with an asterisk, and the shift in EC50 relative to wild-type α7-nAChR is marked with a black arrow. Right panels, concentration-response curves from the data shown on the left. Currents were normalized to unity for maximal response. The continuous line through the data points is the best fit obtained with the Hill equation. [Figure 6] Figure 1 shows the response of four different engineered chimeric LGIC receptors (SEQ ID NO:29, SEQ ID NO:33, SEQ ID NO:35, SEQ ID NO:41) to increasing concentrations of acetylcholine as measured by quenching in YFP fluorescence over time. These quench plots demonstrate by the second approach that the different parental chimeras have different EC50s and activation kinetics to acetylcholine. The time points of acetylcholine stimulation are indicated by arrows. [Figure 7A-7B]Quench plots of two engineered chimeric LGIC receptors against either acetylcholine (ACH) or AZD-0328: SEQ ID NO: 33 (FIG. 7A) and SEQ ID NO: 41 (FIG. 7B) are provided. The parent chimeras respond differently to similar concentrations of different ligands. Chimera #41 responds to lower doses of either ACH or AZD-0328 than chimera #33, indicating that the inclusion of the beta 1-2 loop conveys unique binding and activation properties on the chimeric receptor. [Figure 8A-8I] 8A-8F show a mutant that shows a rightward shift (reduced sensitivity) in response to both acetylcholine and AZD-0328, demonstrating an overlap in amino acids important for binding and activation by both compounds. FIG. 8G shows a mutant that shows a leftward shift in response to acetylcholine, but a rightward shift in response to AZD-0328, demonstrating the ability of a single mutation to separate responses to ligands. FIG. 8H shows a mutant that shows a substantial rightward shift to acetylcholine compared to the parent chimera, but no significant change in response to AZD-0328, demonstrating the ability of a single mutation to significantly reduce activation by acetylcholine without affecting activation by the other ligand. Figure 8I shows a mutant that shows a strong leftward shift in response (enhanced sensitivity) to both acetylcholine and AZD-0328. Ligand doses are written at the top of each chart (n=2 for each dose). Numbers in boxes indicate the absolute amount of quenching observed. Dark blue = 80% maximal quenching of the YFP reporter. Light blue = 30-80% quenching. White = 10-30%. Orange = 0-10% quenching. Negative values ​​represent non-responders with negative quenching due to stimulation artifacts. SEQ ID NO: 29 is a non-responsive chimera used as a negative control. [Figure 9A-9B]Provides dose-response curves of selected mutants of engineered chimeric SEQ ID NO:33 to acetylcholine and AZD-0328. Figure 9A shows the response of mutants containing substitutions L131S (open squares), L131T (open triangles pointing up), and S172D (open triangles pointing down), demonstrating a significant rightward shift in the dose-response curve for acetylcholine (i.e., a 2 log (100-fold) increase in EC50) compared to that of non-mutated SEQ ID NO:33 (open circle). In contrast, the W77M substitution (open diamond) shows no shift in dose-response to acetylcholine. Figure 9B shows the response of mutants containing substitutions at L131S (open squares), L131T (open triangles pointing up), and S172D (open triangles pointing down), which result in a slight rightward shift in dose response (i.e., a 1 log increase in EC50) to AZD-0328 compared to the unmutated SEQ ID NO:33 chimera, while the W77M substitution results in a dramatic rightward shift in dose response (a 2 log increase in EC50). [Figure 10A-10D]Electrophysiological data are provided showing how a single amino acid substitution in the engineered chimera (SEQ ID NO: 33) confers a preferential response to non-natural ligands over acetylcholine. Figure 10A shows that the L131S substitution causes a significant rightward shift (80-fold) in the EC50 for acetylcholine relative to the parent chimera SEQ ID NO: 33 (see Figure 4E), while the EC50 for AZD-0328 is only a (2-fold) rightward shift. Figure 10B shows that the S172D substitution causes a significant rightward shift (58-fold) in the EC50 for acetylcholine relative to the parent chimera, while the EC50 for AZD-0328 for S172D is only a (2-fold) rightward shift. Figure 10C shows that the W77M substitution causes a moderate rightward shift in the EC50 of acetylcholine (2-fold) relative to the parent chimera, while the EC50 for W77M to AZD-0328 is a significant rightward shift (>2.5 log). Figure 10D shows that the L131T substitution causes a significant rightward shift in the EC50 of acetylcholine (about 2.5 log) relative to the parent chimera, while the EC50 for this mutant to AZD-0328 is a moderate rightward shift (about 1 log). The asterisk marks the estimated EC50 for each ligand for L131S. The arrow indicates the degree of EC50 shift for SEQ ID NO: 33. The triangle marks the estimated EC50 for each ligand for wild-type α7-nAChR.

[0011] Quick summary Compositions and methods are provided for modulating cellular activity using engineered receptors, polynucleotides encoding the engineered receptors, and gene therapy vectors comprising polynucleotides encoding the engineered receptors. These compositions and methods find particular use in modulating neuronal activity, for example, in treating disease or studying neural circuits.

[0012] In some aspects of the disclosure, the disclosure is directed to an engineered receptor, the engineered receptor being a chimeric ligand-gated ion channel (LGIC) receptor, comprising a ligand binding domain derived from a first wild-type Cys-loop LGIC receptor, a Cys-loop domain from a second wild-type Cys-loop LGIC receptor, and an ion pore domain derived from the second wild-type Cys-loop LGIC receptor. In some embodiments, the first and second wild-type Cys-loop LGIC receptors are the same. In other embodiments, the first and second wild-type Cys-loop LGIC receptors are different. In some embodiments, the first wild-type Cys-loop LGIC receptor is selected from an acetylcholine receptor (AchR), e.g., α7-nAChR, a glycine receptor (GlyR), e.g., GlyR α1, a λ-aminobutyric acid (GABA) receptor, and a serotonin receptor, e.g., 5HT3. In some embodiments, the second wild-type Cys-loop LGIC receptor is selected from an acetylcholine receptor (AchR), e.g., α7-nAChR, a glycine receptor (GlyR), e.g., GlyR α1, a λ-aminobutyric acid (GABA) receptor, and a serotonin receptor, e.g., 5HT3. In certain embodiments, the first wild-type Cys loop LGIC receptor is α7-nAChR. In certain embodiments, the second wild-type Cys loop LGIC receptor is GlyR α1. In some such embodiments, the Cys loop domain comprises amino acids 166-180 of GlyR α1. In other such embodiments, the Cys loop domain comprises amino acids 166-172 of GlyR α1. In some such embodiments, the engineered receptor has 85% or greater sequence identity to SEQ ID NO: 33. In some embodiments, the receptor further comprises a β1-2 loop domain from the second wild-type Cys loop LGIC receptor. In some such embodiments, the β1-2 loop domain comprises amino acids 81-84 of GlyR α1. In some such embodiments, the engineered receptor has 85% or greater sequence identity to SEQ ID NO:41.

[0013] In some embodiments, the ligand-binding domain comprises one or more amino acid substitutions of residues corresponding to residues of α7-nAChR selected from the group consisting of W77, Y94, R101, W108, Y115, T128, N129, V130, L131, Q139, L141, Y151, S170, W171, S172, S188, Y190, Y210, C212, C213, and Y217. In some embodiments, the one or more amino acid substitutions are loss-of-function mutations that reduce the potency of acetylcholine on the receptor while substantially maintaining the potency of the non-natural ligand on the receptor. In certain such embodiments, the substitutions are selected from the substitutions corresponding to L131S, L131T, L131D, or S172D of α7-nAChR. In certain such embodiments, the non-natural ligand is selected from AZD-0328, TC6987, ABT-126, and facinicline / RG3487. In other embodiments, one or more amino acid substitutions are gain-of-function mutations that increase the potency of acetylcholine on the receptor. In certain such embodiments, the substitution is selected from the substitutions corresponding to L131N, L141W, S170G, S170A, S170L, S170I, S170V, S170P, S170F, S170M, S170T, S170C, S172T, S172C, S188I, S188V, S188F, S188M, S188Q, S188T, S188P, or S188W of α7-nAChR.

[0014] In some aspects of the disclosure, the disclosure is directed to a polynucleotide encoding an engineered receptor described herein. In some aspects of the disclosure, the disclosure is directed to a vector comprising a polynucleotide encoding an engineered receptor described herein. In some aspects of the disclosure, the disclosure is directed to a pharmaceutical composition comprising a polynucleotide encoding an engineered receptor described herein, or a vector comprising a polynucleotide encoding an engineered receptor described herein, and a pharma- ceutically acceptable vehicle.

[0015] In some aspects of the disclosure, the disclosure is directed to an engineered receptor, the engineered receptor being a ligand-gated ion channel (LGIC) receptor, comprising (a) a ligand-binding domain derived from a first wild-type LGIC receptor, the ligand-binding domain comprising at least one amino acid mutation that alters the function of the ligand-binding domain relative to the wild-type receptor, and (b) an ion pore domain derived from a second wild-type LGIC receptor. In some embodiments, the at least one amino acid mutation is a loss-of-function mutation. In some embodiments, the at least one amino acid mutation is a gain-of-function mutation. In some embodiments, the at least one amino acid mutation is both a loss-of-function and a gain-of-function mutation, i.e., the mutations that provide the loss-of-function and the gain-of-function are the same mutation. In other embodiments, the at least one loss-of-function amino acid mutation and at least one The gain-of-function amino acid mutations are mutations in different amino acid residues in the ligand-binding domain. In some embodiments, the first and second wild-type LGIC receptors are the same. In some embodiments, the first and second wild-type LGIC receptors are different. In some embodiments, the first and / or second LGIC receptor is a Cys-loop receptor LGIC. In some such embodiments, the first and / or second wild-type LGIC receptor is selected from the group consisting of glycine receptor (GlyR), lambda-aminobutyric acid (GABA) receptor, serotonin receptor, and acetylcholine receptor (AchR). In some embodiments, the first and / or second LGIC receptor is selected from ATP-gated cation channel receptor, inward rectifier potassium channel receptor (Kir), potassium voltage-gated channel receptor, and ATP-binding cassette transporter receptor.

[0016] In some embodiments, the first and / or second LGIC receptor is GABA AIn some embodiments, the first and / or second LGIC receptor is a 5-hydroxytryptamine (5-HT3) receptor. In some embodiments, the first and / or second LGIC receptor is a nicotinic AchR (nAchR). In some embodiments, the first and / or second LGIC receptor is a P2X receptor. In some embodiments, the first and / or second LGIC receptor is a KCNQ or K v 7 receptor. In some embodiments, the first and / or second LGIC receptor is a cystic fibrosis transmembrane conductance regulator (CFTR) receptor.

[0017] In some embodiments, the engineered receptor of the present disclosure is a homomeric receptor. In some embodiments, the engineered receptor is a heteromeric receptor.

[0018] In some embodiments, an engineered receptor of the present disclosure comprises a ligand binding domain that is less than 99%, 98%, 97%, 95%, or 90% homologous to the native or wild-type ligand binding domain. In some embodiments, an engineered receptor of the present disclosure comprises a ligand binding domain that shares 85% or more sequence identity to the wild-type ligand binding domain. In some embodiments, an engineered receptor of the present disclosure comprises a ligand binding domain that shares 90% or more sequence identity to the wild-type ligand binding domain. In some embodiments, an engineered receptor of the present disclosure comprises a ligand binding domain that shares 95% or more sequence identity to the wild-type ligand binding domain. In some embodiments, an engineered receptor of the present disclosure comprises one or more amino acid mutations introduced into the ligand binding domain. In some embodiments, the one or more amino acid mutations are introduced into the ligand binding domain by error-prone polymerase chain reaction (PCR). In some embodiments, the one or more amino acid mutations are introduced into the ligand binding domain by site-directed mutagenesis. In some embodiments, the one or more amino acid mutations are introduced into the ligand binding domain by de novo gene synthesis.

[0019] In some embodiments, the engineered receptors of the present disclosure comprise at least one loss-of-function amino acid mutation that inhibits binding of an endogenous ligand to the engineered receptor or reduces the binding affinity of an endogenous ligand to the engineered receptor. In some embodiments, the engineered receptors of the present disclosure comprise at least one gain-of-function amino acid mutation that increases the binding affinity of a binding agent to the engineered receptor or modulates the effect of a binding agent on the engineered receptor.

[0020] In some embodiments, at least one gain-of-function amino acid mutation increases the affinity of the engineered receptor for an agonist ligand compared to the affinity of the wild-type receptor for an agonist ligand. In some embodiments, the agonist ligand is selected from the group consisting of ABT-089, ABT-126, ABT-418, ABT-894, alphadolone, AQW-051, AZD0328, AZD7325, busmisanil, bilobalide, cannabidiol, cilansetron, CP-409092, DDP733, EVP-6124, GTS-21, iptakalim, MK-0777 / L83098, MDL-27 531, MEM-3454 / RG3487, MEM-63908, moxidectin, NRX-1050, NRX-1060, P-9939, PH-399733, QH-ii-066, rapastinel, renzapride, retigabine, S-18841, SL-75102, SL-651498, SR-57227, SSR-180711, and TC-5619 / AT-101. In certain embodiments, the ligand is selected from the group consisting of AZD0328, ABT-126, AQW-051, cannabidiol, cilansetron, PH-399733, facinicline / RG3487 / MEM-3454, and TC-5619 / AT-101.

[0021] In some embodiments, at least one gain-of-function mutation results in an antagonist ligand that functions as an agonist ligand. In some embodiments, the antagonist ligand is selected from the group consisting of 468816, ACEA-2085, DA-9701, eslicarbazepine acetate, gavestinel, GV-196771, GW-468816, HMR-2371, L-695902, L-701324, MDL-100748, MDL-102288, MDL-105519, PD-165650, tedatioxetine, UK-315716, and ZD-9379.

[0022] In some embodiments, at least one gain-of-function amino acid mutation results in the modulator ligand functioning as an agonist ligand. In some embodiments, the modulator ligand is selected from the group consisting of AQW-051, AZD7325, CTP-656, gavestenel, and ivermectin.

[0023] In some embodiments, the engineered receptor of the present disclosure comprises a ligand binding domain derived from a GlyR. In some embodiments, the engineered receptor of the present disclosure comprises a ligand binding domain derived from a GABA receptor. In some embodiments, the engineered receptor of the present disclosure comprises a ligand binding domain derived from a nAChR. In some embodiments, the engineered receptor of the present disclosure comprises a ligand binding domain derived from a 5HT3. In some embodiments, the engineered receptor of the present disclosure comprises a ligand binding domain derived from a P2X receptor. In some embodiments, the engineered receptor of the present disclosure comprises a ligand binding domain derived from a Kir receptor. In some embodiments, the engineered receptor of the present disclosure comprises a ligand binding domain derived from a KCNQ receptor. In some embodiments, the engineered receptor of the present disclosure comprises a ligand binding domain derived from a CFTR receptor.

[0024] In some embodiments, the engineered receptor of the present disclosure comprises an ion pore domain from a GlyR. In some embodiments, the engineered receptor of the present disclosure comprises an ion pore domain from a GABA receptor. In some embodiments, the engineered receptor of the present disclosure comprises an ion pore domain from a nAChR. In some embodiments, the engineered receptor of the present disclosure comprises an ion pore domain from a 5HT3 receptor. In some embodiments, the engineered receptor of the present disclosure comprises an ion pore domain from a P2X receptor. In some embodiments, the engineered receptor of the present disclosure comprises an ion pore domain from a Kir receptor. In some embodiments, the engineered receptor of the present disclosure comprises an ion pore domain from a KCNQ receptor. In some embodiments, the engineered receptor of the present disclosure comprises an ion pore domain from a CFTR receptor. In some embodiments, the ion pore domain comprises a non-desensitizing mutation.

[0025] In some embodiments, the disclosure includes a polynucleotide encoding an engineered receptor as described herein. In some embodiments, the disclosure includes a viral vector comprising a polynucleotide encoding an engineered receptor as described herein. In some embodiments, the viral vector is an adenoviral vector, a retroviral vector, an adeno-associated virus (AAV) vector, or a herpes simplex type 1 virus vector (HSV-1). In some embodiments, the AAV vector is selected from the group consisting of AAV1, AAV2, AAV3b, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, and AAVrhlO. In some embodiments, the AAV vector is selected from AAV5, AAV6, and AAV9. In some embodiments, the vector is derived from a vector selected from the group consisting of AAV1, AAV2, AAV3b, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, and AAVrhlO. In some embodiments, the AAV vector is derived from AAV-5, AAV-6, or AAV-9.

[0026] In some aspects of the present disclosure, a method of treating a neuropathy in a subject in need thereof is provided, comprising administering to said subject a polynucleotide encoding an engineered ligand-gated ion channel (LGIC) receptor, and administering to said subject a binding agent that acts as an agonist of the engineered LGIC receptor. In some embodiments, the polynucleotide is delivered to the subject by a non-viral method. In some embodiments, the non-viral method is lipofection, nanoparticle delivery, biolistics, electroporation, sonication, or microinjection. In some embodiments, the polynucleotide is delivered to the subject in a viral vector. In some embodiments, the viral vector is an adenoviral vector, a retroviral vector, an adeno-associated viral (AAV) vector, or a herpes simplex type 1 viral vector (HSV-1). In some embodiments, the AAV vector is selected from the group consisting of AAV1, AAV2, AAV3b, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAVrhlO. In some embodiments, the AAV vector is selected from AAV5, AAV6, and AAV9. In some embodiments, the vector is derived from a vector selected from the group consisting of AAV1, AAV2, AAV3 b, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, and AAVrhlO. In some embodiments, the AAV vector is derived from AAV-5, AAV-6, or AAV-9.

[0027] In some embodiments, the method comprises expressing the engineered receptor in an excitable cell. In some embodiments, the excitable cell is a neuron or a muscle cell. In some embodiments, the neuron is a dorsal root ganglion, a motor neuron, an excitatory neuron, an inhibitory neuron, or a sensory neuron.

[0028] In some embodiments, the subject suffers from pain. In some embodiments, the subject suffers from a seizure disorder. In some embodiments, the subject suffers from a movement disorder. In some embodiments, the subject suffers from an eating disorder. In some embodiments, the subject suffers from a spinal cord injury. In some embodiments, the subject suffers from neurogenic bladder. In some embodiments, the subject suffers from a spastic disorder. In some embodiments, the subject suffers from pruritus. In some embodiments, the subject suffers from Alzheimer's disease, Parkinson's disease, post-traumatic stress disorder (PTSD), gastroesophageal reflux disease (GERD), addiction, anxiety, depression, memory loss, dementia, sleep apnea, stroke, narcolepsy, urinary incontinence, essential tremor, movement disorder, or atrial fibrillation. In some embodiments, the method further comprises measuring a symptom of the disease after administration of the binding agent, wherein the symptom of the disease is alleviated. In some embodiments, And the subject is human.

[0029] In some embodiments, the binding agent is 468816, ABT-089, ABT-126, ABT-418, ABT-894, ACEA-2085, alphadolone, AQW-051, AZD0328, AZD7325, busmisanil, bilobalide, cannabidiol, cilansetron, CP-409092, CTP-656, DA-9701, DDP733, eslicarbazepine acetate, EVP-6124, gavestenel, gavestenel, GTS-21, GV-196771, GW-468816, HMR-2371, iptakalim, L-695902, L-701324, MK- 0777 / L83098, MDL-100748, MDL-102288, MDL-105519, MDL-27531, MEM-3454 / RG3487, MEM-63908, moxidectin, NRX-1050, NRX-1060, P-9939, PD-165650, PH-399733, QH-ii-066, rapastinel, retigabine, S-18841, SL-75102, SL-651, 498, SR-57227, SSR-180, 711, TC-5619 / AT-101, tedatioxetine, UK-315716, and ZD-9379. In certain embodiments, the ligand is selected from the group consisting of AZD0328, ABT-126, AQW-051, cannabidiol, cilansetron, PH-399733, facinicline / RG3487 / MEM-3454, and TC-5619 / AT-101. In some embodiments, the polynucleotide and / or binding agent is administered subcutaneously, orally, intrathecally, topically, intravenously, intraganglionally, intracranially, intraspinal, intracisternally, or intraneurally. In some embodiments of this method, the binding agent is administered at least one week after the polynucleotide.

[0030] In some embodiments, the disclosure includes a composition comprising an engineered receptor described herein, a polynucleotide described herein, or a viral vector described herein. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0031] A. Overview Compositions and methods are provided for regulating the activity of cells using engineered ligand-gated ion channel (LGIC) receptors, polynucleotides encoding engineered LGIC receptors, and gene therapy vectors that include polynucleotides encoding engineered receptors.These compositions and methods find particular use in regulating the activity of neurons, for example, in treating disease or studying neural circuits.In addition, reagents, devices, and kits thereof are provided that find use in implementing the methods of the present invention.

[0032] In particular, the present disclosure provides engineered receptors that bind and signal in response to known drugs, ligands, and / or binders. In some embodiments, the engineered receptors described herein exhibit increased affinity for known agonist binders. In some embodiments, the engineered receptors described herein exhibit affinity for antagonist or modulator binders and respond to antagonists and / or modulators as if they were agonist agents. The present disclosure further provides a method of treating a neurological disease in a subject in need thereof. The present disclosure increases the number of clinical indications in which known drugs can be used by utilizing engineered receptors that respond to known drugs in a manner different from wild-type endogenous receptors.

[0033] Before the present methods and compositions are described, it is to be understood that this disclosure is not limited to the particular methods or compositions described. Such methods or compositions may, of course, vary. Moreover, the terminology used herein is for the purpose of describing particular embodiments only and is not intended to be limiting, since the scope of the present disclosure will be limited only by the appended claims. It should be understood that this is not intended to

[0034] Where a range of values ​​is provided, it is understood that each intervening value, to the tenth of the unit of the lower limit, between the upper and lower limits of that range is also specifically disclosed, unless the context clearly dictates otherwise. Each smaller range between any stated or intervening value in a stated range and any other stated or intervening value in that stated range is encompassed within the disclosure. The upper and lower limits of these smaller ranges may independently be included or excluded in the range, and each range in which either, either or both limits are included in the smaller range is also encompassed within the disclosure, subject to any specifically excluded limits in the stated range. Where a stated range includes one or both of the limits, ranges excluding one or both of those included limits are also included in the disclosure.

[0035] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by those skilled in the art to which this disclosure belongs.Any method and material similar or equivalent to the method and material described herein can be used in the practice or testing of this disclosure, but some potential and preferred methods and materials will be described here.All publications mentioned herein are incorporated by reference to disclose and describe the method and / or material in relation to the cited publication.It should be understood that this disclosure supersedes any disclosure of the incorporated publication in case of conflict.

[0036] As will be apparent to those skilled in the art upon reading this disclosure, each of the individual embodiments described and illustrated herein has distinct components and features which may be readily separated from or combined with the features of any of the other several embodiments without departing from the scope or spirit of the disclosure. Any recited method can be carried out in the order of events recited or in any other order which is logically possible.

[0037] Publications discussed herein are provided solely for their disclosure prior to the filing date of the present application. Nothing herein should be construed as an admission that the present disclosure is not entitled to antedate such publications by virtue of prior disclosure. Further, the dates of publication provided may be different from the actual publication dates, which may need to be independently confirmed.

[0038] B. Definition As used in this specification and the appended claims, the singular forms "a," "an," and "the" include plural references unless the context clearly dictates otherwise. Thus, for example, reference to "a cell" includes a plural of such cells, and reference to "the peptide" includes reference to one or more peptides and equivalents thereof, such as polypeptides known to those of skill in the art.

[0039] As used herein, the term "and / or" refers to either "and" or "or" in this disclosure, unless otherwise indicated.

[0040] Throughout this specification, unless the context requires otherwise, the term "comprise" or variations such as "comprises" or "comprising" refers to the inclusion of a stated element or integer or group of elements or integers, but does not imply the exclusion of any other element or integer or group of elements or integers. Moreover, recitations of numerical ranges throughout this specification specifically include all integers and decimal points between the ranges.

[0041] Throughout this specification, unless the context requires otherwise, the phrase "consisting essentially of" refers to limitations of the scope of the described composition, method, or kit to particular materials or steps that do not materially affect the basic and novel feature(s) of the subject disclosure. For example, a ligand binding domain "consisting essentially of" a disclosed sequence has, at the boundary of the sequence, the amino acid sequence of the disclosed sequence plus or minus about 5 amino acid residues, e.g., about 5, 4, 3, 2, or about 1 less than the recited binding amino acid residues, or about 1, 2, 3, 4, or 5 more than the recited binding amino acid residues.

[0042] Throughout this specification, unless the context requires otherwise, the phrase "consisting of" refers to the exclusion of a composition, method, or kit from any element, step, or ingredient not specified in the claim. For example, a ligand binding domain "consisting of" a disclosed sequence consists only of the disclosed amino acid sequence.

[0043] As used in this application, the terms "about" and "approximately" are used as equivalents. Any numerical values ​​used in this application, with or without about / approximately, are meant to cover any normal variations understood by those skilled in the relevant art. In certain embodiments, the term "about" or "approximately" refers to a range of values ​​that is 25%, 20%, 19%, 18%, 17%, 16%, 15%, 14%, 13%, 12%, 11%, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1%, or less in either direction of the stated reference value (more or less), unless otherwise stated or otherwise clear from the context (except when such number exceeds 100% of the possible value).

[0044] As used herein, the term "isolated" means that the material is substantially or essentially free from components which normally accompany it, as found in its natural state. In some embodiments, the terms "obtained" or "derived" are used synonymously with isolated.

[0045] The terms "subject", "patient" and "individual" are used interchangeably to refer to any animal exhibiting pain that can be treated with the vectors, compositions and methods contemplated herein. In some embodiments, a subject may refer to a vertebrate, preferably a mammal. Mammals include, but are not limited to, mice, monkeys, humans, farm animals, sport animals and pets. Suitable subjects (e.g., patients) include laboratory animals (such as mice, rats, rabbits or guinea pigs), farm animals and livestock or pets (such as cats or dogs). Non-human primates, preferably human patients, are included. In some embodiments, a "sample" may be taken from a subject.

[0046] The term "sample" refers to a volume and / or mass of biological material subjected to analysis. In some embodiments, a sample includes a tissue sample, a cell sample, a fluid sample, etc. In some embodiments, a sample is taken from or provided by a subject (e.g., a human subject). In some embodiments, a sample includes a portion of tissue taken from any internal organ, a cancerous, precancerous, or noncancerous tumor, brain, skin, hair (including hair roots), eye, muscle, bone marrow, cartilage, white adipose tissue, and / or brown adipose tissue. In some embodiments, a fluid sample includes a buccal swab, blood, umbilical cord blood, saliva, semen, urine, peritoneal fluid, pleural fluid, spinal fluid, lung lavage, tears, sweat, etc. One of skill in the art will appreciate that in some embodiments, a "sample" is a "primary sample" in that it is obtained directly from a source (e.g., a subject). In some embodiments, a "sample" is the result of processing of a primary sample, for example, to remove certain potential contaminating components, to isolate certain components, and / or to purify certain components of interest. In some embodiments, a sample includes cells or The cell sample may be a cell population (e.g., neurons). The cell sample may be directly derived from a subject (e.g., a primary sample) or may be a cell line. The cell line may include non-mammalian cells (e.g., insect cells, yeast cells, and / or bacterial cells) or mammalian cells (e.g., immortalized cell lines).

[0047] As used herein, "treating" or "treatment" refers to the delivery of a composition (e.g., engineered receptor and / or binding agent) to a subject and / or cell population to affect a physiological outcome. In certain embodiments, treatment results in an improvement (e.g., reduction, amelioration, or correction) of one or more disease symptoms. The improvement can be an observable or measurable improvement, or an improvement in the subject's general sense of health. Treatment of a disease can refer to a reduction in the severity of disease symptoms. In some embodiments, treatment can refer to a reduction in the severity of disease symptoms to a level comparable to that before the onset of the disease. In some embodiments, treatment can refer to a short-term (e.g., temporary or acute) and / or long-term (e.g., persistent or chronic) reduction in disease symptoms. In some embodiments, treatment can refer to the remission of disease symptoms. In some embodiments, treatment can refer to prophylactic treatment of a subject at risk of developing a particular disease to prevent the onset of the disease. Prevention of disease onset can refer to complete prevention of disease symptoms, delaying disease onset, reducing the severity of symptoms in a subsequently developed disease, or reducing the likelihood of disease onset.

[0048] As used herein, "management" or "control" refers to the use of the compositions or methods contemplated herein to improve the quality of life of an individual suffering from a particular disease. In certain embodiments, the compositions and methods described herein provide analgesia to a subject suffering from pain.

[0049] A "therapeutically effective amount" is the amount of a composition required to achieve a desired therapeutic result. The therapeutically effective amount may vary depending on factors such as, but not limited to, the disease state and the age, sex, and weight of the subject. In general, a therapeutically effective amount is also an amount in which any toxic or adverse effects of the composition are outweighed by the therapeutically beneficial effects. A "therapeutically effective amount" includes an amount of a composition effective to treat a subject. A "prophylactically effective amount" refers to the amount of a composition required to achieve a desired prophylactic result. In some embodiments, a prophylactically effective amount may be less than a therapeutically effective amount, since a prophylactic dose is used in subjects before or at an early stage of disease.

[0050] "Increase" refers to an increase in value (e.g., increased binding affinity, increased physiological response, increased therapeutic effect, etc.) of at least 5% compared to a reference or control level. For example, an increase can include an increase of 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 35, 40, 45, 50, 60, 70, 80, 90, 100, 150, 200, 250, 500, 1000% or more. Increase also means an increase of 1.1, 1.2, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 30 or more fold (e.g., 500, 1000 fold) over a reference or control level.

[0051] "Reduction" refers to a decrease in value (e.g., decreased binding affinity, decreased physiological response, decreased therapeutic effect, etc.) of at least 5% compared to a reference or control level. For example, reduction can include a decrease of 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 35, 40, 45, 50, 60, 70, 80, 90, 100, 150, 200, 250, 500, 1000% or more. Reduction also refers to a decrease of 1.1, 1.2, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 30 or more times (e.g., 500, 1000 times) lower than a reference or control level.

[0052] "Maintain" or "Keep" or "Maintain" or "No change" or "No substantial change" "No substantial reduction" or "no substantial reduction" generally refers to a physiological and / or therapeutic effect that is comparable to that caused by either a vehicle or a control molecule / composition. A comparable response is one that is not significantly different or has no measurable difference from the reference response.

[0053] The terms "reference" or "control" level are used interchangeably herein and refer to the value of a particular physiological and / or therapeutic effect in a subject or sample not treated with a composition described herein, or in a subject or sample treated with a vehicle control. In some embodiments, a reference level refers to the value of a particular physiological and / or therapeutic effect measured in a subject or sample prior to administration of a composition described herein (e.g., a baseline level).

[0054] "Receptor-ligand binding" and "ligand binding" are used interchangeably herein and refer to the physical interaction between a receptor (e.g., LGIC) and a ligand. The term "ligand" as used herein can refer to endogenous or naturally occurring ligands. For example, in some embodiments, a ligand refers to neurotransmitters (e.g., λ-aminobutyric acid (GABA), acetylcholine, serotonin, and others) as well as signal transduction intermediates (e.g., phosphatidylinositol 4,5-bisphosphate (PIP2)), amino acids (e.g., glycine), or nucleotides (e.g., ATP). In some embodiments, a ligand may refer to non-natural, i.e., synthetic or non-naturally occurring ligands (e.g., binding agents). For example, in some embodiments, a ligand refers to a small molecule. Ligand binding can be measured by various methods known in the art (e.g., detection of association with a radioactively labeled ligand).

[0055] "Binding affinity" generally refers to the strength of the sum of non-covalent interactions between a single binding site of a receptor and a ligand. Unless otherwise indicated, as used herein, "binding affinity" refers to the intrinsic binding affinity that reflects a 1:1 interaction between members of a binding pair (e.g., receptor and ligand). The affinity of a molecule X for a partner Y is generally determined by the dissociation constant (K d Affinity can be measured by common methods known in the art, including those described herein.

[0056] The terms "specific binding affinity" or "specific binding" are used interchangeably throughout the specification and claims and refer to the binding that occurs between paired molecular species, such as a receptor and a ligand. When the interaction of two species results in a non-covalent complex, the resulting binding is typically the result of electrostatic, hydrogen bonding, or lipophilic interactions. In various embodiments, the specific binding between one or more species is direct. In one embodiment, the affinity of the specific binding is about 2 times greater than background binding (non-specific binding), about 5 times greater than background binding, about 10 times greater than background binding, about 20 times greater than background binding, about 50 times greater than background binding, about 100 times greater than background binding, or about 1000 times greater than background binding.

[0057] "Signaling" refers to the production of a biochemical or physiological response as a result of ligand binding to a receptor (e.g., as a result of binding of a binding agent to an engineered receptor described herein).

[0058] The terms "native" and "wild-type" are used interchangeably throughout the specification and claims and refer to compositions found in nature.

[0059] The terms "non-naturally occurring," "variant," and "mutant" are used interchangeably throughout this specification and the claims to refer to native or wild-type compositions, e.g., variant polypeptides having less than 100% sequence identity to the native or wild-type sequence.

[0060] The terms "parent" or "initiator" are used interchangeably throughout this specification and the claims to refer to an initial composition that is modified or derivatized to create an engineered composition with new properties.

[0061] The term "engineered" is used throughout this specification and the claims to refer to a non-naturally occurring composition that has properties that differ from the parent composition from which it is derivatized.

[0062] Generally, "sequence identity" or "sequence homology" refers to the nucleotide-to-nucleotide or amino acid-to-amino acid correspondence of two polynucleotide or polypeptide sequences, respectively. Typically, techniques for determining sequence identity include determining the nucleotide sequence of a polynucleotide and / or determining the amino acid sequence encoded thereby, and comparing these sequences to a second nucleotide or amino acid sequence. Two or more sequences (polynucleotide or amino acid) can be compared by determining their "percent identity". The percent identity of two sequences, whether nucleic acid or amino acid sequences, is the number of exact matches between the two aligned sequences divided by the length of the shorter sequence, multiplied by 100. Percent identity may also be determined by comparing sequence information using, for example, an advanced BLAST computer program, including version 2.2.9 available from the National Institutes of Health. The BLAST program is based on the alignment method of Karlin and Altschul, Proc. Natl. Acad. Sci. USA 87:2264-2268 (1990), and is based on the alignment method of Altschul et al., J. Mol. Biol. 215:403-410 (1990); Karlin and Altschul, Proc. Natl. Acad. Sci. USA 90:5873-5877 (1993); and Altschul et al., Nucleic Acids. Acids Res. 25:3389-3402 (1997). Briefly, the BLAST program defines identity as the number of identical aligned symbols (generally nucleotides or amino acids) divided by the total number of symbols in the shorter of the two sequences. The program can be used to determine percent identity over the entire length of the compared proteins. For example, default parameters are provided to optimize searches with a short query sequence using the BLAST program. The program also allows the use of SEG filters to mask off segments of the query sequence as determined by the SEG program of Wootton and Federhen, Computers and Chemistry 17:149-163 (1993). The desired degree of sequence identity ranges from about 80% to 100%, with intervening integer values. Typically, the percent identity between the disclosed and claimed sequences is at least 80%, at least 85%, at least 90%, at least 95%, or at least 98%.

[0063] As used herein, "substantially identical" refers to having sequence identity that is 85% or greater, e.g., 90% or greater, e.g., 95%, 96%, 97%, 98%, 99%, 99.5%, 99.9%, or 100%, and the activity of the composition is not altered by modifications in the sequence that result in differences in sequence identity.

[0064] C. Engineered Receptors The present disclosure relates to engineered receptors, engineered receptor variants, and methods of use thereof. The term "receptor" as used herein refers to any protein located on the surface of a cell and capable of mediating signaling to and / or from a cell. The term "engineered receptor" is used herein to refer to a receptor that has been experimentally modified to be physically and / or functionally different from the corresponding parent receptor. In some embodiments, the parent receptor is a wild-type receptor. The term "wild-type receptor" is used herein to refer to a receptor that has a polypeptide sequence that is identical to the polypeptide sequence of a protein found in nature. Wild-type receptors include receptors that occur naturally in humans, as well as orthologs that occur naturally in other eukaryotes, e.g., protists, fungi, plants or animals, e.g., yeast, insects, nematodes, sponges, mammals, non-mammalian vertebrates. In other embodiments, the parent receptor is a non-natural receptor, i.e., it is a receptor that does not occur in nature, e.g., a receptor engineered from a wild-type receptor. For example, the parent receptor can be an engineered receptor that includes one or more subunits from one wild-type receptor along with one or more subunits from a second wild-type receptor. Thus, the resulting protein is composed of subunits from two or more wild-type receptors. Engineered receptors of the present disclosure include, for example, parent receptors, parent receptor mutants, and switch receptors.

[0065] In some embodiments, the engineered receptor of the present disclosure comprises at least one amino acid mutation relative to the corresponding parent receptor, e.g., one or more mutations in one or more domains of the wild-type receptor. By "amino acid mutation" is meant any difference in the amino acid sequence compared to the corresponding parent sequence, e.g., amino acid substitution, deletion, and / or insertion. In some embodiments, the engineered receptor shares 99%, 98%, 95%, 90%, 85%, 80%, 70%, 60%, 50%, or less sequence identity with the corresponding parent receptor. In some embodiments, the parent receptor mutant has 85% or more sequence identity with the corresponding parent receptor, e.g., 90% or more or 95% or more identity with the corresponding parent receptor, e.g., 96%, 97%, 98% or 99% identity. In some embodiments, the engineered receptor (e.g., parent receptor mutant) is generated by error-prone PCR.

[0066] In some embodiments, the amino acid mutation is a loss-of-function amino acid mutation relative to the corresponding parent receptor. A "loss-of-function" amino acid mutation refers to one or more mutations that reduce, substantially reduce, or abolish the function of the engineered receptor relative to the parent receptor, for example, by reducing the binding of an endogenous ligand to the engineered receptor compared to the binding of the endogenous ligand to the parent receptor, or by reducing the activity of a downstream signaling pathway(s) of the engineered receptor that is typically activated in response to binding of a binding agent to the corresponding parent receptor.

[0067] In some embodiments, the amino acid mutation is a gain-of-function amino acid mutation relative to the corresponding parent receptor. A "gain-of-function" amino acid mutation refers to one or more mutations that reduce, substantially reduce, or abolish the function of the engineered receptor relative to the parent receptor, for example, by reducing binding of an endogenous ligand to the engineered receptor relative to the binding of the endogenous ligand to the parent receptor, or by reducing the activity of a downstream signaling pathway(s) of the engineered receptor that is typically activated in response to binding of a binding agent to the corresponding parent receptor. In some embodiments, the gain-of-function mutation results in an increase in the affinity of the engineered receptor for a binding agent. In certain embodiments, the gain-of-function mutation results in an increase in the affinity of the engineered receptor for an agonist binding agent. In some embodiments, the gain-of-function mutation results in an antagonist binding agent that acts as an agonist binding agent upon binding to the engineered receptor (e.g., resulting in activation of an agonist signaling pathway instead of an antagonist signaling pathway). In some embodiments, the gain-of-function mutation results in a modulator binding agent that acts as an agonist binding agent upon binding to the engineered receptor. In some embodiments, the engineered receptor of the subject of the present disclosure is a mutated receptor that ... The entities contain one or more loss-of-function amino acid mutations and one or more gain-of-function amino acid mutations relative to the corresponding parent receptor.

[0068] In some embodiments, the loss-of-function mutation and the gain-of-function mutation are at the same residue, i.e., they are the same mutation. In other embodiments, the loss-of-function mutation and the gain-of-function mutation are mutations at different amino acid residues. In some embodiments, the subject engineered receptors comprising loss-of-function mutations and / or gain-of-function mutations share 99%, 98%, 95%, 90%, 85%, 80%, 70%, 60%, 50%, or less sequence identity with the corresponding parent receptor, e.g., a wild-type receptor or a non-natural receptor. In some embodiments, the subject engineered receptors share 85% or more sequence identity, e.g., 85%, 90%, or 95% or more sequence identity, and in some cases 96%, 97%, 98% or more sequence identity, e.g., 99% or 99.5% sequence identity, with the corresponding parent receptor.

[0069] In some embodiments, the engineered receptor of the present disclosure comprises a receptor that is generated by combining one or more amino acid sequences, e.g., subunits, from one or more wild-type receptors with one or more amino acid sequences, e.g., subunits, from a second wild-type receptor. That is, the engineered receptor comprises amino acid sequences that are heterologous to each other, where "heterologous" means that they do not exist together in nature. Such receptors are referred to herein as "chimeric receptors". In some embodiments, the chimeric receptor serves as the parent receptor from which the engineered receptor of the present disclosure is generated.

[0070] In some embodiments, the parent receptor mutant exhibits increased affinity for agonist binding agents, hi some embodiments, a ligand or binding agent that functions as an antagonist or modulator when bound to the wild-type receptor functions as an agonist when bound to the parent receptor mutant.

[0071] In some embodiments, the engineered receptor is a "ligand-gated ion channel" or LGIC. LGICs refer to a large group of transmembrane proteins that allow the passage of ions upon activation by specific ligands (e.g., chemical or binding agents). LGICs are composed of at least two domains: a ligand-binding domain and a transmembrane ion pore domain. Ligand binding to a LGIC results in the activation of the LGIC and the opening of the ion pore. Ligand binding causes a dramatic change in the permeability of the channel to a specific ion(s). Indeed, while no ions can pass through the channel when inactive or closed, upon ligand binding, up to 10 ions can pass through the channel. 7 ions / second can pass through. In some embodiments, LGICs respond to extracellular ligands (e.g., neurotransmitters) and facilitate the influx of ions into the cytosol. In some embodiments, LGICs respond to intracellular ligands (e.g., nucleotides in ATP and signaling intermediates such as PIP2) and facilitate the efflux of ions from the cytosol to the extracellular environment. Importantly, activation of LGICs increases the transport of ions across the cell membrane (e.g., Ca 2+ , Na + , K + , Cl - etc.), and does not result in transport of the ligand itself.

[0072] LGIC receptors are composed of multiple subunits and can be either homomeric or heteromeric receptors. Homomeric receptors are composed of subunits that are all of the same type. Heteromeric receptors are composed of subunits where at least one subunit is different from at least one other subunit contained within the receptor. For example, the glycine receptor is composed of five subunits, of which there are two types: four isoforms (α 1~ There are two known isoforms of α-subunits: α1-GlyR and α4-GlyR. An exemplary homomeric GlyR is a β-subunit with five α1-GlyRs. Similarly, homomeric GABA A The receptor is β3-GABA A Subunits may be composed of, and nAchR receptors may be composed of α7-nAchR subunits. Exemplary heteromeric GlyRs may be composed of one or more α-subunits and one or more β-subunits (e.g., α1β-GlyR). Exemplary LGIC receptor subunits are shown in Table 1. [Table 1-1] [Table 1-2] [Table 1-3]

[0073] Illustrative examples of families of LGICs suitable for use in certain embodiments include, but are not limited to, Cys-loop receptors, such as glycine receptors (GlyRs), serotonin receptors (e.g., 5-HT3 receptors), lambda-aminobutyric acid A (GABA-A) receptors, and nicotinic acetylcholine receptors (nAchRs), as well as acid-sensing (proton-gated) ion channels (ASICs), epithelial sodium channels (ENaCs), ionotropic glutamate receptors, IP3 receptors, P2X receptors, ryanodine receptors, and zinc-activated channels (ZACs).

[0074] Specific non-limiting examples of LGICs suitable for use with the methods described herein include HTR3A;HTR3B;HTR3C;HTR3D;HTR3E;ASIC1;ASIC2;ASIC3;SCNN1A;SCNN1B;SCNN1D;SCNN1G;GABRA1;GABRA2;GABRA3;GABRA4;GABRA5;GABRA6;GABRB1;GABRB2;GABRB3;GABRG1;GABRG2;GABRG3;GABRD;GABRE;GABRQ;GABRP;GABRR1;GABRR2;GABRR3;GLRA1;GLRA2;GLRA3;GLRA4;GLRB;GRIA1;GRIA2;GRIA3 ;GRIA4;GRID1;GRID2;GRIK1;GRIK2;GRIK3;GRIK4;GRIK5;GRIN1;GRIN2A;GRIN2B;GRIN2C;GRIN2D;GRIN3A;GRIN3B;ITPR1;ITPR2;ITPR3;CHRNA1;CHRNA2;CHRNA3;CHRNA4;CHRNA5;CHRNA6;CHRNA7;CHRNA9;CHRNA10;CHRNB1;CHRNB2;CHRNB3;CHRNB4;CHRNG;CHRND;CHRNE;P2RX1;P2RX2;P2RX3;P2RX4;P2RX5;P2RX6;P2RX7;RYR1;RYR2;RYR3; and ZACN.

[0075] TRPV1, TRPM8 and P2X2 are members of the large LGIC family that share structural features and gate principles.For example, TRPV4 is triggered by heat, as TRPV1 is, but also by capsaicin, and P2X3 is triggered by ATP, but is desensitized more quickly than P2X2.Therefore, TRPV1, TRPM8 and P2X2 are non-limiting examples of LGIC suitable for use in certain embodiments.

[0076] In one embodiment, the engineered receptor is the TRPV1 or TRPM8 receptor or a mutant protein thereof. TRPV1 and TRPM8 are vanilloid and menthol receptors expressed by nociceptive neurons in the peripheral nervous system. Both channels are believed to function as nonselective, sodium and calcium permeable homotetramers. Furthermore, both channels and their main agonists, cold-sensing compounds such as capsaicin and menthol, respectively, are virtually absent from the central nervous system. Capsaicin, as well as some cold-sensing compounds, including menthol and icilin, contain potential acceptor sites for photosensitive blocking groups. The association of photosensitive blocking groups with such acceptors results in ligand-gated ion channels, where light acts as an indirect trigger by releasing active ligands.

[0077] In one embodiment, the engineered receptor is P2X2 receptor or its mutant protein.P2X2 is an ATP-dependent non-selective cation channel that is distinguished by its slow desensitization rate.P2X2 can be used as a selectively addressable source of depolarizing current, and presents a platform for generating engineered channel-ligand combinations that completely lack natural agonists.

[0078] Non-limiting examples of wild-type LGIC receptor sequences that find use in generating engineered receptors of the present disclosure include the following, in which the signal peptide is shown in italics, the ligand binding domain is shown in bold, and the ion pore domain is underlined:

[0079] In some embodiments, the wild-type LGIC receptor is the human alpha 1 glycine receptor (GlyR alpha 1) (GenBank Accession No. NP_001139512.1, SEQ ID NO: 2), encoded by the GLRA1 gene (GenBank Accession No. NM_001146040.1 (SEQ ID NO: 1): [ka]

[0080] In some embodiments, the wild-type LGIC receptor is the human nicotinic cholinergic receptor α7 subunit (α7-nAchR) (GenBank Accession No. NP_000737.1, SEQ ID NO: 4), encoded by the CHRNA7 gene (GenBank Accession No. NM_000746.5 (SEQ ID NO: 3): [ka]

[0081] In some embodiments, the wild-type LGIC receptor is the human 5-hydroxytryptamine receptor 3A (5HT3A, GenBank Accession No. NP_998786.2, SEQ ID NO: 6), encoded by the HTR3A gene (GenBank Accession No. NM_213621.3, SEQ ID NO: 5): [ka]

[0082] In some embodiments, the wild-type LGIC receptor is the human 5-hydroxytryptamine receptor 3B (5HT3B GenBank Accession No. NP_006019.1, SEQ ID NO: 57), encoded by the HTR3B gene (GenBank Accession No. NM_006028.4, SEQ ID NO: 56): [ka]

[0083] In some embodiments, the wild-type LGIC receptor is the human gamma-aminobutyric acid receptor A (GABA-A), subunit beta-3 (GABA-A β3) (GenBank Accession No. NP_000805.1, SEQ ID NO: 8), encoded by the GABRB3 gene (GenBank Accession No. NM_000814.5, SEQ ID NO: 7): [ka]

[0084] In some embodiments, the wild-type LGIC receptor is human GABA-A, subunit rho1(ρ1) (GABA-A ρ1), encoded by the GABRR1 gene (GenBank Accession No. NM_002042.4, SEQ ID NO:9) (GenBank Accession No. NP_002033.2, SEQ ID NO:10): [ka]

[0085] In some embodiments, the wild-type LGIC receptor is human GABA-A, subunit rho2(ρ2) (GABA-A ρ2) (GenBank Accession No. NP_002034.3, SEQ ID NO: 12), encoded by the GABRR2 gene (GenBank Accession No. NM_002043.4, SEQ ID NO: 11): [ka]

[0086] In some embodiments, the wild-type LGIC receptor is human GABA-A, subunit rho 3 (ρ3) (GABA-A ρ3) encoded by the GABRR 3 gene (GenBank Accession No. NM_001105580.2, SEQ ID NO: 13) (GenBank Accession No. NP_001099050.1, SEQ ID NO: 14): [ka]

[0087] In some embodiments, the subject engineered receptor is a chimeric receptor. In some embodiments, the chimeric receptor comprises a ligand binding domain sequence from at least a first LGIC and an ion pore conduction domain sequence from at least a second LGIC, or more simply, an "ion pore domain sequence". In some embodiments, the first and second LGICs are Cys loop receptors. The ligand binding domain sequence and the ion pore domain sequence of Cys loop receptors are well known in the art and can be easily identified from the literature by using public software such as PubMed, Genbank, Uniprot, etc. In the above sequences, the ligand binding domain is shown in bold and the ion pore domain is shown in underline.

[0088] In some embodiments, the ligand binding domain of the chimeric receptor comprises the ligand binding domain sequence of a human glycine receptor. In some embodiments, the human glycine receptor is human GlyR α1 (SEQ ID NO:2). In some such embodiments, the ligand binding domain comprises approximately amino acids 29-235 of GlyR α1, e.g., amino acids 29-235, amino acids 29-240, amino acids 29-246, amino acids 29-248, amino acids 29-250, or amino acids 29-252 of SEQ ID NO:2. In certain such embodiments, the ligand binding domain consists essentially of amino acids 29-235 of SEQ ID NO:2, essentially of amino acids 29-240 of SEQ ID NO:2, essentially of amino acids 29-246 of SEQ ID NO:2, essentially of amino acids 29-248 of SEQ ID NO:2, essentially of amino acids 29-250 of SEQ ID NO:2, or essentially of amino acids 29-252 of SEQ ID NO:2. In some embodiments, the ion pore domain sequence is from a Cys loop receptor other than human GlyR α1.

[0089] In some embodiments, the ligand binding domain of the chimeric receptor comprises a ligand binding domain sequence of a human nicotinic cholinergic receptor. In some embodiments, the human nicotinic cholinergic receptor is a human α7-nAChR. In some such embodiments, the ligand binding domain comprises approximately amino acids 23-220 of α7-nAChR (SEQ ID NO: 4), e.g., amino acids 23-220, amino acids 23-226, amino acids 23-229, amino acids 23-230, and in some cases, amino acids 23-231 of SEQ ID NO: 4. In certain such embodiments, the ligand binding domain consists essentially of amino acids 23-220 of SEQ ID NO: 4, essentially of amino acids 23-226 of SEQ ID NO: 4, essentially of amino acids 23-229 of SEQ ID NO: 4, essentially of amino acids 23-230 of SEQ ID NO: 4, or essentially of amino acids 23-231 of SEQ ID NO: 4. In some embodiments, the ion pore domain sequence is from a Cys loop receptor other than the human α7-nAChR-.

[0090] In some embodiments, the ligand binding domain of the chimeric receptor comprises a ligand binding domain sequence of a human serotonin receptor. In some embodiments, the human serotonin receptor is human 5HT3A or 5HT3B. In some such embodiments, the ligand binding domain comprises approximately amino acids 23-247 of 5HT3A (SEQ ID NO:6), e.g., amino acids 23-240, amino acids 30-245, amino acids 23-247, amino acids 23-250, and in some cases, amino acids 30-255 of SEQ ID NO:6. In certain embodiments, the ligand binding domain consists essentially of amino acids 23-240 of SEQ ID NO:6, essentially of amino acids 23-245 of SEQ ID NO:6, essentially of amino acids 30-247 of SEQ ID NO:6, essentially of amino acids 23-250 of SEQ ID NO:6, and essentially of amino acids 23-255 of SEQ ID NO:6. In some such embodiments, the ligand binding domain comprises approximately amino acids 21-239 of 5HT3B (SEQ ID NO:57), e.g., amino acids 21-232, amino acids 21-235, amino acids 21-240, amino acids 21-245, and in some cases amino acids 21-247 of SEQ ID NO:57. In certain embodiments, the ligand binding domain consists essentially of amino acids 21-239 of SEQ ID NO:57, consists essentially of amino acids 21-232 of SEQ ID NO:57, consists essentially of amino acids 21-235 of SEQ ID NO:57, consists essentially of amino acids 21-240 of SEQ ID NO:57, or consists essentially of amino acids 21-245 of SEQ ID NO:57. In some embodiments, the ion pore domain sequence is derived from a Cys loop receptor other than the human 5-hydroxytryptamine receptor 3.

[0091] In some embodiments, the ligand binding domain of the chimeric receptor comprises a ligand binding domain sequence of a human GABA receptor. In some embodiments, the human GABA receptor is human GABA-Aβ3. In some such embodiments, the ligand binding domain comprises approximately amino acids 26-245 of GABA-A β3 (SEQ ID NO:8), e.g., amino acids 26-240, amino acids 26-245, amino acids 26-248, amino acids 26-250, and in some cases, amino acids 26-255 of SEQ ID NO:8. In certain such embodiments, the ligand binding domain consists essentially of amino acids 26-240 of SEQ ID NO:8, essentially of amino acids 26-245 of SEQ ID NO:8, essentially of amino acids 26-248 of SEQ ID NO:8, essentially of amino acids 26-250 of SEQ ID NO:8, or essentially of amino acids 26-255 of SEQ ID NO:8. In some embodiments, the ion pore domain sequence is from a Cys loop receptor other than a human GABA-A receptor.

[0092] In some embodiments, the ion pore domain to which the ligand binding domain is fused conducts anions, e.g., it comprises the ion pore domain sequence of the human glycine receptor or the human serotonin receptor, in other embodiments, the ion conducting pore domain to which the ligand binding domain is fused conducts cations, e.g., it comprises the ion pore domain sequence of the human acetylcholine receptor or the human gamma-aminobutyric acid receptor A.

[0093] In some embodiments, the ion pore domain comprises the ion pore domain sequence of a human glycine receptor. In some embodiments, the human glycine receptor comprises the ion pore domain sequence of a human GlyR In some such embodiments, the ion pore domain is GlyR The ion pore domain comprises approximately amino acids 245-457 of α1 (SEQ ID NO:2), e.g., amino acids 240-457, amino acids 245-457, amino acids 248-457, amino acids 249-457, amino acids 250-457, amino acids 255-457, or amino acids 260-457 of SEQ ID NO:2. In certain such embodiments, the ion pore domain consists essentially of amino acids 245-457 of SEQ ID NO:2, consists essentially of amino acids 248-457 of SEQ ID NO:2, consists essentially of amino acids 249-457 of SEQ ID NO:2, or consists essentially of amino acids 250-457 of SEQ ID NO:2.

[0094] In some embodiments, the ion pore domain comprises an ion pore domain sequence of a human nicotinic cholinergic receptor. In some embodiments, the human nicotinic cholinergic receptor is a human α7-nAChR. In some such embodiments, the ion pore domain comprises approximately amino acids 230-502 of α7-nAChR (SEQ ID NO:4), e.g., amino acids 227-502, amino acids 230-502, amino acids 231-502, amino acids 232-502, or amino acids 235-502. In certain such embodiments, the ion pore domain consists essentially of amino acids 227-502 of SEQ ID NO:4, essentially of amino acids 230-502 of SEQ ID NO:4, essentially of amino acids 231-502 of SEQ ID NO:4, essentially of amino acids 232-502 of SEQ ID NO:4, or essentially of amino acids 235-502 of SEQ ID NO:4.

[0095] In some embodiments, the ion pore domain comprises an ion pore domain sequence of a human serotonin receptor. In some embodiments, the human serotonin receptor is human 5HT3A or 5HT3B. In some such embodiments, the ion pore domain comprises approximately amino acids 248-516 of 5HT3A (SEQ ID NO:6), e.g., amino acids 240-516, amino acids 245-516, amino acids 248-516, amino acids 250-516, or amino acids 255-516 of SEQ ID NO:6. In certain such embodiments, the ion pore domain consists essentially of amino acids 240-516 of SEQ ID NO:6, essentially of amino acids 245-516 of SEQ ID NO:6, essentially of amino acids 248-516 of SEQ ID NO:6, essentially of amino acids 250-516 of SEQ ID NO:6, or essentially of amino acids 253-516. In some such embodiments, the ion pore domain comprises approximately amino acids 240-441 of 5HT3B (SEQ ID NO:57), e.g., amino acids 230-441, amino acids 235-441, amino acids 240-441, amino acids 245-441, or amino acids 250-441 of SEQ ID NO:57. In certain such embodiments, the ion pore domain consists essentially of amino acids 230-441 of SEQ ID NO:57, consists essentially of amino acids 235-441 of SEQ ID NO:57, consists essentially of amino acids 240-441 of SEQ ID NO:57, consists essentially of amino acids 245-441 of SEQ ID NO:57, or consists essentially of amino acids 250-441.

[0096] In some embodiments, the ion pore domain comprises an ion pore domain sequence of a human GABA receptor. In some embodiments, the human GABA receptor is human GABA-A β3. In certain such embodiments, the ion pore domain comprises amino acids 246-473 of GABA-A β3 (SEQ ID NO:8), e.g., amino acids 240-473, amino acids 245-473, amino acids 247-473, amino acids 250-473, amino acids 253-473 of SEQ ID NO:8. In certain such embodiments, the ion pore domain consists essentially of amino acids 240-473 of SEQ ID NO:8, amino acids 245-473 of SEQ ID NO:8, amino acids 247-473 of SEQ ID NO:8, amino acids 250-473 of SEQ ID NO:8, or amino acids 253-473 of SEQ ID NO:8.

[0097] In some embodiments, the ion pore domain of a subject chimeric ligand-gated ion channel comprises an M2-M3 linker domain that is heterologous to the M2-M3 linker domain of the ion pore domain. By "M2-M3 linker domain", or "M2-M3 linker", is meant a sequence within the ion pore domain of an LGIC that is adjacent at its amino (N) terminus to the C-terminus of transmembrane domain 2 (M2) of the receptor and adjacent at its carboxy (C) terminus to the N-terminus of transmembrane domain 3 (M3) of the receptor. The M2-M3 linker of an LGIC can be readily determined by using any protein analysis tool known in the art and / or published, e.g., Expasy, uniProt, etc. Typically, when the ion pore domain of a chimeric receptor comprises a heterologous M2-M3 linker, The M2-M3 linker is derived from the same receptor as the ligand binding domain of the chimeric receptor. For example, if a subject ligand-gated ion channel comprises a ligand binding domain from AChR and an ion pore domain from GlyR, the subject ligand-gated ion channel may comprise the ion pore domain sequence from GlyR, except for the M2-M3 linker, which would instead be derived from AChR. In some embodiments, the ion pore domain is from GlyR α1 and the M2-M3 linker is from α7-nAChR. In some such embodiments, the M2-M3 linker sequence removed from GlyR α1 is amino acids 293-311, e.g., amino acids 304-310, 293-306, 298-310, 305-311, etc., of GlyR α1 (SEQ ID NO:2). In some such embodiments, the inserted M2-M3 linker is approximately amino acids 281-295 of the α7-nAChR (SEQ ID NO: 4), e.g., amino acids 290-295, 281-290, 281-295, 287-292, etc., or a sequence having about 95% or greater identity to amino acids 281-295 of the α7-nAChR.

[0098] In some embodiments, the ligand-binding domain of the subject chimeric ligand-gated ion channel comprises a Cys loop domain sequence that is heterologous to the Cys loop sequence of the ligand-binding domain. By "Cys loop domain sequence" or "Cys loop sequence" is meant a domain within the ligand-binding domain of the Cys loop LGIC that forms a loop structure adjacent to cysteines at the N-terminus and C-terminus. Without wishing to be bound by theory, it is believed that upon ligand binding to the ligand-binding domain, the Cys loop structurally moves closer to the M2-M3 loop, which mediates the biophysical translation of ligand binding in the extracellular domain to signal in the ion pore domain (Miller and Smart, Trends in Pharmacological Sci 2009:31(4)). Substituting the endogenous Cys loop sequence with a heterologous Cys loop sequence may increase the conductivity of the LGIC by 1.5-fold or more, e.g., at least 2-fold, 3-fold, or 4-fold, in some cases at least 5-fold or 6-fold, and at certain doses at least 7-fold, 8-fold, 9-fold, or 10-fold. The Cys loop domain of a Cys loop receptor can be easily determined by using any protein analysis tool available in the art and / or published, e.g., Expasy, uniProt, etc. Typically, when the ligand binding domain of a chimeric receptor comprises a heterologous Cys loop sequence, the Cys loop sequence is derived from the same receptor as the ion pore domain of the chimeric receptor. For example, when a subject chimeric ligand-gated ion channel comprises a ligand binding domain from AChR and an ion pore domain from GlyR, the subject ligand-gated ion channel may instead comprise the ligand binding domain sequence from AChR, except for the sequence of the Cys loop domain from GlyR. In some embodiments, the ligand binding domain is from α7-nAChR and the Cys loop sequence is from GlyR α1.In some such embodiments, the Cys loop sequence removed from α7-nAChR is approximately amino acids 150-164 of α7-nAChR (SEQ ID NO:4), e.g., amino acids 150-157 of α7-nAChR. In some such embodiments, the Cys loop sequence inserted is approximately amino acids 166-180 of GlyR α1 (SEQ ID NO:2), e.g., amino acids 166-172 of GlyR α1, or a sequence having about 95% or greater identity to amino acids 166-180 of GlyR α1.

[0099] In some embodiments, the ligand-binding domain of a subject chimeric ligand-gated ion channel comprises a β1-2 loop domain sequence that is heterologous to the β1-2 loop domain sequence of the ligand-binding domain. By "β1-2 loop domain sequence," or "β1-2 loop, or β1-β2 loop," we mean a domain within the ligand-binding domain of the Cys loop LGIC that is flanked at its N-terminus by the C-terminus of the β1 sheet, and at its C-terminus by the N-terminus of the β2 sheet. Without wishing to be bound by theory, it is believed that the β1 The -2 loop is believed to help mediate the biophysical translation of ligand binding in the extracellular domain to the ion pore domain and subsequent signal transduction (i.e., chloride influx in the case of GlyR). Upon ligand binding, the β1-2 loop, together with the Cys loop, in close proximity to the M2-M3 loop, is believed to mediate the biophysical translation of ligand binding in the extracellular domain to signal transduction in the ion pore domain where the M2-M3 loop resides (as outlined in Miller and Smart, supra). Replacing the endogenous β1-2 loop sequence with a heterologous β1-2 loop sequence may increase the conductivity of the LGIC by 1.5-fold or more, e.g., at least 2-fold, 3-fold, or 4-fold, in some cases at least 5-fold or 6-fold, and at certain doses at least 7-fold, 8-fold, 9-fold, or 10-fold. The β1-2 loop domain of Cys loop receptors can be easily determined by using any protein analysis tool available in the art and / or published, e.g., Expasy, uniProt, etc. Typically, when the ligand-binding domain of the chimeric receptor comprises a heterologous β1-2 loop sequence, the β1-2 loop sequence is derived from the same receptor as the ion pore domain of the chimeric receptor. For example, when a subject chimeric ligand-gated ion channel comprises a ligand-binding domain from AChR and an ion pore domain from GlyR, the subject ligand-gated ion channel may instead comprise the ligand-binding domain sequence from AChR, except for the sequence of the β1-2 loop domain, which is derived from GlyR. In some embodiments, the ligand-binding domain is derived from α7-nAChR, and the β1-2 loop sequence is derived from GlyR α1. In some embodiments, the β1-2 loop sequence removed from α7-nAChR is approximately amino acids 67-70 of α7-nAChR (SEQ ID NO: 4), e.g., amino acids 67-70, 66-71, or 64-72 of α7-nAChR. In some embodiments, the β1-2 loop sequence inserted is approximately amino acids 67-70, 66-71, or 64-72 of α7-nAChR. It is a sequence having about 95% or more identity to approximately amino acids 79 to 85 of α1 (SEQ ID NO: 2), for example, amino acids 81 to 84, 79 to 85, or 81 to 84 of GlyR α1, or amino acids 79 to 85 of GlyR α1.

[0100] Non-limiting examples of sequences of chimeric LGIC receptors of the present disclosure include the sequences disclosed herein as SEQ ID NO: 15 to SEQ ID NO: 52. In some embodiments, the chimeric LGIC receptor or a polynucleotide encoding same has 85% or more sequence identity to the sequences provided herein in SEQ ID NO: 15 to SEQ ID NO: 52, e.g., 90% or more, 93% or more, or 95% or more, i.e., 96%, 97%, 98%, 99% or 100% sequence identity to the sequences provided herein in SEQ ID NO: 15 to SEQ ID NO: 52. In the sequences, the signal peptide is shown in italics, the ligand binding domain is shown in bold, and the ion pore domain is underlined:

[0101] In some embodiments, the chimeric LGIC receptor is a CHRNA7 / GLRA1 chimera (R229 junction) that includes the human α7-nAChR signal peptide (italics) and ligand binding domain (bold) fused to the human GlyR α1 ion pore domain (underlined) (e.g., SEQ ID NO: 16 in FIG. 3 ); [ka]

[0102] In some embodiments, the chimeric LGIC receptor is a CHRNA7 / GLRA1(R228 junction) chimera, comprising the human α7-nAChR signal peptide (italics) and ligand binding domain (bold) fused to the human GlyR α1 ion pore domain (underlined); [ka]

[0103] In some embodiments, the chimeric LGIC receptor is a CHRNA7 / GLRA1 (V224 junction) chimera, comprising the human α7-nAChR signal peptide (italics) and ligand binding domain (bold) fused to the human GlyR α1 ion pore domain (underlined); [ka]

[0104] In some embodiments, the chimeric LGIC receptor is a CHRNA7 / GLRA1 (Y233 junction) chimera, comprising the human α7-nAChR signal peptide (italics) and ligand binding domain (bold) fused to the human GlyR α1 ion pore domain (underlined); [ka]

[0105] In some embodiments, the chimeric LGIC receptor is a CHRNA7 / GLRA1 chimera (R229 junction) that contains the human α7-nAChR signal peptide (italics) and ligand binding domain (bold) fused to the human GlyR α1 ion pore domain (underlined) containing the α7-nAChR M2-M3 linker (lowercase); [ka] [ka] [ka] [ka] [ka] [ka]

[0106] In some embodiments, the chimeric LGIC receptor is a CHRNA7 / GLRA1 chimera that includes GlyRα1 Cys, human α7-nAChR signal peptide (italics) including loop sequence (lowercase) and ligand binding domain (bold) fused to the human GlyR α1 ion pore domain (underlined) (see, e.g., SEQ ID NO:34 in FIG. 3 );

[0107] [ka] [ka]

[0108] In some embodiments, the chimeric LGIC receptor is a CHRNA7 / GLRA1 chimera, comprising the human α7-nAChR signal peptide (italics) and ligand binding domain (bold) containing the GlyRα1 β1-2 loop sequence (lowercase) fused to the human GlyR α1 ion pore domain (underlined); [ka]

[0109] In some embodiments, the chimeric LGIC receptor comprises the human α7-nAChR signal peptide (italics) containing the GlyRα1 β1-2 loop sequence (lowercase) and the Cys loop sequence (lowercase) fused to the human GlyR α1 ion pore domain (underlined). and a ligand binding domain (bold) (e.g., SEQ ID NO: 41 in FIG. 3 ); [ka] [ka] [ka] [ka]

[0110] In some embodiments, the chimeric LGIC receptor is a CHRNA7 / GLRA1 chimera, comprising the human α7-nAChR signal peptide (italics) and ligand binding domain (bold) containing the GlyRα1 β1-2 loop sequence (lowercase) fused to the human GlyR α1 ion pore domain (underlined) containing the human α7-nAChR M2-M3 linker (lowercase); [ka]

[0111] In some embodiments, the chimeric LGIC receptor is a CHRNA7 / GLRA1 chimera, comprising the human α7-nAChR signal peptide (italics) and ligand binding domain (bold) including GlyRα1 Cys, loop sequence (lowercase), fused to the human GlyR α1 ion pore domain (underlined) including the human α7-nAChR M2-M3 linker (lowercase); [ka]

[0112] In some embodiments, the chimeric LGIC receptor is an HTR3A / GLRA1 chimera (R241 junction) that contains the human 5HT3A serotonin receptor signal peptide (italics) and ligand binding domain (bold) fused to the human GlyR α1 ion pore domain (underlined); [ka]

[0113] In some embodiments, the chimeric LGIC receptor is an HTR3A / GLRA1 chimera (V236 junction) that contains the human 5HT3A serotonin receptor signal peptide (italics) and ligand binding domain (bold) fused to the human GlyR α1 ion pore domain (underlined); [ka]

[0114] In some embodiments, the chimeric LGIC receptor is a GABRB3 / GLRA1 chimera (Y245 junction) that contains the human GABA-A β3 signal peptide (italics) and ligand binding domain (bold) fused to the human GlyR α1 ion pore domain (underlined); [ka]

[0115] As mentioned above, in some embodiments, the subject engineered receptor comprises at least one amino acid mutation that changes the potency of a ligand on the engineered receptor compared to its potency on the non-mutated parent receptor.In other words, one or more amino acid mutations, such as loss-of-function mutations or gain-of-function mutations, change the responsiveness of the engineered receptor to a ligand compared to the responsiveness of the non-mutated parent receptor.In some such embodiments, the one or more mutations are in the ligand-binding domain of the engineered receptor. In some embodiments, as in the case where the ligand-binding domain of the engineered receptor is a Cys-loop receptor protein, one or more amino acid mutations are substitutions at residues corresponding to residues of α7-nAChR (SEQ ID NO: 4) selected from the group consisting of W77, Y94, R101, W108, Y115, T128, N129, V130, L131, Q139, L141, Y151, S170, W171, S172, S188, Y190, Y210, C212, C213, and Y217.In some embodiments, one residue is substituted.In some embodiments, 2, 3, 4, or 5 or more residues are substituted, for example, 6, 7, 8, 9, or 10 residues are substituted. In certain embodiments, the residue corresponds to a residue in α7-nAChR (SEQ ID NO: 4) selected from the group consisting of W77, R101, Y115, N129, L131, S170, S172, and S188. In embodiments, the one or more substitutions are selected from those listed in Figures 8A-I. In certain embodiments, the one or more substitutions are in the α7-nAChR sequence.

[0116] In some embodiments, the one or more substitutions reduce the responsiveness of the engineered receptor to acetylcholine and the non-natural ligand, e.g., by 2-fold or more, 3-fold or more, 4-fold or more, 5-fold or more, 10-fold or more, 20-fold or more, 30-fold or more, 50-fold or more, or 100-fold. In some such embodiments, the one or more substitutions correspond to amino acid substitutions in the α7-nAChR sequences set forth in Figures 8A-F and 8H. In certain embodiments, the one or more substitutions correspond to R101I, R101S, R101D, Y115L, Y115M, Y115D, Y115T, T128M, T128R, T128I, N129I, N129V, N129P, N129W, N129T, N129D, N129E, L131P, L131T, L131D, L131S, L141S, L141R, W171F, W171H, S172F, S172Y, S172R, S172D, C212A, C212L, or C213P of α7-nAChR.In other cases, the one or more substitutions selectively reduce the potency of acetylcholine to the engineered receptor. That is, the one or more substitutions reduce the responsiveness of the engineered receptor to acetylcholine while essentially maintaining responsiveness to the non-natural ligand, or reduce the responsiveness of the engineered receptor to acetylcholine by more than two-fold, e.g., three-fold, four-fold, five-fold or more, and in some cases, ten-fold, twenty-fold, fifty-fold, or even one hundred-fold or more, than they reduce the responsiveness of the engineered receptor to the non-natural ligand. Exemplary substitutions include those shown in Figure 8H, i.e., substitutions corresponding to L131S, L131T, L131D, or S172D of the α7-nAChR. In yet other embodiments, the one or more substitutions selectively reduce the potency of the non-natural ligand on the engineered receptor. That is, one or more substitutions reduce the responsiveness of the engineered receptor to a non-natural ligand while maintaining responsiveness to acetylcholine, or alternatively, reduce the responsiveness of the engineered receptor to a non-natural ligand by more than two-fold, e.g., three-fold, five-fold, or more, and in some cases, ten-fold, twenty-fold, fifty-fold, or more, more than it reduces the responsiveness of the engineered receptor to acetylcholine.Exemplary substitutions include those shown in Figure 8G, i.e., substitutions corresponding to W77M, Y115W, S172T, or S172C of α7-nAChR. In certain embodiments, one or more substitutions are in the α7-nAChR sequence. In certain embodiments, the non-natural ligand is selected from AZD-0328, TC6987, ABT-126, and facinicline / RG3487.

[0117] In other embodiments, the one or more substitutions increase the responsiveness of the engineered receptor to acetylcholine and / or a non-natural ligand, e.g., by 2-fold or more, 3-fold or more, 4-fold or more, 5-fold or more, 10-fold or more, 20-fold or more, 30-fold or more, 50-fold or more, or 100-fold. Exemplary substitutions include those depicted in Figures 8G or 8I, i.e., substitutions corresponding to L131N, L141W, S170G, S170A, S170L, S170I, S170V, S170P, S170F, S170M, S170T, S170C, S172T, S172C, S188I, S188V, S188F, S188M, S188Q, S188T, S188P, or S188W. In some cases, the one or more substitutions increase the potency of both acetylcholine and non-natural ligands, for example, substitutions corresponding to L131N, S170G, S170A, S170L, S170I, S170V, S170P, S170F, S170M, S170T, S170C, S172T, S188I, S188V, S188F, S188M, S188Q, and S188T of α7-nAChR.In other cases, the one or more substitutions selectively increase the potency of acetylcholine for the engineered receptor.That is, the one or more substitutions, for example, substitutions corresponding to L141W, S172T, S172C, S188P, or S188W of α7-nAChR, selectively increase the potency of acetylcholine for the engineered receptor, rather than increasing the responsiveness of the engineered receptor to non-natural ligands. fold or more, for example, 3-fold, 4-fold, or 5-fold or more, and in some cases, 10-fold, 20-fold, 50-fold, or 100-fold, increase the responsiveness of the engineered receptor to the non-natural ligand. In certain embodiments, the one or more substitutions are in the α7-nAChR sequence. In certain embodiments, the non-natural ligand is selected from AZD-0328, TC6987, ABT-126, and facinicline / RG3487. In still other cases, the one or more substitutions selectively increase the potency of the non-natural ligand on the engineered receptor. That is, the one or more substitutions increase the responsiveness of the engineered receptor to the non-natural ligand by 2-fold or more, for example, 3-fold, 5-fold, or more, and in some cases, 10-fold, 20-fold, or 50-fold, more than it increases the responsiveness of the engineered receptor to acetylcholine.

[0118] Typically, the amino acid residues to be mutated in the engineered receptor of interest are the wild-type a7 The substitution is not an amino acid corresponding to R27, E41, Q79, Q139, 141, G175, Y210, P216, Y217, or D219 of the nAChR (SEQ ID NO: 4). Even more typically, the substitution is not a substitution corresponding to W77F, W77Y, W77M, Q79A, Q79Q, Q79S, Q79G, Y115F, L131A, L131G, L131M, L131N, L131Q, L131V, L131F, Q139G, Q139L, G175K, G175A, G175F, G175H, G175M, G175R, G175S, G175V, Y210F, P216I, Y217F, or D219A in the wild-type α7 nAChR. Alternatively, if such a substitution is indeed present in the engineered receptor, it is present in combination with one or more of the amino acid mutations described herein.

[0119] For example, it has been found that residues Y94, Y115, Y151 and Y190 of α7-nAChR (SEQ ID NO: 4) mediate the binding of natural ligand acetylcholine.Mutations in these residues reduce the binding of acetylcholine, and therefore are loss-of-function mutations.In contrast, residues W77, Y115, N129, V130, L131, Q139, L141, S170, Y210, C212, C213 and Y217 of α7-nAChR mediate the binding of non-natural ligand AZD0328 to this receptor, and mutations in these residues can increase the affinity of AZD0328 and / or other ligands to this receptor, and therefore can be gain-of-function mutations. In some embodiments, the subject engineered receptor comprises a mutation in one or more amino acid residues in the ligand binding domain region of the α7-nAChR (SEQ ID NO: 4), or in the ligand binding domain of a chimeric receptor comprising the ligand binding domain region of the α7-nAChR, wherein the one or more amino acid residues are selected from the group consisting of W77, Y94, Y115, N129, V130, L131, Q139, L141, Y151, S170, Y190, Y210, C212, C213, and Y217. In certain embodiments, the mutations in one or more amino acid residues in the ligand binding domain region of α7-nAChR (SEQ ID NO: 4), or in the ligand binding domain of a chimeric receptor comprising the ligand binding domain region of α7-nAChR, are one or more amino acid residues selected from the group consisting of W77, Y94, Y115, N129, V130, L131, Q139, L141, Y151, S170, Y190, Y210, C212, C213, and Y217.

[0120] As another example, it has been found that residues Y115, L131, L141, S170, W171, S172, C212, and Y217 of α7-nAChR (SEQ ID NO: 4) mediate the binding of acetylcholine and / or nicotine, and mutations in one or more of these residues reduce the binding of acetylcholine and / or nicotine.R101, Y115, L131, L141, W171, S172, S188, Y210, and Y217 of α7-nAChR mediate the binding of the non-natural ligand ABT126, and mutations in one or more of these residues are expected to increase the affinity of ABT126 and / or other ligands to α7-nAChR.R101, Y115, T Residues R128, N129, L131, L141, W171, S172, Y210, C212, C213, and Y217 of the α7-nAChR mediate binding of the non-natural ligand TC6987, and mutation of one or more of these residues is expected to increase the affinity of TC6987 and / or other ligands for the α7-nAChR. Residues R101, N120, L131, L141, S170, W171, S172, Y210, and Y217 of the α7-nAChR mediate binding of the non-natural ligand facinicline / RG3487, and mutation of one or more of these residues is expected to increase the affinity of facinicline / RG3487 and / or other ligands for the α7-nAChR. In some embodiments, the subject engineered receptor comprises a mutation in one or more amino acid residues in the ligand binding domain region of the α7-nAChR or the ligand binding domain of a chimeric receptor comprising the ligand binding domain region of the α7-nAChR, wherein the one or more amino acid residues are selected from the group consisting of R101, Y115, T128, N120, N129, L131, L141, S170, W171, S172, S188, Y210, C212, C213, and Y217. In some embodiments, the one or more amino acid residues alter the binding of acetylcholine and / or nicotine to the α7-nAChR, wherein the amino acid is selected from the group consisting of Y115, L131, L141, S170, W171, S172, C212, and Y217 of the α7-nAChR. In certain such embodiments, the amino acid is selected from C212 and S170. In some embodiments, mutations in one or more amino acid residues alter the binding of ABT126 to the α7-nAChR, and the one or more amino acid residues are selected from the group consisting of R101, Y115, L131, L141, W171, S172, S188, Y210, and Y217 of the α7-nAChR. In certain such embodiments, the amino acids are selected from R101, S188, and Y210.In some embodiments, the mutations in one or more amino acid residues alter the binding of TC6987 to the α7-nAChR, and the one or more amino acid residues are selected from the group consisting of R101, Y115, T128, N129, L131, L141, W171, S172, Y210, C212, C213, and Y217 of the α7-nAChR. In certain such embodiments, the amino acids are selected from R101, T128, N129, Y210, and C213. In some embodiments, the mutations in one or more amino acid residues alter the binding of fasiniculline / RG3487 to the α7-nAChR, and the one or more amino acid residues are selected from the group consisting of R101, N120, L131, L141, S170, W171, S172, Y210, and Y217 of the α7-nAChR. In certain such embodiments, the amino acids are selected from Y210, R101, and N129.

[0121] As another example, it has been found that residues W85, R87, Y136, Y138, G146, N147, Y148, K149, S177, S178, L179, Y228, and Y229 of 5HT3 (SEQ ID NO: 6) mediate the binding of serotonin, and mutations at one or more of these residues reduce the binding of serotonin to 5HT3.D64, I66, W85, R87, Y89, N123, G146, Y148, T176, S177, S178, W190, R191, F221, E224, Y228, Y229, and E231 of 5HT3 mediate the binding of the non-natural ligand silansetron, and mutations at one or more of these residues are expected to increase the affinity of silansetron and / or other ligands for 5HT3. In some embodiments, the subject engineered receptor comprises a mutation in one or more amino acid residues in the ligand binding domain region of 5HT3 or a ligand binding domain of a chimeric receptor comprising the ligand binding domain region of 5HT3A, wherein the one or more amino acid residues are selected from the group consisting of D64, I66, W85, R87, Y89, N123, Y136, Y138, G146, N147, Y148, K149, T176, S177, S178, L179, W190, R191, F221, E224, Y228, Y229, and E231. In some embodiments, the mutation in the one or more amino acid residues alters the binding of serotonin to 5HT3, wherein The amino acid is selected from the group consisting of W85, R87, Y136, Y138, G146, N147, Y148, K149, S177, S178, L179, Y228 and Y229 of 5HT3A.In certain such embodiments, the amino acid is selected from Y136, Y138, N147, K149 and L179.In some embodiments, the mutation in one or more amino acid residues changes the binding of cilansetron to 5HT3, wherein one or more amino acid residues are selected from the group consisting of D64, I66, W85, R87, Y89, N123, G146, Y148, T176, S177, S178, W190, R191, F221, E224, Y228, Y229 and E231 of 5HT3A. In certain such embodiments, the amino acids are selected from D64, I66, Y89, N123, T176, W190, R191, F221, E224, and E231.

[0122] In some embodiments, one or more mutations that affect the ability of the ligand to regulate the activity of LGIC are located in the ion pore domain of LGIC. For example, residue T279 of serotonin receptor 5HT3A mediates the way that ligand regulates the activity of the channel, such that mutation of this residue, for example, to serine (T279S), converts the effect from antagonistic (i.e., reducing the activity of LGIC) to agonistic (i.e., promoting the activity of the channel). In some embodiments, the subject ligand-gated ion channel comprises a mutation in one or more amino acid residues of the ion pore domain of human 5HT3A (SEQ ID NO: 6) or the ion pore domain of a chimeric LGIC receptor comprising the ion pore domain of 5HT3A, where the substitution is within the amino acid corresponding to 279 of SEQ ID NO: 6. In certain embodiments, the substitution is a T279S substitution for SEQ ID NO: 6.

[0123] In some embodiments, the subject ligand-gated ion channel comprises one or more non-desensitizing mutations. When used in the context of a ligand-gated ion channel, "desensitization" refers to a progressive reduction in ion flux in the presence of an agonist for a long time. This causes a gradual loss of neuronal responsiveness to the ligand. A non-desensitizing mutation refers to an amino acid mutation that prevents the LGIC from being desensitized to the ligand, thereby preventing the neuron from becoming hyporesponsive or non-responsive to the ligand. A non-desensitizing mutation can be easily identified by introducing a LGIC with the mutation into a neuron and analyzing the current flow over time during prolonged exposure to the ligand. If the LGIC does not comprise a non-desensitizing mutation, the current will return from the peak to a steady state during prolonged exposure, whereas if the LGIC comprises a non-desensitizing mutation, the current will remain at the peak flux for the duration of exposure to the ligand. Exemplary amino acid mutations that result in desensitization include the V322L mutation in human GlyR α1 (V294L post-processing of the proprotein to remove the signal peptide) and the L321V mutation in human GABA-A receptor GABRB3 (L296V post-processing of the proprotein to remove the signal peptide). In some embodiments, the desensitizing mutation is replacing amino acid residues at or near the C-terminus of LGIC with a sequence having 90% or greater identity to a desensitizing sequence, e.g., IDRLSRIAFPLLFGIFNLVYWATYLNREPQL (SEQ ID NO: 53) from the C-terminus of the protein encoded by GABAR1, e.g., replacing residues 455-479 in GABRR1 with IDRLSRIAFPLLFGIFNLVYWATYLNREPQL (SEQ ID NO: 53). LGIC desensitization, methods for measuring LGIC desensitization, and non-desensitizing mutations are well known in the art, see, e.g., Gielen et al., Nat Commun 2015 Apr 20, 6:6829, and Keramidas et al., Cell Mol Life Sci. 2013 Apr;70(7):1241-53, the entire disclosures of which are incorporated herein by reference.

[0124] In some embodiments, the subject ligand-gated ion channels include one or more converting mutations. By converting mutation is meant a mutation that changes the permeability of the ion pore domain of the LGIC, making it permissive for the conduction of non-native ions, i.e., ions that cannot pass naturally. In some cases, the mutation converts the permeability from cations to anions, for example, replacing amino acid residues 260-281 in human α7-nAChR (CHRNA7) (EKISLGITVLLSLTVFMLLVAE, SEQ ID NO: 54), or the corresponding amino acids in another cation-permeable LGIC, with the peptide sequence PAKIGLGITVLLSLTTFMSGVAN (SEQ ID NO: 55). In some cases, the mutation converts permeability from anions to cations, for example, substitution of amino acid residue 279 of GLRA1 or a corresponding amino acid in another anion-permeable LGIC with glutamic acid (E) (such as A293E substitution in GLRA1, which converts the LGIC from anion permeable to calcium permeable), or deletion of amino acid residue 278 of GLRA1 or a corresponding amino acid in another anion-permeable LGIC, substitution of amino acid residue 279 of GLRA1 or a corresponding amino acid in another anion-permeable LGIC with glutamic acid (E), and substitution of amino acid residue 293 of GLRA1 or a corresponding amino acid in another anion-permeable LGIC with valine (V) (such as P278Δ, A279E, T293V of GLRA1, which converts the LGIC from anion permeable to cation permeable).

[0125] Further engineered receptors beyond those described herein can be readily identified by in vitro screening and validation methods, for example, as described in FIG. 2 and in the Examples herein. In some embodiments, a library of parent receptor mutants is generated from a limited number of parent receptors, such as those shown in FIG. 1 and described elsewhere herein. The parent receptors can be mutated using methods known in the art, including error-prone PCR. In some embodiments, the library of parent receptor mutants is then transfected into yeast or mammalian cells and screened in high throughput to identify functional receptors (e.g., to identify parent receptor mutants that can signal in response to a binding agent or ligand). In some embodiments, the functional parent receptor mutants identified in this primary screen are then expressed in mammalian cells and screened for responsiveness to a binding agent or ligand, for example, by plate reader and / or electrophysiology assays described herein. Parent receptor mutants that show increased binding affinity to agonist binders or that allow the use of antagonist or modulator binders as agonists in secondary screens can then be selected to carry out further in vitro and / or in vivo validation and characterization assays.Such screening assays are known in the art and are described, for example, in Armbruster, BN et al. (2007) PNAS, 104, 5163-5168; Nichols, CD and Roth, BL (2009) Front. Mol. Neurosci. 2, 16; Dong, S. et al. (2010) Nat. Protoc. 5, 561-573; Alexander, GM et al. (2009) Neuron 63, 27-39; Guettier, JM et al. (2009) PNAS 106, 19197-19202; Ellefson JW et al. (2014) Nat Biotechnol. 32(1):97-101; Maranhao AC and Ellington AD. (2017) ACS Synth Biol. 20;6(1):108-119; Talwar S et al. (2013) PLoS One;8(3):e58479; Gilbert DF et al. (2009) Front Mol Neurosci.30;2:17; Lynagh and Lynch (2010), Biol Chem.14:285(20), 14890-14897; Islam R. et al. (2016) ACS Chem Neurosci.21;7(12):1647-1657; and Myers et al. (2008) Neuron.8:58(3):362-373.

[0126] D. Binder The terms "binding agent" or "agent" are used interchangeably herein and refer to an exogenous drug or compound that has a known mechanism of action on mammalian cells (e.g., known to function as an agonist, antagonist, or modulator of a receptor). Binding agents can include proteins, lipids, nucleic acids, and / or small molecules. In some embodiments, binding agents include drugs or compounds approved by the U.S. Food and Drug Administration (FDA) for clinical use in the treatment of a particular disease (e.g., neurological disease). In some embodiments, binding agents include drugs or compounds that have not been approved by the FDA for clinical use but have been tested in one or more clinical trials, are currently being tested in one or more clinical trials, and / or are expected to be tested in one or more clinical trials. In some embodiments, binding agents include drugs or compounds that have not been approved by the FDA for clinical use but are routinely used in laboratory research. In some embodiments, the binding agent is an analog of one of the aforementioned agents. In certain embodiments, the binding agent is selected from any one of the agents in Tables 2-9. In some such embodiments, the binding agent is selected from the group consisting of AZD0328, ABT-126, AQW-051, cannabidiol, cilansetron, PH-399733, facinicline / RG3487 / MEM-3454, and TC-5619 / AT-101. In certain embodiments, the binding agent is an analog of cilansetron, such as those described by one of formulas 2-7, its R or S enantiomer: [ka]

[0127] In some embodiments, the binding agent acts as an agonist. As used herein, the term "agonist" refers to a ligand or binding agent that induces a signaling response. In some embodiments, the binding agent acts as an antagonist. The term antagonist is used herein to refer to an agent that inhibits a signaling response. do.

[0128] In some embodiments, the binding agent is an anti-anxiety agent, an anti-convulsant, an anti-depressant, an anti-psychotic agent, an anti-emetic agent, a nootropic agent, an antibiotic, an anti-fungal agent, an anti-viral agent, or an anti-parasitic agent. [Table 2-1] [Table 2-2] [Table 3-1] [Table 3-2] [Table 3-3] [Table 3-4] [Table 3-5] [Table 3-6] [Table 4-1] [Table 4-2] [Table 5-1] [Table 5-2] [Table 5-3] [Table 6-1] [Table 6-2] [Table 7] [Table 8] [Table 9]

[0129] E. Polynucleotides In various exemplary embodiments, the present disclosure contemplates, in part, polynucleotides encoding engineered receptor polypeptides comprising LGICs, and subunits and mutant proteins thereof, as well as fusion polypeptides, viral vector polynucleotides, and compositions comprising the same.

[0130] As used herein, the terms "polynucleotide," "nucleotide," "nucleotide sequence," or "nucleic acid" are used interchangeably. They refer to any length of nucleotides, either deoxyribonucleotides or ribonucleotides, or analogs thereof. Polynucleotides refer to the polymeric form of a nucleotide. A polynucleotide may have any three-dimensional structure and may perform any function, known or unknown. The following are non-limiting examples of polynucleotides: coding or non-coding regions of a gene or gene fragment, multiple loci (single locus) defined from binding analysis, exons, introns, messenger RNA (mRNA), transfer RNA (tRNA), ribosomal RNA (rRNA), short interfering RNA (siRNA), short hairpin RNA (shRNA), microRNA (miRNA), ribozymes, cDNA, recombinant polynucleotides, branched polynucleotides, plasmids, vectors, isolated DNA of any sequence, isolated RNA of any sequence, nucleic acid probes, and primers. A polynucleotide may contain one or more modified nucleotides, such as methylated nucleotides and nucleotide analogs. If present, modifications to the nucleotide structure may be imparted before or after assembly of the polymer. The nucleotide sequence may be interrupted by non-nucleotide components. A polynucleotide may be further modified after polymerization, for example, by conjugation with a label component. The polynucleotide may be deoxyribonucleic acid (DNA), ribonucleic acid (RNA), or a DNA / RNA hybrid. The polynucleotide may be single-stranded or double-stranded. The polynucleotide may include, but is not limited to, pre-messenger RNA (pre-mRNA), messenger RNA (mRNA), RNA, short interfering RNA (siRNA), short hairpin RNA (shRNA), microRNA (miRNA), ribozyme, synthetic RNA, genomic RNA (gRNA), positive strand RNA (RNA+), negative strand RNA (RNA-), synthetic RNA, genomic DNA (gDNA), PCR amplified DNA, complementary DNA (cDNA), synthetic DNA, or recombinant DNA.Polynucleotide refers to a polymeric form of nucleotides of at least 5, at least 10, at least 15, at least 20, at least 25, at least 30, at least 40, at least 50, at least 100, at least 200, at least 300, at least 400, at least 500, at least 1000, at least 5000, at least 10000, or at least 15000 or more nucleotides in length, either ribonucleotides or deoxynucleotides, or modified forms of any type of nucleotide, as well as all intermediate lengths of nucleotides. It will be readily understood that "intermediate lengths" in this context means any length between the cited values, e.g., 6, 7, 8, 9, etc., 101, 102, 103, etc., 151, 152, 153, etc., 201, 202, 203, etc. In certain embodiments, a polynucleotide or variant has at least or about 50%, 55%, 60%, 65%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to a reference sequence described herein or known in the art, and typically the variant retains at least one biological activity of the reference sequence, unless otherwise specified.

[0131] As used herein, the term "gene" can refer to a polynucleotide sequence that includes enhancers, promoters, introns, exons, etc. In certain embodiments, the term "gene" refers to a polynucleotide sequence that encodes a polypeptide, regardless of whether the polynucleotide sequence is identical to a genomic sequence that encodes the polypeptide.

[0132] As used herein, "cis-acting sequence," "cis-acting regulatory sequence," or "cis-acting nucleotide sequence" or equivalents refer to a polynucleotide sequence that is associated with the expression, e.g., transcription and / or translation, of a gene. In one embodiment, a cis-acting sequence regulates transcription because it is a binding site for a polypeptide that represses or reduces transcription, or is a polynucleotide associated with a transcription factor binding site that contributes to transcription repression. To regulate expression of a polynucleotide sequence and regulate expression of a subject engineered receptor. Examples of cis-acting sequences that can be operably linked to the polynucleotides of the present disclosure are well known in the art and include elements such as promoter sequences (e.g., CAG, CMV, SYN, CamKII, TRPV1), Kozak sequences, enhancers, post-transcriptional regulatory elements, miRNA binding elements, and polyadenylation sequences.

[0133] As one non-limiting example, a promoter sequence is a DNA regulatory region that can bind RNA polymerase in a cell and initiate transcription of a downstream (3' direction) coding sequence. For purposes of defining the present invention, a promoter sequence is extended upstream (5' direction) so that its 3' end is bound to a transcription initiation site and includes the minimum number of bases or elements necessary to initiate transcription at a level detectable above background. Within the promoter sequence, a transcription initiation site is found, as well as a protein binding domain responsible for binding RNA polymerase. Eukaryotic promoters often, but not always, contain "TATA" and "CAT" boxes. Various promoters may be used to drive the various vectors of the present invention. For example, the promoter may be a constitutively active promoter, i.e., a promoter that is active in the absence of an externally applied agent, such as a CMV IE1 promoter, a SV40 promoter, a GAPDH promoter, an actin promoter. The promoter may be an inducible promoter, i.e., a promoter whose activity is modulated when an agent such as doxycycline is applied to the cell, a tet-on or tet-off promoter, an estrogen receptor promoter, etc. The promoter may be a tissue-specific promoter, ie, a promoter that is active on a particular type of cell.

[0134] In some embodiments, the promoter is active in excitable cells. "Excitable cells" refers to cells that are activated by changes in membrane potential, such as neurons or muscle cells, such as dorsal root ganglion neurons, motor neurons, excitatory neurons, inhibitory neurons, or sensory neurons. Promoters active in excitable cells that can be used in the polynucleotide compositions of the present invention include neuronal promoters, such as synapsin (SYN), TRPV1, Na v 1.7, Na v 1.8, Na v1.9, CamKII, NSE, and advillin promoters, muscle cell promoters such as desmin (Des), α-myosin heavy chain (α-MHC), myosin light chain 2 (MLC-2), and cardiac troponin C (cTnC) promoters, and ubiquitous acting promoters such as CAG, CBA, E1Fa, Ubc, CMV, and SV40 promoters.

[0135] As used herein, a "regulatory element for inducible expression" refers to a polynucleotide sequence that is a promoter, enhancer, or functional fragment thereof, operably linked to a polynucleotide to be expressed and that responds to the presence or absence of a molecule that binds to the element to increase (on) or decrease (off) expression of the operably linked polynucleotide. Exemplary regulatory elements for inducible expression include, but are not limited to, tetracycline-responsive promoters, ecdysone-responsive promoters, cumate-responsive promoters, glucocorticoid-responsive promoters, estrogen-responsive promoters, RU-486-responsive promoters, PPAR-gamma promoters, and peroxide-inducible promoters.

[0136] "Regulatory elements for transient expression" refers to polynucleotide sequences that can be used to briefly or temporarily express a polynucleotide sequence. In certain embodiments, one or more regulatory elements for transient expression can be used to limit the duration of a polynucleotide. In certain embodiments, the preferred duration of polynucleotide expression is on the order of minutes, hours, or days. Exemplary regulatory elements for transient expression include, but are not limited to, nuclease target sites, recombinase recognition sites, and and inhibitory RNA target sites. In addition, to some extent, in certain embodiments, regulatory elements for inducible expression may also contribute to controlling the duration of polynucleotide expression.

[0137] As used herein, the terms "polynucleotide variant" and "variant" and the like refer to a polynucleotide that exhibits substantial sequence identity with a reference polynucleotide sequence or polynucleotide that hybridizes with a reference sequence under stringent conditions as defined below.These terms also encompass polynucleotides that are differentiated from a reference polynucleotide by the addition, deletion, substitution, or modification of at least one nucleotide.Thus, the terms "polynucleotide variant" and "variant" include polynucleotides in which one or more nucleotides are added or deleted, or modified, or replaced with different nucleotides.In this regard, it is well understood in the art that certain changes, including mutations, additions, deletions, and substitutions, can be made to a reference polynucleotide such that the altered polynucleotide retains the biological function or activity of the reference polynucleotide. In certain embodiments, a polynucleotide or variant has at least or about 50%, 55%, 60%, 65%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to a reference sequence described herein or known in the art, and typically the variant retains at least one biological activity of the reference sequence, unless otherwise specified.

[0138] In one embodiment, the polynucleotide comprises a nucleotide sequence that hybridizes to a target nucleic acid sequence under stringent conditions. Hybridization under "stringent conditions" describes a hybridization protocol in which nucleotide sequences that are at least 60% identical to each other remain hybridized. In general, stringent conditions are selected to be about 5°C lower than the thermal melting point (Tm) of a particular sequence at a defined ionic strength and pH. Tm is the temperature (under defined ionic strength, pH and nucleic acid concentration) at which 50% of the probes that are complementary to the target sequence hybridize to the target sequence at equilibrium. Target sequences are generally present in excess, so that at Tm, 50% of the probes are at equilibrium.

[0139] As used herein, "sequence identity" or a recitation including, for example, "a sequence 50% identical to" refers to the degree to which sequences are identical nucleotide-by-nucleotide or amino acid-by-amino acid over a comparison window. Thus, "percentage of sequence identity" may be calculated by comparing two optimally aligned sequences over a comparison window, determining the number of positions at which identical nucleic acid bases (e.g., A, T, C, G, I) or identical amino acid residues (e.g., Ala, Pro, Ser, Thr, Gly, Val, Leu, Ile, Phe, Tyr, Trp, Lys, Arg, His, Asp, Glu, Asn, Gln, Cys and Met) are present in both sequences, calculating the number of matched positions, dividing the number of matched positions by the total number of positions in the comparison window (i.e., the window size), and multiplying the result by 100 to obtain the percentage of sequence identity. Terms used to describe sequence relationships between two or more polynucleotides or polypeptides include "reference sequence," "comparison window," "sequence identity," "percentage of sequence identity," and "substantial identity." A "reference sequence" is at least 12, often 15-18, and often at least 25, monomeric units in length, including nucleotides and amino acid residues. Because two polynucleotides may each contain (1) sequences that are similar between the two polynucleotides (i.e., only a portion of the complete polynucleotide sequence), and (2) sequences that are dispersed between the two polynucleotides, sequence comparison between two (or more) polynucleotides typically involves a 2-fold comparison. This is done by comparing the sequences of two polynucleotides over a "comparison window" to identify and compare local regions of sequence similarity. A "comparison window" refers to a conceptual segment of at least six contiguous positions, usually about 50 to about 100, more usually about 100 to about 150, in which a sequence is compared to a reference sequence at the same number of contiguous positions after the two sequences have been optimally aligned. The comparison window may contain no more than about 20% additions or deletions (i.e., gaps) compared to the reference sequence (which does not contain additions or deletions) for optimal alignment of the two sequences. Optimal alignment of sequences to align the comparison window may be performed by computer implementations of algorithms (GAP, BESTFIT, FASTA, and TFASTA from the Wisconsin Genetics Software Package Release 7.0, Genetics Computer Group, 575 Science Drive Madison, WI, USA) or by inspection and best alignment (i.e., resulting in the highest percentage of homology over the comparison window) generated by any of a variety of selected methods. Reference is made, for example, to the BLAST family of programs as disclosed by Altschul et al., 1997, Nucl. Acids Res. 25: 3389. A detailed discussion of sequence analysis can be found in Ausubel et al., Current Protocols in Molecular Biology, John Wiley & Sons Inc, 1994-1998, Chapter 15, Unit 19.3.

[0140] As used herein, an "isolated polynucleotide" refers to a polynucleotide that has been purified from sequences that flank it in its naturally occurring state, e.g., a DNA fragment that has been removed from sequences that normally flank the fragment. In certain embodiments, an "isolated polynucleotide" refers to a complementary DNA (cDNA), recombinant DNA, or other polynucleotide that does not occur in nature and has been created artificially.

[0141] Terms describing the orientation of a polynucleotide include 5' (usually the end of a polynucleotide having a free phosphate group) and 3' (usually the end of a polynucleotide having a free hydroxyl (OH) group). A polynucleotide sequence can be annotated in a 5' to 3' or 3' to 5' direction. For DNA and mRNA, the 5' to 3' strand is designated the "sense", "plus", or "coding" strand because its sequence is identical to that of the pre-messenger (pre-RNA) [except for uracil (U) in RNA instead of thymine (T) in DNA]. For DNA and mRNA, the complementary 3' to 5' strand, which is the strand transcribed by RNA polymerase, is designated as the "template", "antisense", "minus", or "non-coding" strand. As used herein, the term "reverse" refers to a 5' to 3' sequence written in a 3' to 5' direction or a 3' to 5' sequence written in a 5' to 3' direction.

[0142] The term "flanking" refers to a polynucleotide sequence that is between an upstream polynucleotide sequence and / or a downstream polynucleotide sequence, i.e., 5' and / or 3' to a sequence. For example, a sequence that is "flanking" two other elements (e.g., ITRs) indicates that one element is located 5' to the sequence and the other element is located 3' to the sequence, although there may be an intervening sequence between them.

[0143] The terms "complementary" and "complementarity" refer to polynucleotides (i.e., a series of nucleotides) related by the base-pairing rules. For example, the complementary strand of the DNA sequence 5'AGTCATG3' is 3'TCAGTAC5'. The latter sequence is often written as the reverse complement, 5'CATGACT3', with the 5' end on the left and the 3' end on the right. A sequence equal to its reverse complement is said to be a palindrome. Complementarity may be "partial," where only some of the bases of the nucleic acids are matched according to the base-pairing rules, or there may be a "perfect" complementarity between the nucleic acids. There can be "single" or "general" complementarity.

[0144] The term "nucleic acid cassette" or "expression cassette" as used herein refers to a polynucleotide sequence within a larger polynucleotide, such as a vector, sufficient to express one or more RNAs from a polynucleotide. The expressed RNA may be translated into a protein or may function as a guide RNA or an inhibitory RNA to target other polynucleotide sequences for cleavage and / or degradation. In one embodiment, the nucleic acid cassette contains one or more polynucleotide(s) of interest. In another embodiment, the nucleic acid cassette contains one or more expression control sequences operably linked to one or more polynucleotide(s) of interest. The polynucleotide includes the polynucleotide(s) of interest. As used herein, the term "polynucleotide of interest" refers to a polynucleotide that encodes a polypeptide or fusion polypeptide, or a polynucleotide that serves as a template for transcription of an inhibitory polynucleotide, such as LGIC, and its subunits and mutant proteins, as contemplated herein. In certain embodiments, the polynucleotide of interest encodes a polypeptide or fusion polypeptide having one or more enzymatic activities, such as nuclease activity and / or chromatin remodeling or epigenetic modification activity.

[0145] The vector may contain 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 or more nucleic acid cassettes. In a preferred embodiment of the present disclosure, the nucleic acid cassette comprises one or more expression control sequences (e.g., promoters or enhancers operable in neuronal cells) operably linked to a polynucleotide encoding an engineered receptor, e.g., LGIC, or a subunit or mutant protein thereof. The cassette can be removed from or inserted into another polynucleotide sequence, e.g., a plasmid or viral vector, as a single unit.

[0146] In one embodiment, a polynucleotide contemplated herein comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, or more nucleic acid cassettes, any number or combination of which may be in the same or opposite orientation.

[0147] Furthermore, as a result of the degeneracy of the genetic code, those skilled in the art will understand that there are many nucleotide sequences that can code for a polypeptide, or fragments of variants thereof, as contemplated herein. Some of these polynucleotides have minimal homology with the nucleotide sequence of any native gene. Nevertheless, polynucleotides that vary due to differences in codon usage are specifically contemplated by the present disclosure, including, for example, polynucleotides that are optimized for human and / or primate codon selection. In one embodiment, a polynucleotide is provided that comprises a specific allele sequence. An allele is an endogenous polynucleotide sequence that varies as a result of one or more mutations, such as deletion, addition, and / or substitution of nucleotides.

[0148] F. Vector In some aspects of the disclosure, a nucleic acid molecule, i.e., a polynucleotide encoding an engineered receptor, is delivered to a subject. In some cases, the nucleic acid molecule encoding an engineered receptor is delivered to a subject by a vector. In various embodiments, the vector comprises one or more polynucleotide sequences contemplated herein. The term "vector" is used herein to refer to a nucleic acid molecule capable of transcribing or transporting another nucleic acid molecule. The transcribed polynucleotide is generally linked, e.g., inserted, into a vector nucleic acid molecule. The vector may contain sequences directing autonomous replication within a cell or may contain sequences sufficient to allow integration into a host cell DNA. The vector can deliver a target polynucleotide to an organism, cell, or cellular component. In some cases, the vector may be capable of delivering a target polynucleotide to a target cell, cell, or cellular component. In some cases, the vector is an expression vector. As used herein, "expression vector" refers to a vector, such as a plasmid, that can promote the expression and replication of a polynucleotide incorporated therein. Typically, the nucleic acid sequence to be expressed is operably linked to a cis-acting regulatory sequence, such as a promoter and / or enhancer sequence, and is subject to transcriptional regulatory control by the promoter and / or enhancer. In certain cases, the vector is used to deliver the nucleic acid molecule encoding the engineered receptor of the present disclosure to a subject.

[0149] In certain embodiments, any vector suitable for introducing an expression cassette or polynucleotide encoding an engineered receptor into a neuronal cell can be used. Illustrative examples of suitable vectors include plasmids (e.g., DNA or RNA plasmids), transposons, cosmids, bacterial artificial chromosomes, and viral vectors. In some cases, the vector is a circular nucleic acid, e.g., a plasmid, BAC, PAC, YAC, cosmid, fosmid, etc. In some cases, a circular nucleic acid molecule can be utilized to deliver a nucleic acid molecule encoding an engineered receptor to a subject. For example, a plasmid DNA molecule encoding an engineered receptor can be introduced into a cell of a subject, whereby the DNA sequence encoding the engineered receptor is transcribed into mRNA, and the "message" of the mRNA is translated into a protein product. A circular nucleic acid vector generally includes regulatory elements that regulate the expression of a target protein. For example, a circular nucleic acid vector may include any number of promoters, enhancers, terminators, splice signals, origins of replication, initiation signals, etc.

[0150] In some cases, the vector can contain a replicon. The replicon can be any nucleic acid molecule capable of self-replication. In some cases, the replicon is an RNA replicon derived from a virus. A variety of suitable viruses (e.g., RNA viruses) are available, including but not limited to alphavirus, picornavirus, flavivirus, coronavirus, pestivirus, rubivirus, calcivirus, and hepacivirus.

[0151] In some embodiments, the vector is a non-viral vector. By "non-viral vector" is meant any delivery vehicle that does not contain a viral capsid or envelope, such as lipid nanoparticles (anionic (negatively charged), neutral or cationic (positively charged)), heavy metal nanoparticles, polymer-based particles, plasmid DNA, minicircle DNA, minivector DNA, ccDNA, synthetic RNA, exosomes, etc. Non-viral vectors can be delivered by any suitable method well understood in the art, including, for example, nanoparticle delivery, biolistics, electroporation, sonication, or microinjection. See, for example, Chen et al., Mol. Therapy, Methods and Clinical Development. 2016 Jan; Vol 3, issue 1; and Hardy, CE et al., Genes (Basel). 2017 Feb; 8(2): 65.

[0152] In other embodiments, the vector is a viral vector. "Viral vector" refers to a delivery vehicle that includes a viral capsid or envelope surrounding a polynucleotide encoding an RNA or polypeptide of interest. In some cases, the viral vector is derived from a replication-defective virus. Non-limiting examples of viral vectors suitable for delivering the nucleic acid molecules of the present disclosure to a subject include those derived from adenovirus, retrovirus (e.g., lentivirus), adeno-associated virus (AAV), and herpes simplex-1 (HSV-1). Illustrative examples of suitable viral vectors include, but are not limited to, retroviral vectors (e.g., lentiviral vectors), herpes virus-based vectors, and parvovirus-based vectors (e.g., adeno-associated virus, These include AAV-based vectors, AAV-adenovirus chimeric vectors, and adenovirus-based vectors.

[0153] The term "parvovirus" as used herein encompasses all parvoviruses, including autonomously replicating parvoviruses and dependoviruses. Autonomous parvoviruses include members of the Parvovirus, Erythrovirus, Densovirus, Iteravirus, and Contravirus genera. Exemplary autonomous parvoviruses include, but are not limited to, minute virus of mice, bovine parvovirus, canine parvovirus, avian parvovirus, feline panleukopenia virus, feline parvovirus, goose parvovirus, and B19 virus. Other autonomous parvoviruses are known to those skilled in the art. See, for example, Fields et al., 1996 Virology, volume 2, chapter 69 (3d ed., Lippincott-Raven Publishers).

[0154] The Dependovirus genus includes adeno-associated viruses (AAV), including, but not limited to, AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAVrhlO, avian AAV, bovine AAV, canine AAV, equine AAV, and ovine AAV.

[0155] In a preferred embodiment, the vector is an AAV vector. In certain cases, the viral vector is an AAV-6 or AAV-9 vector.

[0156] The genomic organization of all known AAV serotypes is similar. The genome of AAV is a linear, single-stranded DNA molecule less than approximately 5,000 nucleotides (nt) in length. Inverted terminal repeats (ITRs) flank unique coding nucleotide sequences for nonstructural replication (Rep) and structural (VP) proteins. The VP proteins (VP1, -2 and -3) form the capsid and contribute to the tropism of the virus. The terminal 145 nt ITRs are self-complementary and organized such that energetically stable intramolecular duplexes forming T-shaped hairpins can form. These hairpin structures serve as origins of viral DNA replication and as primers for the cellular DNA polymerase complex. Following wild-type (wt) AAV infection in mammalian cells, the Rep genes are expressed and function in the replication of the viral genome.

[0157] In some cases, the outer protein "capsid" of the viral vector is naturally occurring, e.g., AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, or AAV10. In certain cases, the capsid is synthetically engineered (e.g., through directed evolution or rational design) to have certain unique characteristics that do not exist in nature, such as altered tropism, increased transduction efficiency, or immune evasion. An example of a rationally designed capsid is the mutation of one or more surface-exposed tyrosine (Y), serine (S), threonine (T), and lysine (K) residues on the VP3 viral capsid protein. Non-limiting examples of viral vectors in which the VP3 capsid protein has been synthetically engineered and can be used with the compositions and methods provided herein include AAV1 (Y705+731F+T492V), AAV2 (Y444+500+730F+T491V), AAV3 (Y705+731F), AAV5 (Y436+693+719F), AAV6 (Y705+731F+T492V), AAV8 (Y733F), AAV9 (Y731F), and AAV10 (Y733F). Non-limiting examples of viral vectors engineered through directed evolution that can be used with the compositions and methods provided herein include AAV-7m8 and AAV-ShH10.

[0158] A "recombinant parvovirus or AAV vector" (or "rAAV vector") herein refers to a vector comprising one or more polynucleotides contemplated herein flanked by one or more AAVITRs. Such polynucleotides are said to be "heterologous" to the ITRs because the combination does not normally occur in nature. Such rAAV vectors can replicate and package into infectious viral particles when present in an insect host cell expressing the AAVrep and Cap gene products (i.e., AAVRep and Cap proteins). When rAAV vectors are incorporated into a larger nucleic acid construct (e.g., in a chromosome or in another vector such as a plasmid or baculovirus used for cloning or transfection), they are typically referred to as "pro-vectors" that can be "rescued" by replication and packaging in the presence of AAV packaging functions and necessary helper functions.

[0159] In certain embodiments, any AAV ITR may be used in the AAV vector, including ITRs from AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV10, AAV11, AAV12, AAV13, AAV14, AAV15, and AAV 16. In a preferred embodiment, the AAV vectors contemplated herein include one or more AAV2 ITRs.

[0160] A rAAV vector that contains two ITRs has a payload capacity of about 4.4 kB. A self-complementary rAAV vector contains a third ITR and packages the two strands of the recombinant portion of the vector, leaving only about 2.1 kB for the polynucleotide contemplated herein. In one embodiment, the AAV vector is a scAAV vector.

[0161] Using a double rAAV vector strategy, an expanded packaging capacity of approximately twice that of rAAV (approximately 9 kB) has been achieved. The double vector strategies useful for producing rAAV contemplated herein include, but are not limited to, splicing (trans-splicing), homologous recombination (overlap), or a combination of the two (hybrid). In the double AAV trans-splicing strategy, a splice donor (SD) signal is placed at the 3' end of the 5' half vector, and a splice acceptor (SA) signal is placed at the 5' end of the 3' half vector. By coinfection of the same cell with the double AAV vector and inverted terminal repeat (ITR)-mediated head-to-tail concatemerization of the two halves, trans-splicing leads to the production of mature mRNA and full-size protein (Yan et al., 2000). Trans-splicing has been successfully used to express large genes in muscle and retina (Reich et al., 2003; Lai et al., 2005). Alternatively, the two halves of a large transgene expression cassette contained in a double AAV vector may contain homologous overlapping sequences (double AAV overlap at the 3' end of the 5' half vector and the 5' end of the 3' half vector) that mediate the reconstitution of a single large genome by homologous recombination (Duan et al., 2001). This strategy relies on the recombination properties of the transgene overlapping sequences (Ghosh et al., 2006). The third double AAV strategy (hybrid) is based on adding a highly recombinogenic region from an exogenous gene (i.e., alkaline phosphatase; Ghosh et al., 2008, Ghosh et al., 2011) to a trans-splicing vector. The added region is placed downstream of the SD signal of the 5' half vector and upstream of the SA signal of the 3' half vector to increase recombination between the double AAVs.

[0162] "Hybrid AAV" or "hybrid rAAV" refers to a rAAV genome packaged with a capsid of a different AAV serotype (and preferably with one or more AAV ITRs of a different serotype), which may otherwise be referred to as a pseudotyped rAAV. For example, rAAV1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108 A genome of type 1, 12, 13, 14, 15, or 16 may be encapsulated within an AAV type 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, or 16 capsid or variants thereof. In certain embodiments, pseudotyped rAAV particles may be referred to as "x / y" type, where "x" indicates the source of the ITRs and "y" indicates the serotype of the capsid, e.g., a 2 / 5 rAAV particle has ITRs from AAV2 and a capsid from AAV6.

[0163] "Host cells" include cells that have been transfected, infected, or transduced in vivo, ex vivo, or in vitro with a recombinant vector or polynucleotide of the present disclosure. Host cells may include virus-producing cells and cells infected with a viral vector. In certain embodiments, in vivo host cells are infected with a viral vector contemplated herein. In certain embodiments, the term "target cell" is used interchangeably with host cell and refers to an infected cell of a desired cell type.

[0164] High titer AAV preparations can be produced using techniques well known in the art, for example, as described in U.S. Pat. Nos. 5,658,776, 6,566,118, 6,989,264, and 6,995,006, US 2006 / 0188484, WO 98 / 22607, WO 2005 / 072364, and WO / 1999 / 011764, and in Viral Vectors for Gene Therapy: Methods and Protocols, ed. Machida, Humana Press, 2003; Samulski et al., (1989) J. Virology 63, 3822; Xiao et al., (1998) J. Virology 72, 2224; Ilnoue et al., (1998) J. Virol. 72, 7024. Methods for producing pseudotyped AAV vectors have also been reported (e.g., WO 00 / 28004), as well as various modifications or formulations of AAV vectors to reduce their immunogenicity upon in vivo administration (see, e.g., WO 01 / 23001, WO 00 / 73316, WO 04 / 1 12727, WO 05 / 005610, WO 99 / 06562).

[0165] G. Pharmaceutical Compositions Also provided are pharmaceutical preparations, including pharmaceutical preparations of vectors and pharmaceutical preparations of binding agents. The pharmaceutical preparations include the subject polynucleotides (RNA or DNA) encoding the engineered receptors, the vectors carrying the polynucleotides (RNA or DNA) encoding the subject engineered receptors, or the binding agents present in a pharmaceutically acceptable vehicle. A "pharmaceutically acceptable vehicle" can be a vehicle approved by a federal or state regulatory agency for use in mammals, such as humans, or listed in the United States Pharmacopeia or other generally recognized pharmacopoeias. The term "vehicle" refers to a diluent, adjuvant, excipient, or carrier in which the compounds of the present disclosure are formulated for administration to a mammal. Such pharmaceutical vehicles can be liquids, such as water and oils, including those of petroleum, animal, vegetable, or synthetic origin, such as peanut oil, soybean oil, mineral oil, sesame oil, and the like. The pharmaceutical vehicle can be saline, gum acacia, gelatin, starch paste, talc, keratin, colloidal silica, urea, and the like. In addition, auxiliary agents, stabilizers, thickeners, lubricants and coloring agents may be used.When administered to mammals, the compounds and compositions of the present disclosure and pharma-ceutically acceptable vehicles, excipients or diluents can be sterilized.In some cases, when the compounds of the present disclosure are administered intravenously, aqueous media such as water, saline solution, and dextrose and glycerol aqueous solution are used as vehicles.

[0166] The pharmaceutical compositions may be in the form of capsules, tablets, pills, pellets, lozenges, powders, granules, syrups, elixirs, solutions, suspensions, emulsions, suppositories, or sustained release formulations thereof, or for use in mammalian applications. The pharmaceutical composition may take any other form suitable for administration to a subject. In some cases, the pharmaceutical composition is formulated for administration in accordance with routine procedures as a pharmaceutical composition adapted for oral or intravenous administration to humans. Examples of suitable pharmaceutical vehicles and methods for their formulation can be found in Remington: The Science and Practice of Pharmacy, Alfonso R. Gennaro ed., Mack Publishing Co. Easton, Pa., 19th ed., 1995, Chapters 86, 87, 88, 91, and 92, which is incorporated herein by reference.

[0167] The choice of excipient will be determined in part by the particular vector, as well as the particular method used to administer the composition. Accordingly, suitable formulations of pharmaceutical compositions of the present disclosure are widely varied.

[0168] For example, the vectors may be formulated into preparations for injection by dissolving, suspending, or emulsifying them in aqueous or non-aqueous solvents such as vegetable oils or other similar oils, synthetic fatty acid glycerides, esters of higher fatty acids, or propylene glycol, and may be formulated with conventional additives such as solubilizers, isotonic agents, suspending agents, emulsifying agents, stabilizers, and preservatives, as necessary.

[0169] As another example, the vector may be formulated into a preparation suitable for oral administration, which includes (a) a liquid solution, e.g., an effective amount of the compound dissolved in a diluent such as water or saline, (b) capsules, sachets or tablets, each containing a predetermined amount of the active ingredient as a solid or granules, (c) a suspension in a suitable liquid, and (d) a suitable emulsion. Tablet forms may contain one or more of lactose, mannitol, corn starch, potato starch, microcrystalline cellulose, acacia, gelatin, colloidal silicon dioxide, croscarmellose sodium, talc, magnesium stearate, stearic acid, and other excipients, colorants, diluents, buffers, humectants, preservatives, flavoring agents, and pharmacologically compatible excipients. Lozenge forms can include a flavoring, the active ingredient in usually sucrose and acacia or tragacanth, and a pastille containing the active ingredient in an inert base such as gelatin and glycerin, or sucrose and acacia, an emulsion, a gel, etc., containing in addition to the active ingredient excipients as described herein.

[0170] As another example, the formulations of the presently disclosed subject matter can be made into aerosol formulations to be administered via inhalation. These aerosol formulations can be placed into pressurized acceptable propellants, such as dichlorodifluoromethane, propane, nitrogen, etc. They can also be formulated as pharmaceuticals in non-pressurized preparations, such as for use in nebulizers or atomizers.

[0171] In some embodiments, formulations suitable for parenteral administration include aqueous and non-aqueous isotonic sterile injection solutions that may contain antioxidants, buffers, bacteriostatic agents, and solutes that render the formulation isotonic with the blood of the intended recipient, and aqueous and non-aqueous sterile suspensions that may contain suspending agents, solubilizers, thickening agents, stabilizers, and preservatives.The formulations may be provided in unit-dose or multi-dose sealed containers such as ampoules and vials, and may be stored in a frozen and dried (lyophilized) state, requiring only the addition of a sterile liquid excipient for injection, such as water, immediately prior to use.Extemporaneous injection solutions and suspensions may be prepared from sterile powders, granules, and tablets of the type previously described.

[0172] Formulations suitable for topical administration may be provided as creams, gels, pastes, or foams containing, in addition to the active ingredient, suitable carriers, etc. In some embodiments, the topical formulation comprises one selected from a structuring agent, a thickening or gelling agent, and an emollient or lubricant. The above ingredients are included. Frequently used structuring agents include long chain alcohols such as stearyl alcohol, and its glyceryl ethers or esters and oligo(ethylene oxide) ethers or esters. Thickeners and gelling agents include, for example, polymers of acrylic or methacrylic acid and their esters, polyacrylamides, and natural thickeners such as agar, carrageenan, gelatin, and guar gum. Examples of emollients include triglyceride esters, fatty acid esters and amides, waxes such as beeswax, spermaceti, or carnauba wax, phospholipids such as lecithin, and their sterols and fatty acid esters. Topical formulations may further include other ingredients such as astringents, fragrances, pigments, skin penetration enhancers, sunscreens (i.e., sunblocks), and the like.

[0173] The compounds of the present disclosure can be formulated for topical administration. The vehicle for topical application can be one of various forms, for example, lotion, cream, gel, ointment, stick, spray, or paste. They may contain various types of carriers, including but not limited to solution, aerosol, emulsion, gel, and liposome. The carrier may be formulated as an emulsion, for example, with an oil-in-water or water-in-oil base. Suitable hydrophobic (oily) components used in emulsions include, for example, vegetable oils, animal fats and oils, synthetic hydrocarbons, and their esters, including polyesters, and alcohols, and organopolysiloxane oils. Such emulsions also include emulsifiers and / or surfactants, for example, nonionic surfactants, for dispersing and suspending discontinuous phase within continuous phase.

[0174] Suppository formulations may also be provided by mixing with a variety of bases, such as emulsifying bases or water-soluble bases. Formulations suitable for vaginal administration may be provided as pessaries, tampons, creams, gels, pastes, or foams.

[0175] Unit dosage forms for oral or rectal administration, such as syrups, elixirs, and suspensions, may be provided, with each dosage unit, e.g., teaspoon, tablespoon, tablet, or suppository, containing a predetermined amount of the composition containing one or more inhibitors. Similarly, unit dosage forms for injection or intravenous administration may contain the inhibitor(s) in a composition as a solution in sterile water, normal saline, or another pharma- ceutically acceptable carrier.

[0176] The term "unit dosage form" as used herein refers to physically discrete units suitable as unitary dosage forms for human and animal subjects, each unit containing a predetermined amount of the compound of the present disclosure calculated in an amount sufficient to produce the desired effect in association with a pharma- ceutically acceptable diluent, carrier, or vehicle. The specifications for the novel unit dosage forms of the present disclosure depend on the particular compound used and the effect to be achieved, as well as the pharmacodynamics associated with each compound in the host.

[0177] Dosage levels can vary as a function of the particular compound, the nature of the delivery vehicle, etc. The desired dose of a given compound can be readily determined by a variety of means.

[0178] In the context of the present disclosure, the dose administered to an animal, particularly a human, should be sufficient to produce a preventive or therapeutic response in the animal over a reasonable period of time, for example, as described in more detail below. The dose will depend on a variety of factors, including the strength of the particular compound used, the condition of the animal, and the weight of the animal, as well as the severity and stage of the disease. The size of the dose will also be determined by the existence, nature, and extent of any side effects that may accompany the administration of a particular compound.

[0179] In pharmaceutical dosage forms, the ASC inducer compounds may be administered in the form of a free base, a pharma- ceutically acceptable salt thereof, or they may be used alone or in appropriate association with, as well as in combination with, other pharma- ceutically active compounds.

[0180] G. Clinical Applications and Treatment Methods The compositions and methods disclosed herein can be used to treat neurological disease or disorder.In some embodiments of the present disclosure, a method for treating neurological disease or disorder in a subject is provided, which comprises introducing an engineered receptor into neuronal cells, and providing an effective amount of a ligand that activates the engineered receptor to control the activity of the cells, thereby relieving pain in the subject.In some embodiments, the vector or composition disclosed herein is used to manufacture a medicament for treating neurological disease or disorder.

[0181] In some cases, the disclosed methods and compositions are utilized to treat epilepsy. The compositions described herein can be used to prevent or control epileptic seizures. Epileptic seizures can be classified as tonic-thinning, tonic, thinning, myoclonic, absence, or atonic seizures. In some cases, the disclosed compositions and methods can prevent or reduce the number of epileptic seizures experienced by a subject by about 5%, about 10%, about 10%, about 15%, about 20%, about 25%, about 30%, about 35%, about 40%, about 45%, about 50%, about 55%, about 60%, about 65%, about 70%, about 75%, about 80%, about 85%, about 90%, about 95%, about 99% or 100%.

[0182] In some cases, the disclosed method and composition are utilized to treat eating disorders. Eating disorders can be mental disorders defined by abnormal eating behaviors that negatively affect the subject's physical and mental health. In some cases, the eating disorder is anorexia. In other cases, the eating disorder is bulimia. In some cases, the eating disorder is pica, rumination disorder, avoidant / restrictive food intake disorder, binge eating disorder (BED), otherwise specified feeding and feeding disorder (OSFED), compulsive overeating, diabetic eating disorder (diabulimia), orthorexia, selective eating disorder, alcoholism-related anorexia (drunkorexia), pregnancy eating disorder (pregorexia), or bulimia-grumand syndrome. In some cases, the composition comprises a G protein-coupled receptor that increases or decreases the production of one or more molecules associated with eating disorders. In other cases, the composition comprises a ligand-gated ion channel that changes the production of one or more molecules associated with eating disorders. The one or more molecules associated with eating disorders may include, but are not limited to, molecules of the hypothalamic-pituitary-adrenal (HPA) axis, including vasopressin, corticotropin releasing hormone (CRH), adrenocorticotropic hormone (ACTH), cortisol, epinephrine, or norepinephrine, as well as serotonin, dopamine, neuropeptide Y, leptin, or ghrelin.

[0183] In some cases, the compositions and methods are utilized to treat post-traumatic stress disorder (PTSD), gastroesophageal reflux disease (GERD), addiction (e.g., alcohol, drugs), anxiety, depression, memory loss, dementia, sleep apnea, stroke, urinary incontinence, narcolepsy, essential tremor, movement disorders, atrial fibrillation, cancer (e.g., brain tumors), Parkinson's disease, or Alzheimer's disease. Other non-limiting examples of neurological diseases or disorders that may be treated by the compositions and methods herein include: abulia, agraphia, alcoholism, dyslexia, aneurysm, amaurosis fugax, memory loss, amyotrophic lateral sclerosis (ALS), Angelman syndrome, aphasia, apraxia, arachnoiditis, Arnold-Chiari malformation, Asperger's syndrome, ataxia, ataxia-telangiectasia, attention deficit hyperactivity disorder, auditory perceptual disorders, autism spectrum, bipolar disorder, facial paralysis, brachial plexus injury, brain injury, brain injury, brain tumor, Canavan disease, Capgras syndrome, carpal tunnel syndrome, causalgia, central pain syndrome, central pontine myelinolysis, centronuclear myopathy, cephalic disorders, cerebral aneurysm, cerebral arteriosclerosis, cerebral atrophy, autosomal dominant cerebral arteriopathy with subcortical infarction and leukoencephalopathy (CADASIL), cerebral gigantism, cerebral palsy, cerebral vasculitis, cervical spinal stenosis, Charcot-Marie-Tooth disease, Chiari malformation, Correa, chronic fatigue syndrome, chronic inflammatory demyelinating polyneuropathy (CIDP), chronic pain, Coffin-Marie-Tooth disease, Lowry syndrome, coma, complex regional pain syndrome, compressive neuropathy, congenital ophthalmoplegia, corticobasal degeneration, cranial arteritis, craniosynostosis, Creutzfeldt-Jakob disease, cumulative trauma disorder, Cushing's syndrome, cyclothymic disorder, cytomegalic inclusion body disease (CIBD), cytomegalovirus infection, Dandy-Walker syndrome, Dawson's disease, Domorsia syndrome, Dejerine-Klumpke palsy, Dejerine-Sottas disease, delayed sleep phase syndrome, dementia, dermatomyositis, developmental coordination disorder, diabetic neuropathy, diffuse sclerosis, diplopia, Down's syndrome, Dravet syndrome, Duchenne syndrome, Chenne muscular dystrophy, dysarthria, autonomic imbalance, dyscalculia, dysgraphia, dyskinesia, dyslexia, dystonia, empty sella syndrome, encephalitis, brain herniation, trigeminal nerve region hemangioma, encopresis, nocturnal enuresis, epilepsy, intellectual disability in women, Erb's palsy, erythromelalgia, exploding head syndrome, Fabry disease, Fahr's syndrome, syncope, familial spastic paraplegia, febrile convulsions, Fisher syndrome, Friedreich's ataxia, fibromyalgia, Fauville syndrome, fetal alcohol syndrome, fragile X syndrome, fragile X-associated tremor ataxia syndrome (FXTAS), Gaucher disease, generalized seizures Febrile convulsions plus, Gerstmann's syndrome, giant cell arteritis, giant cell inclusion body disease, globoid cell leukodystrophy, ectopic grey matter, Guillain-Barré syndrome, generalized anxiety disorder, HTLV-1-associated myelopathy, Hallervorden-Spatz syndrome, head injury, headache, hemifacial spasm, hereditary spastic paraplegia, polyneuropathy-type hereditary ataxia, herpes zoster oticus, herpes zoster, Hirayama syndrome, Hirschsprung's disease, Holmes-Adie syndrome, holoprosencephaly, Huntington's disease, hydrocephalus, hydrocephalus, hypercortisolism, hypoxia, immune-mediated encephalomyelitis, inclusion body myositis, achromatopsia Tone syndrome, infantile Refsum's disease, infantile spasms, inflammatory myopathy, intracranial cysts, intracranial hypertension, isodicentric 15, Joubert syndrome, Karak syndrome, Cairns-Sayre syndrome, Kinsbourne syndrome, Kleine-Lewin syndrome, Klippel-Feil syndrome, Krabbe disease, Lafora disease, Lambert-Eaton myasthenic syndrome, Landau-Kleffner syndrome, lateral medullary (Wallenberg) syndrome, learning disabilities, Leigh's disease, Lennox-Gastaut syndrome, Lesch-Nyhan syndrome, leukodystrophies, leukoencephalopathy with loss of white matter,Dementia with Lewy bodies, Agliosis, Locked-in syndrome, Lumbar discopathy, Lumbar spinal stenosis, Lyme disease - neurological sequelae, Machado-Joseph disease (Spinocerebellar ataxia type 3), Megaencephalopathy, Macropsia, Mal de debarquement, Macrocephalic leukoencephalopathy with subcortical cysts, Megaencephaly, Melkersson-Rosenthal syndrome, Meniere's disease, Meningitis, Menkes disease, Metachromatic leukodystrophy, Microcephaly, Micropsia, Migraine, Miller-Fisher syndrome, Petit mal (transient ischemic attack), Misophonia, Mitochondrial myopathy, Moebius syndrome, Unilateral upper limb muscular atrophy, Motor skills disorder, Moyamoya disease, Mucopolysaccharidosis, Multiple infarct dementia, Multifocal motor neuropathy, Multiple sclerosis, Multiple system atrophy, Muscular dystrophy, Myalgia encephalomyelitis, myasthenia gravis, myelin destructive diffuse sclerosis, myoclonus encephalopathy of infancy, myoclonus, myopathy, myotubular myopathy, congenital myotonia, narcolepsy, neuro-Behçet's disease, neurofibromatosis, neuroleptic malignant syndrome, neurological symptoms of AIDS, neurological sequelae of lupus, neurogenic myotonia, neuronal ceroid lipofuscinosis, neuronal migration disorder, neuropathy, neurosis, Niemann-Pick disease, non-24-hour sleep-wake disorder, nonverbal learning disorder, O'Sullivan-McLeod syndrome, occipital neuralgia, Sequelae of latent spinal neural tube defects, Ohtahara syndrome, olivopontocerebellar atrophy, opsoclonus-myoclonus ataxia, optic neuritis, orthostatic hypotension, otosclerosis, overuse syndrome, recurrent vision, abnormal sensations, Parkinson's disease, congenital paramyotonia, paraneoplastic disease, paroxysmal seizures, Parry-Romberg syndrome, PANDAS, Pelizaeus-Merzbacher disease, periodic paralysis, peripheral neuropathy, pervasive developmental disorder, photophotic sneeze reflex, phytanic acid storage disease, Pick's disease, shortened nerves, pituitary tumors, PMG, polyneuropathy, polio, Polymicrogyria, polymyositis, porosis, post-polio syndrome, post-herpetic neuralgia (PHN), postural hypotension, Prader-Willi syndrome, primary lateral sclerosis, prion disease, progressive facial hemimetrophy, progressive multifocal leukoencephalopathy, progressive supranuclear palsy, prosopagnosia, pseudotumor cerebri, quadrantal blindness, quadriplegia, rabies, radicular paralysis, Ramsay Hunt syndrome type 1, Ramsay Hunt syndrome type 2, Ramsay Hunt syndrome type 3, Rasmussen's encephalitis, reflex neurovascular dystrophy, Refsum's disease, REM sleep behavior disorder, repetitive stress injury, immobile legs, ataxia, retrovirus-associated myelopathy, Rett syndrome, Reier syndrome, rhythmic movement disorder, Romberg syndrome, chorea, Sandhoff disease, Schilder's disease, schizencephaly, sensory processing disorder, septo-optic dysplasia, shaken baby syndrome, shingles, Shy-Drager syndrome, Sjogren's syndrome, sleep apnea, sleeping sickness, sneezing after meals, Sotos syndrome, spasticity, vertebral rupture, spinal cord injury, spinal cord tumor, spinal muscular atrophy, spinal-bulbar muscular atrophy, spinocerebellar ataxia, split encephalopathy, Steele-Richardson-Olszewski syndrome, stiff-headed syndrome, seizures, Sturge-Weber syndrome, stuttering, subacute sclerosing panencephalitis, subcortical arteriosclerotic encephalopathy, superficial siderosis, Sydenham chorea disease, syncope, synesthesia, syringomyelia, tarsal tunnel syndrome, tardive dyskinesia, tardive dysphrenia, Tarlov cyst, Tisachs disease, temporal arteritis, temporal lobe epilepsy, tetanus, tethered cord syndrome, Thomsen's disease, thoracic outlet syndrome, trigeminal neuralgia, Todd's palsy, Tourette's syndrome, toxic encephalopathy, transient ischemic attack, transmissible spongiform encephalopathy, transverse myelitis, traumatic brain injury, tremor, trichotillomania, trigeminal neuralgia, tropical spastic paraparesis, trypanosomiasis, tuberous sclerosis, Unverricht-Lundborg disease, von Hippel-Lindau disease (VHL), Vilius encephalomyelitis (VE), Wallenberg complex, West syndrome, whiplash, Williams syndrome, Wilson's disease, or Zellweger syndrome.

[0184] In some cases, the compositions and methods disclosed herein can be used to treat brain cancer or brain tumors. Non-limiting examples of brain cancer or brain tumors that can be treated using the vectors and compositions described herein include gliomas, including malignant astrocytoma (grade III glioma), astrocytoma (grade II glioma), brain stem glioma, ependymoma, ganglioglioma, ganglioneuroma, glioblastoma (grade IV glioma), glioma, juvenile pilocytic astrocytoma (JPA), low grade astrocytoma (LGA), medulloblastoma, mixed glioma, oligodendroglioma, optic nerve glioma, pilocytic astrocytoma (grade I glioma), and primitive neuroectodermal (PNET). tumors of the skull base, including acoustic neuroma (vestibular schwannoma), acromegaly, adenoma, chondrosarcoma, chordoma, craniopharyngioma, epidermoid tumor, jugular body tumor, infratentorial meningioma, meningioma, pituitary adenoma, pituitary tumor, Rathke's cleft cyst; metastatic carcinomas, including brain metastases, metastatic brain tumors; other brain tumors, including brain cyst, choroid plexus papilloma, CNS lymphoma, colloid cyst, cystic tumor, dermoid tumor, germinoma, lymphoma, nasal carcinoma, nasopharyngeal tumor, pineal gland tumor, pineoblastoma, pineocytoma, supratentorial meningioma, and vascular tumors; tumors of the spinal cord, including astrocytoma, ependymoma, meningioma, and schwannoma.

[0185] The present disclosure contemplates, in part, compositions and methods for controlling, managing, preventing, or treating pain in a subject. "Pain" refers to discomfort and / or unpleasant sensations in a subject's body. Pain sensations can range from mild and occasional to severe and constant. Pain can be classified as acute pain or chronic pain. Pain can be sensory pain (i.e., pain caused by tissue damage), neuropathic pain, or psychological pain. In some cases, pain is caused by or associated with disease (e.g., cancer, arthritis, diabetes). In other cases, pain is caused by injury (e.g., sports injury, trauma). Non-limiting examples of pain suitable for treatment with the compositions and methods herein include neuropathic pain including peripheral neuropathy, diabetic neuropathy, post-herpetic neuralgia, trigeminal neuralgia, lower back pain, cancer-associated neuropathy, HIV / AIDS-associated neuropathy, phantom limb pain, brachial tunnel syndrome, central post-stroke pain, chronic alcoholism-associated pain, hypothyroidism, uremia, multiple sclerosis-associated pain, spinal cord injury-associated pain, Parkinson's disease-associated pain, epilepsy, osteoarthritis pain, rheumatoid arthritis pain, visceral pain, and vitamin deficiency-associated pain, as well as sensory pain including pain associated with central nervous system trauma, strains / sprains, and burns, myocardial infarction, acute pancreatitis, post-operative pain, renal pain, cancer-associated arthritis pain, fibromyalgia-associated pain, and lower back pain.

[0186] The compositions and methods herein can be utilized to improve the pain level of a subject. In some cases, the pain level of a subject is improved by at least 5%, at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99% or 100%. The pain level in a subject can be assessed by various methods. In some cases, the pain level is assessed by self-report (i.e., a human subject verbally reports the level of pain they are experiencing). In some cases, the pain level is assessed by behavioral indicators of pain, such as facial expressions, limb movements, vocalizations, restlessness, and alert behavior. These types of assessments can be useful, for example, when a subject is unable to self-report (e.g., infants, unconscious subjects, non-human subjects). The level of pain can be assessed after treatment with a composition of the present disclosure compared to the level of pain the subject was experiencing prior to treatment with the composition.

[0187] In various embodiments, a method for controlling, managing, preventing, or treating pain in a subject comprises administering to the subject an effective amount of an engineered receptor contemplated herein. Without wishing to be bound by any particular theory, the present disclosure contemplates using the vectors disclosed herein to modulate neuronal activity to alleviate pain in a subject.

[0188] In various embodiments, a vector encoding an engineered receptor that activates or depolarizes a neuronal cell is administered to (or introduced into) one or more neuronal cells, e.g., inhibitory interneurons, that reduce pain sensation. In the presence of a ligand, neurons expressing the engineered receptor are activated, reducing sensitivity to pain enhancing the analgesic effect of stimulating these neuronal cells.

[0189] In various embodiments, a vector encoding an engineered receptor that inactivates or hyperpolarizes a neuronal cell is administered to (or introduced into) one or more neuronal cells that increase pain sensation or sensitivity to pain, e.g., nociceptors, peripheral sensory neurons, C fibers, Aδ fibers, Aβ fibers, DRG neurons, TGG neurons, etc. In the presence of the ligand, neurons expressing the engineered receptor are inactivated, decreasing sensitivity to pain and enhancing the analgesic effect.

[0190] Targeting expression of engineered receptors to subpopulations of nociceptors can be accomplished by one or more of the following: choice of vector (e.g., AAV1, AAV1(Y705+731F+T492V), AAV2(Y444+500+730F+T491V), AAV3(Y705+731F), AAV5, AAV5(Y436+693+719F), AAV6, AAV6(VP3 variant Y705F / Y731F / T492V), AAV-7m8, AAV8, AAV8(Y733F), AAV9, AAV9(VP3 variant Y731F), AAV10(Y733F), and AAV-ShH10), choice of promoter, and delivery means.

[0191] In certain embodiments, the compositions and methods contemplated herein are effective in alleviating pain. Illustrative examples of pain suitable for treatment with the vectors, compositions, and methods contemplated herein include acute pain, chronic pain, neuropathic pain, nociceptive pain, allodynia, inflammatory pain, inflammatory hyperalgesia, neuropathy, neuralgia, diabetic neuropathy, human immunodeficiency virus-associated neuropathy, nerve injury, rheumatoid arthritis pain, osteoarthritis pain, burns, back pain, eye pain, visceral pain, cancer pain (e.g., bone cancer pain), dental pain, headache, migraine, carpal tunnel syndrome, fibromyalgia, neuritis, sciatica, pelvic hypersensitivity, pelvic pain, post-herpetic neuralgia, post-operative pain. These include, but are not limited to, abdominal pain, post-stroke pain, and menstrual pain.

[0192] Pain can be classified as acute or chronic. "Acute pain" refers to pain that begins suddenly and is usually sharp in quality. Acute pain can be mild and last just a moment or intense and last for weeks or months. In most cases, acute pain does not last more than three months and disappears once the underlying cause of the pain is treated or cured. However, unrelieved acute pain can lead to chronic pain. "Chronic pain" refers to ongoing or recurrent pain that lasts beyond the usual course of an acute illness or injury or lasts for more than three to six months, adversely affecting the health of the individual. In certain embodiments, the term "chronic pain" refers to pain that continues when it should not. Chronic pain can be nociceptive pain or neuropathic pain.

[0193] In certain embodiments, the compositions and methods contemplated herein are effective in reducing acute pain. In certain embodiments, the compositions and methods contemplated herein are effective in reducing chronic pain.

[0194] Clinical pain is present when the patient's symptoms are characterized by discomfort or abnormal sensitivity. Individuals may present with a variety of pain symptoms. Such symptoms include: 1) spontaneous pain that is dull, burning, or stabbing; 2) an exaggerated pain response to noxious stimuli (hyperalgesia); and 3) pain caused by normally innocuous stimuli (allodynia-Meyer et al., 1994, Textbook of Pain, 13-44). Patients suffering from various forms of acute and chronic pain may have similar symptoms, but the underlying mechanisms may be different, thus necessitating different treatment strategies. Pain may therefore be divided into a number of different subtypes according to different pathophysiology, including nociceptive pain, inflammatory pain, and neuropathic pain.

[0195] In certain embodiments, the compositions and methods contemplated herein are effective in reducing nociceptive pain. In certain embodiments, the compositions and methods contemplated herein are effective in reducing inflammatory pain. In certain embodiments, the compositions and methods contemplated herein are effective in reducing neuropathic pain.

[0196] Nociceptive pain is caused by tissue damage or by strong stimuli that can cause injury. Moderate to severe acute nociceptive pain is a prominent feature of pain from central nervous system trauma, strain / sprain, burn, myocardial infarction and acute pancreatitis, postoperative pain (pain after any type of surgical procedure), posttraumatic pain, renal colic, cancer pain and low back pain. Cancer pain can be chronic pain such as pain associated with tumors (e.g., bone pain, headache, facial pain or visceral pain) or pain associated with cancer therapy (e.g., postchemotherapy syndrome, chronic postoperative pain syndrome or postradiation syndrome). Cancer pain can also occur in response to chemotherapy, immunotherapy, hormonal therapy or radiation therapy. Low back pain can be due to herniated or ruptured intervertebral discs or abnormalities of the lumbar facet joints, sacral joints, paraspinal muscles or posterior longitudinal ligament. Low back pain may resolve spontaneously, but in some patients that last for more than 12 weeks, it becomes a chronic condition that is particularly debilitating.

[0197] Neuropathic pain can be defined as the pain that is initiated or caused by the primary lesion or dysfunction of the nervous system.The etiology of neuropathic pain includes, for example, peripheral neuropathy, diabetic neuropathy, post-herpetic neuralgia, trigeminal neuralgia, low back pain, cancer neuropathy, HIV neuropathy, phantom limb pain, carpal tunnel syndrome, post-stroke central pain, and chronic alcoholism-related pain, hypothyroidism, uremia, multiple sclerosis, spinal cord injury, Parkinson's disease, epilepsy, and vitamin deficiency.

[0198] Neuropathic pain is associated with pain disorders, and the term refers to pain-related or pain-caused disorders. Illustrative examples of pain disorders include arthritis, allodynia, classic trigeminal neuralgia, trigeminal neuralgia, somatoform disorder, hypoesthesia, hyperesthesia, neuralgia, neuritis, neurogenic pain, analgesia, These include pain associated with anesthesia, causlagia, sciatica disorders, degenerative joint disorders, fibromyalgia, visceral diseases, chronic pain disorders, migraines / headaches, chronic fatigue syndrome, complex regional pain syndrome, neurological dystrophies, plantar fasciitis or cancer.

[0199] The inflammatory process is a complex series of biochemical and cellular events that are activated in response to tissue injury or the presence of a foreign body, resulting in swelling and pain. Joint pain is a common type of inflammatory pain.

[0200] Other types of pain suitable for treatment with the vectors, compositions, and methods contemplated herein include, but are not limited to, pain resulting from musculoskeletal disorders including myalgia, fibromyalgia, spondylitis, seronegative (non-rheumatic) arthropathy, non-articular rheumatism, dystrophinopathy, glycogenolysis, polymyositis, and pyomyositis; cardiac and vascular pain including tonsillitis, myocardial infarction, mitral stenosis, pericarditis, Raynaud's phenomenon, scleredoma, and skeletal muscle ischemia; headaches, e.g., migraine (including migraine with aura and migraine without aura), cluster headaches, mixed tension-type headaches, headaches associated with vascular disorders; and orofacial pain including toothache, earache, burning mouth syndrome, and temporomandibular joint myofascial pain.

[0201] The effective amount of the compositions and methods contemplated herein for reducing the amount of pain experienced by a human subject can be determined using various pain scales. Patient self-report can be used to assess whether pain is reduced. See, for example, Katz and Melzack (1999) Surg. Clin. North Am. 79:231. Alternatively, observational pain scales can be used. The LANSS pain scale can be used to assess whether pain is reduced. See, for example, Bennett (2001) Pain 92:147. Visual analog pain scales can be used, see, for example, Schmader (2002) Clin. J. Pain 18:350. Likert pain scales can be used, where, for example, 0 is no pain, 5 is moderate pain, and 10 is the worst pain possible. Self-report pain scales for children include, for example, facial pain scales, Wong-Baker facial pain rating scales, and color analog scales. Self-report pain scales for adults include, for example, visual analog scales, verbal numerical rating scales, verbal written scales, and brief pain inventory. Pain measurement scales include, for example, the Alder Hey Triage Pain Score (Stewart et al. (2004) Arch. Dis. Child. 89:625), the Behavioral Pain Scale (Payen et al. (2001) Critical Care Medicine 29:2258), the Brief Pain Inventory (Cleeland and Ryan (1994) Ann. Acad. Med. Singapore 23:129); the Nonverbal Pain Indicator Checklist (Feldt (2000) Pain Manag. Nurse. 1:13), the Critical Care Pain Observation Tool (Gelinas et al. (2006) Am. J. Crit. Care 15:420); the Comfort Scale (Ambuel et al. (1992) J. Pediatric Psychol. 17:95), and the Dallas Pain Questionnaire (Ozguler et al. (2002) Spine 27:1783);Algometer pain index (Hardy et al. (1952)Pain Sensations and Reactions Baltimore: The Williams & Wilkins Co.); Revised Face Pain Scale (Hicks et al. (2001) Pain 93:173); Face Legs Activity Cry Consolability Scale (Fast Legs Activity Cry Consolability Scale); McGill Pain Questionnaire (Melzack (1975) Pain 1:277); Written Differential Scale (Gracely and Kwilosz (1988) Pain 35:279); the numeric 11-point box (Jensen et al. (1989) Clin. J. Pain 5:153); the numeric rating scale (Hartrick et al. (2003) Pain Pract. 3:310); the Wong-Baker facial pain rating scale; and the visual analog scale (Huskisson (1982) J. Rheumatol. 9:768).

[0202] In certain embodiments, a method of alleviating pain in a subject is provided, the method comprising: introducing an engineered receptor into a neuronal cell; controlling the activity of the cell by providing an effective amount of a ligand that activates the engineered receptor; and thereby alleviating pain in the subject. The method provides significant analgesia for pain without off-target effects such as general central nervous system depression. In certain embodiments, the method provides a 1%, 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more reduction in neuropathic pain in the subject compared to untreated subjects. In some embodiments, the method includes measuring pain in the subject before and after administration of the binding agent, and the pain in the subject is reduced by 1%, 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or more. In such cases, the measurement can be performed 4 hours or more after administration of the binding agent, e.g., 8 hours, 12 hours, 16 hours, 24 hours, 36 hours, 48 ​​hours, 3 days, or 4 days or more after administration of the binding agent.

[0203] In certain embodiments, the vector contemplated herein is administered or introduced into one or more neuronal cells. The neuronal cells may be the same type of neuronal cells or a mixed population of different types of neuronal cells. In one embodiment, the neuronal cells are nociceptive or peripheral sensory neurons. Illustrative examples of sensory neurons include, but are not limited to, dorsal root ganglion (DRG) neurons and trigeminal ganglion (TGG) neurons. In one embodiment, the neuronal cells are inhibitory interneurons involved in neuronal pain circuits.

[0204] In some cases, the vector encoding the engineered receptor is administered to a subject in need thereof. Non-limiting examples of administration methods include subcutaneous administration, intravenous administration, intramuscular administration, intradermal administration, intraperitoneal administration, oral administration, injection, intracranial administration, intrathecal administration, intranasal administration, intraganglionic administration, intraspinal administration, cisternal administration, and intraneuronal administration. In some cases, administration may include injection of a liquid formulation of the vector. In other cases, administration may include oral delivery of a solid formulation of the vector. In some cases, the oral formulation may be administered with food. In certain embodiments, the vector is administered parenterally, intravenously, intramuscularly, intraperitoneally, intrathecally, intraneurally, intraganglionously, spinally, or intracerebroventricularly to introduce the vector into one or more neuronal cells. In various embodiments, the vector is rAAV.

[0205] In one embodiment, AAV is administered to sensory neurons or nociceptors, e.g., DRG neurons, TGG neurons, etc., by intrathecal (IT) or intraganglionic (IG) administration. The IT route delivers AAV to the cerebrospinal fluid (CSF). This route of administration may be suitable, for example, for the treatment of chronic pain or other peripheral nervous system (PNS) or central nervous system (CNS) indications. In animals, IT administration is achieved by inserting an IT catheter through the cisterna magna and advancing caudally to the lumbar level. In humans, IT delivery is achieved by lumbar puncture (LP), a routine bedside procedure with an excellent safety profile. This can be easily done.

[0206] In certain cases, the vector can be administered to a subject by intraganglionic administration. Intraganglionic administration can involve direct injection into one or more ganglia. The IG route can deliver AAV directly to the DRG or TGG parenchyma. In animals, IG administration to the DRG is performed by open neurosurgical procedures, which are undesirable in humans because it requires complex and invasive procedures. In humans, minimally invasive CT imaging-guided techniques can be used to safely target the DRG. AAV can be delivered into the DRG parenchyma using a customized needle assembly for convection-enhanced delivery (CED). In a non-limiting example, the vector of the present disclosure can be delivered to one or more dorsal root ganglia and / or trigeminal ganglia for the treatment of chronic pain. In another non-limiting example, the vector of the present disclosure can be delivered to the supragangial ganglion (vagus nerve) for the treatment of epilepsy.

[0207] In yet another particular case, the vector can be administered to the subject by intracranial administration (i.e., administered directly into the brain). In a non-limiting example of intracranial administration, the vector of the present disclosure can be delivered to the cortex of the brain, for example, to treat epileptic seizure focus, to the paraventricular hypothalamus, for example, to treat satisfaction disorder, or to the central nucleus of the amygdala, for example, to treat satisfaction disorder. In another particular case, the vector can be administered to the subject by intraneural injection (i.e., directly into a nerve). The nerve can be selected based on the indication to be treated, for example, injection into the sciatic nerve to treat chronic pain, or injection into the vagus nerve to treat epilepsy or satisfaction disorder. In yet another particular case, the vector can be administered to the subject by subcutaneous injection, for example, into sensory nerve endings to treat chronic pain.

[0208] A vector dose may be expressed as the number of vector genome units delivered to a subject. As used herein, "vector genome unit" refers to the number of individual vector genomes administered in a dose. The size of an individual vector genome generally depends on the type of viral vector used. The vector genomes of the present disclosure may be about 1.0 kilobase, 1.5 kilobase, 2.0 kilobase, 2.5 kilobase, 3.0 kilobase, 3.5 kilobase, 4.0 kilobase, 4.5 kilobase, 5.0 kilobase, 5.5 kilobase, 6.0 kilobase, 6.5 kilobase, 7.0 kilobase, 7.5 kilobase, 8.0 kilobase, 8.5 kilobase, 9.0 kilobase, 9.5 kilobase, 10.0 kilobase, or more than 10.0 kilobase. Thus, a single vector genome may contain up to 10,000 base pairs of nucleotides. In some cases, a vector dose may be about 1x10 6 , 2x10 6 , 3x10 6 , 4x10 6 , 5x10 6 , 6x10 6 , 7x10 6 , 8x10 6 , 9x10 6 , 1x10 7 , 2x10 7 , 3x10 7 , 4x10 7 , 5x10 7 , 6x10 7 , 7x10 7 , 8x10 7 , 9x10 7 , 1x10 8 , 2x10 8 , 3x10 8 , 4x10 8 , 5x10 8 , 6x10 8 , 7x10 8 , 8x10 8 , 9x10 8 , 1x10 9 , 2x10 9 , 3x10 9 , 4x10 9 , 5x10 9 , 6x10 9 , 7x10 9 , 8x10 9、9x10 9 、1x10 10 、2x10 10 、3x10 10 、4x10 10 、5x10 10 、6x10 10 、7x10 10 、8x10 10 、9x10 10 、1x10 11 、2x10 11 、3x10 11 、4x10 11 、5x10 11 、6x10 11 、7x10 11 、8x10 11 、9x10 11 、1x10 12 、2x10 12 、3x10 12 、4x10 12 、5x10 12 、6x10 12 、7x10 12 、8x10 12 、9x10 12 、1x10 13 、2x10 13 、3x10 13 、4x10 13 、5x10 13 、6x10 13 、7x10 13 、8x10 13 、9x10 13 、1x10 14 、2x10 14 、3x10 14 、4x10 14 、5x10 14 、6x10 14 、7x10 14 、8x10 14 、9x10 14 、1x10 15 、2x10 15 、3x10 15 、4x10 15 、5x10 15 、6x10 15 、7x10 15 、8x10 15 、9x10 15 、1x1016 , 2x10 16 , 3x10 16 , 4x10 16 , 5x10 16 , 6x10 16 , 7x10 16 , 8x10 16 , 9x10 16 , 1x10 17 , 2x10 1 7 , 3x10 17 , 4x10 17 , 5x10 17 , 6x10 17 , 7x10 17 , 8x10 17 , 9x10 17 , 1x10 18 , 2x10 18 , 3x10 18 , 4x10 18 , 5x10 18 , 6x10 18 , 7x10 18 , 8x10 18 , 9x10 18 , 1x10 19 , 2x10 19 , 3x10 19 , 4x10 19 , 5x10 19 , 6x10 19 , 7x10 19 , 8x10 19 , 9x10 19 , 1x10 20 , 2x10 20 , 3x10 20 , 4x10 20 , 5x10 20 , 6x10 20 , 7x10 20 , 8x10 20 , 9x10 20 , or more vector genome units.

[0209] In certain embodiments, the vectors contemplated herein are at least about 1×10 9 Genomic particles / mL, at least approximately 1 x 10 10 Genomic particles / mL, at least approximately 5 x 1010 Genomic particles / mL, at least approximately 1 x 10 11 Genomic particles / mL, at least approximately 5 x 10 11 Genomic particles / mL, at least approximately 1 x 10 12 Genomic particles / mL, at least approximately 5 x 10 12 Genomic particles / mL, at least approximately 6 x 10 12 Genomic particles / mL, at least approximately 7 x 10 12 Genomic particles / mL, at least approximately 8 x 10 12 Genomic particles / mL, at least approximately 9 x 10 12 Genomic particles / mL, at least approximately 10 x 10 12 Genomic particles / mL, at least approximately 15 x 10 12 Genomic particles / mL, at least approximately 20 x 10 12 Genomic particles / mL, at least approximately 25 x 10 12 Genomic particles / mL, at least approximately 50x10 12 Genomic particles / mL, or at least about 100x10 12 The titer of genome particles / mL is administered to the subject. The term "genomic particles (gp)" or "genomic equivalent" or "genomic copies" (gc), when used in reference to viral titer, refers to the number of virions containing the recombinant AAV DNA genome, regardless of infectivity or functionality. The number of genome particles in a particular vector preparation can be determined by methods well understood in the art, such as quantitative PCR of genomic DNA, or by quantitative PCR of genomic DNA, as described, for example, in Clark et al. (1999) Hum. Genetics. Ther., 10:1031-1039; Veldwijk et al. (2002) Mol. Ther., 6:272-278.

[0210] The vector of the present disclosure can be administered in a fluid volume. In some cases, the vector can be administered in a volume of about 0.1mL, 0.2mL, 0.3mL, 0.4mL, 0.5mL, 0.6mL, 0.7mL, 0.8mL, 0.9mL, 1.0mL, 2.0mL, 3.0mL, 4.0mL, 5.0mL, 6.0mL, 7.0mL, 8.0mL, 9.0mL, 10.0mL, 11.0mL, 12.0mL, 13.0mL, 14.0mL, 15.0mL, 16.0mL, 17.0mL, 18.0mL, 19.0mL, 20.0mL, or more than 20.0mL. In some cases, the vector dose can be expressed as the concentration or titer of the vector administered to the subject. In this case, the vector dose can be expressed as the number of vector genome units per volume (i.e., genome units / volume).

[0211] In certain embodiments, the vectors contemplated herein are at least about 5×10 9 Infectious units / mL, at least approximately 6 × 10 9 Infectious units / mL, at least approximately 7 × 10 9 Infectious units / mL, at least approximately 8 × 10 9 Infectious units / mL, at least approximately 9 × 10 9 Infectious units / mL, at least approximately 1 × 10 10 Infectious units / mL, at least approximately 1.5 × 10 10 Infectious units / mL, at least approximately 2 × 10 10 Infectious units / mL, at least approximately 2.5 × 10 10 Infectious units / mL, at least approximately 5 × 10 10 Infectious units / mL, at least approximately 1 × 10 11 Infectious units / mL, at least approximately 2.5 × 10 11 Infectious units / mL, at least approximately 5 × 10 11 Infectious units / mL, at least approximately 1 × 10 12 Infectious units / mL, at least approximately 2.5 × 10 12 Infectious units / mL, at least approximately 5x10 12 Infectious units / mL, at least approximately 1x10 13 Infectious units / mL, at least approximately 5x10 13 Infectious units / mL, at least approximately 1x10 14The virus is administered to a subject in titers of infectious units / mL. The terms "infectious unit (iu)", "infectious particle", or "replicative unit" when used in reference to viral titers refer to the infectious center assay, also known as the replication center assay, as described, for example, in McLaughlin et al. (1988) J. Virol., 62:1963-1973. This refers to the number of infectious and replication-competent recombinant AAV vector particles as measured by immunoprecipitation.

[0212] In certain embodiments, the vectors contemplated herein are at least about 5×10 10 Transducing units / mL, at least approximately 1 x 10 11 Transducing units / mL, at least approximately 2.5 x 10 11 Transducing units / mL, at least approximately 5 x 10 11 Transducing units / mL, at least approximately 1 x 10 12 Transducing units / mL, at least approximately 2.5 x 10 12 Transducing units / mL, at least approximately 5 x 10 12 Transducing units / mL, at least approximately 1 x 10 13 Transducing units / mL, at least approximately 5 x 10 13 Transducing units / mL, at least approximately 1 x 10 14 It is administered to a subject in a titer of transducing units / mL. The term "transducing unit" (tu) when used in reference to viral titer refers to the number of infectious recombinant AAV vector particles that result in the production of a functional transgene product, as measured in a functional assay, for example, as described in Xiao et al. (1997) Exp. Neurobiol., 144:113-124; or Fisher et al. (1996) J. Virol., 70:520-532 (LFU assay).

[0213] Vector doses are generally determined by the route of administration. In a particular example, intraganglionic injections are administered in a volume of about 0.1 mL to about 1.0 mL, with a dose of about 1×10 9 ~Approx. 1×10 13In a particular example, an intrathecal injection may contain about 1×10 vector genomes in a volume of about 1.0 mL to about 12.0 mL. 10 ~Approx. 1×10 15 In yet another particular case, the intracranial injection may comprise about 1×10 vector genome in a volume of about 0.1 mL to about 1.0 mL. 9~ Approximately 1×10 13 In another particular embodiment, the intraneural injection may comprise about 1×10 vector genome in a volume of about 0.1 mL to about 1.0 mL. 9~ Approximately 1×10 13 In another specific example, the intrathecal injection may contain about 1×10 vector genome in a volume of about 0.1 mL to about 1.0 mL. 9 ~Approx. 1×10 13 In yet another particular embodiment, the cisterna magna injection may contain about 5×10 vector genomes in a volume of about 0.5 mL to about 5.0 mL. 9 ~Approx. 5×10 13 In yet another particular embodiment, the subcutaneous injection may contain about 1×10 vector genome in a volume of about 0.1 mL to about 1.0 mL. 9 ~Approx. 1×10 13 It may comprise a vector genome.

[0214] In some cases, the vector is delivered to the subject by injection. The vector dose delivered to the subject by injection can be measured as the vector infusion rate. Non-limiting examples of vector infusion rates include 1-10 μL / min for intraganglionic, intraspinal, intracranial or intraneural administration, and 10-1000 μL / min for intrathecal or intracisternal administration. In some cases, the vector is delivered to the subject by MRI-guided convection-enhanced delivery (CED). This technique allows for increased viral diffusion and transduction distributed throughout the large brain volume while reducing vector backflow along the needle path.

[0215] In various embodiments, methods are provided that include administering to one or more neuronal cells an engineered receptor encoding an engineered receptor that inactivates or hyperpolarizes the neuronal cells, increasing pain sensation or sensitivity to pain, and administering to a subject a ligand that specifically binds to the neuronal cells expressing the engineered receptor, thereby inactivating the cells, decreasing sensitivity to pain, and enhancing the analgesic effect.

[0216] In various embodiments, a method is provided that includes administering to one or more neuronal cells a vector encoding an engineered receptor that activates or polarizes the neuronal cells, thereby reducing pain sensation or sensitivity to pain, and administering to a subject a ligand that specifically binds to the neuronal cells expressing the engineered receptor, thereby activating the cells, reducing sensitivity to pain, and enhancing the analgesic effect.

[0217] The formulation of the ligand can be administered to the subject by various routes. Non-limiting examples of administration methods include subcutaneous administration, intravenous administration, intramuscular administration, transdermal administration, intradermal administration, intraperitoneal administration, oral administration, injection, intracranial administration, intrathecal administration, intranasal administration, intraganglionic administration, and intraneural administration. In some cases, administration can include injection of a liquid formulation of the ligand. In other cases, administration can include oral delivery of a solid formulation of the ligand. In certain cases, the ligand is administered by oral administration (e.g., pills, tablets, capsules, etc.). In some cases, the oral composition can be administered with food. In other specific cases, the ligand is administered by intrathecal injection (i.e., into the subarachnoid space of the spinal cord) for delivery to the cerebrospinal fluid (CSF) of the subject. In other specific cases, the ligand is administered locally (e.g., dermal patch, cream, lotion, ointment, etc.).

[0218] The dose of the ligand administered to a subject is not subject to absolute limits, but depends on the nature of the composition and its active ingredients and its undesirable side effects (e.g., immune response to antibodies), the subject being treated and the type of condition being treated, and the method of administration. In general, the dose is a therapeutically effective amount, such as an amount sufficient to achieve a desired biological effect, for example, an amount effective to reduce or attenuate the level of pain experienced by the subject. In certain embodiments, the dose may be a prophylactic or effective amount. The therapeutically effective amount of the ligand may depend on the route of administration, the indication being treated, and / or the ligand selected for use.

[0219] In one embodiment, the ligand is first administered to the subject before the administration of the vector. A therapeutically effective amount of the ligand can be administered to the subject at a certain time after the delivery of the vector. Generally, after the delivery of the vector, there is a period of time that is necessary for one or more cells of the subject to produce the protein (i.e., the engineered receptor) encoded by the vector. During this period, administering the ligand to the subject may not be beneficial to the subject. In this situation, it may be preferable to administer the ligand after a certain amount of engineered receptor is produced by one or more cells of the subject.

[0220] In one embodiment, the ligand is first administered to the subject at approximately the same time that the vector is administered to the subject.

[0221] In one embodiment, the ligand is first administered 1, 2, 3, 4, 5, 6, 7, 8, 9, 11, or 12 hours, days, weeks, months, or years after the vector is administered to the subject. In some cases, the therapeutically effective amount of the ligand can be administered to the subject at least 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, 7 days, 8 days, 9 days, 10 days, 11 days, 12 days, 13 days, 14 days, 15 days, 16 days, 17 days, 18 days, 19 days, 20 days, 21 days, 22 days, 23 days, 24 days, 25 days, 26 days, 27 days, 28 days, 29 days, 30 days, or more than 30 days after the delivery of the vector. In certain embodiments, the therapeutically effective amount of the ligand is administered to the subject at least 1 week after the delivery of the vector. In further embodiments, the therapeutically effective amount of the ligand is administered to the subject daily for at least 3 consecutive days.

[0222] The therapeutically effective amount or dose of the ligand of the present disclosure can be expressed as mg or μg of ligand per kg of the subject's body weight. In some cases, the therapeutically effective amount of the ligand is about 0.001 μg / kg, about 0.005 μg / kg, about 0.01 μg / kg, about 0.05 μg / kg, about 0.1 μg / kg, about 0.5 μg / kg, about 1 μg / kg, about 2 μg / kg, about 3 μg / kg, about 4 μg / kg, about 5 μg / kg, about 6 μg / kg, about 7 μg / kg, about 8 μg / kg, about 9 μg / kg, about 10 ...5 μg / kg, about 6 μg / kg, about 7 μg / kg, about 8 μg / kg, about 9 μg / kg, about 10 μg / kg, about 2 μg / kg, about 3 μg / kg, about 0μg / kg, approximately 30μg / kg, approximately 40μg / kg, approximately 50μg / kg, approximately 60μg / kg, approximately 70μg / kg, approximately 80μg / kg, approximately 90μg / kg, approximately 100μg / kg, approximately 120μg / kg, approximately 140μg / kg, approximately 160μg / kg, approximately 180μg / kg, approximately 200μg / kg, approximately 220μg / kg, approximately 240μg / kg, approximately 260μg / kg, approximately 280μg / kg, approximately 3 00μg / kg, about 320μg / kg, about 340μg / kg, about 360μg / kg, about 380μg / kg, about 400μg / kg, about 420μg / kg, about 440μg / kg, about 460μg / kg, about 480μg / kg, about 500μg / kg, about 52 0μg / kg, approximately 540μg / kg, approximately 560μg / kg, approximately 580μg / kg, approximately 600μg / kg, approximately 620μg / kg, approximately 640μg / kg, approximately 660μg / kg, approximately 680μg / kg, approximately 700μg / kg, approximately 720μg / kg, approximately 740

[0043] In some embodiments, the amount of the agonist is about 1 mg / kg, about 2 mg / kg, about 3 mg / kg, about 4 mg / kg, about 5 mg / kg, about 6 mg / kg, about 7 mg / kg, about 8 mg / kg, about 9 mg / kg, about 10 mg / kg, or more than 10 mg / kg.

[0223] In certain embodiments, the dose of the ligand administered to the subject is at least about 0.001 micrograms per kilogram (μg / kg), at least about 0.005 μg / kg, at least about 0.01 μg / kg, at least about 0.05 μg / kg, at least about 0.1 μg / kg, at least about 0.5 μg / kg, 0.001 milligrams per kilogram (mg / kg), at least about 0.005 mg / kg, at least about 0.01 mg / kg, at least about 0.05 mg / kg, at least about 0.1 mg / kg, at least about 0.5 mg / kg, at least about 1 mg / kg, at least about 2 mg / kg, at least about 3 mg / kg, at least about 4 mg / kg, at least about 5 mg / kg, at least about 5 mg / kg, at least about 6 mg / kg, at least about 7 mg / kg, at least about 8 mg / kg, at least about 8 mg / kg, at least about 9 mg / kg, or at least about 10 mg / kg, or more.

[0224] In certain embodiments, the dose of ligand administered to the subject is at least about 0.001 μg / kg to at least about 10 mg / kg, at least about 0.01 μg / kg to at least about 10 mg / kg, at least about 0.1 μg / kg to at least about 10 mg / kg, at least about 1 μg / kg to at least about 10 mg / kg, at least about 0.01 mg / kg to at least about 10 mg / kg, at least about 0.1 mg / kg to at least about 10 mg / kg, or at least about 1 mg / kg to at least about 10 mg / kg, or any intervening ranges therein.

[0225] In some embodiments, a therapeutically effective amount of a ligand can be expressed as a molar concentration (i.e., M or mol / L). In some cases, a therapeutically effective amount of a ligand can be about 1 nM, 2 nM, 3 nM, 4 nM, 5 nM, 6 nM, 7 nM, 8 nM, 9 nM, 10 nM, 20 nM, 30 nM, 40 nM, 50 nM, 60 nM, 70 nM, 80 nM, 90 nM, 100 nM, 200 nM, 300 nM, 400 nM, 500 nM, 600 nM, 700 nM, 800 nM, 900 nM, 1 mM, It can be 2mM, 3mM, 4mM, 5mM, 6mM, 7mM, 8mM, 9mM, 10mM, 20mM, 30mM, 40mM, 50mM, 60mM, 70mM, 80mM, 90mM, 100mM, 200mM, 300mM, 400mM, 500mM, 600mM, 700mM, 800mM, 800mM, 900mM, 900mM, 1000mM, or more.

[0226] A therapeutically effective amount of the ligand can be administered one or more times daily. In some cases, a therapeutically effective amount of the ligand is administered as needed (e.g., when pain relief is needed). The ligand can be administered continuously (e.g., daily without interruption for the duration of the treatment regimen). In some cases, the treatment regimen can be for less than one week, one week, two weeks, three weeks, less than one month, or more than one month. In some cases, a therapeutically effective amount of the ligand can be administered for one day, at least two consecutive days, at least three consecutive days, at least four consecutive days, at least five consecutive days, at least one consecutive day ... At least 6 consecutive days, at least 7 consecutive days, at least 8 consecutive days, at least 9 consecutive days, at least 10 consecutive days, or at least 10 or more consecutive days. In certain cases, the therapeutically effective amount of the ligand is administered for 3 consecutive days. In some cases, the therapeutically effective amount of the ligand can be administered once a week, twice a week, three times a week, four times a week, five times a week, six times a week, seven times a week, eight times a week, nine times a week, ten times a week, eleven times a week, twelve times a week, thirteen times a week, fourteen times a week, fifteen times a week, sixteen times a week, seventeen times a week, eighteen times a week, nineteen times a week, twenty times a week, twenty-five times a week, thirty times a week, thirty-five times a week, forty times a week, or more than forty times a week. In some cases, a therapeutically effective amount of the ligand can be administered once a day, twice a day, three times a day, four times a day, five times a day, six times a day, seven times a day, eight times a day, nine times a day, ten times a day, or more than ten times a day. In some cases, a therapeutically effective amount of the ligand is administered at least every hour, at least every 2 hours, at least every 3 hours, at least every 4 hours, at least every 5 hours, at least every 6 hours, at least every 7 hours, at least every 8 hours, at least every 9 hours, at least every 10 hours, at least every 11 hours, at least every 12 hours, at least every 13 hours, at least every 14 hours, at least every 15 hours, at least every 16 hours, at least every 17 hours, at least every 18 hours, at least every 19 hours, at least every 20 hours, at least every 21 hours, at least every 22 hours, at least every 23 hours, or at least every day. Doses of the ligand may be administered to the subject continuously, or 1, 2, 3, 4, or 5 times daily, 1, 2, 3, 4, 5, 6, or 7 times weekly, 1, 2, 3, or 4 times monthly, once every 2, 3, 4, 5, or 6 months, or once a year, or at longer intervals. The treatment period can last for 1 day, 1, 2, or 3 weeks, 1, 2, 3, 4, 5, 7, 8, 9, 10, or 11 months, 1, 2, 3, 4, 5 years, or more, or longer.

[0227] The subject treated by the methods and compositions disclosed herein may be a human or a non-human animal. The term "treat" and its grammatical equivalents as used herein generally refer to the use of a composition or method to reduce, eliminate, or prevent the symptoms of a disease, including achieving therapeutic benefit and / or prophylactic benefit. Therapeutic benefit means slowing the progression of, stopping the progression of, reversing the progression of, or eradicating or ameliorating the symptoms of the disorder or condition being treated. Prophylactic benefit of treatment includes reducing the risk of a condition, slowing the progression of a condition, or reducing the likelihood of developing a condition.

[0228] Non-limiting examples of non-human animals include non-human primates, livestock animals, household pets, and laboratory animals. For example, the non-human animal may be an ape (e.g., chimpanzee, baboon, gorilla, or orangutan), an Old World monkey (e.g., rhesus monkey), a New World monkey, a dog, a cat, a bison, a camel, a cow, a deer, a pig, a donkey, a horse, a mule, a llama, a sheep, a goat, a buffalo, a reindeer, a yak, a mouse, a rat, a rabbit, or any other non-human animal. The compositions and methods described herein are suitable for treating veterinary animals. Veterinary animals include, but are not limited to, dogs, cats, horses, cows, sheep, mice, rats, guinea pigs, hamsters, rabbits, snakes, turtles, and lizards. In some embodiments, contacting a tissue or cell population with the composition includes administering the composition to the cell population or subject. In some embodiments, the administration is performed in vitro, for example, by adding the composition to a cell culture system. In some embodiments, administration is performed in vivo, for example, by administering via a specific route. When multiple compositions are administered, the compositions can be administered via the same route at the same time (e.g., on the same day) or via the same route at different times. Alternatively, the compositions can be administered via different routes, at the same time (e.g., on the same day) or via different routes at different times.

[0229] The number of times the composition is administered to a subject in need thereof may be at the discretion of the health care professional, the nature of the disorder, and the nature of the condition. Depends on severity and subject's response to the formulation. In some embodiments, the composition is administered at least once. In further embodiments, the composition is administered one or more times during a given period, for example, two, three, four, five, six, seven, eight, nine, ten or more times. The dosage and / or frequency of each administration can be adjusted as necessary based on the patient's condition and physiological response.

[0230] In some embodiments, the composition may be administered a sufficient number of times to achieve a desired physiological effect or improvement in the subject's condition. If the subject's condition does not improve, at the discretion of the physician, the composition may be administered chronically, i.e., for an extended period of time, including throughout the subject's lifetime, to improve or otherwise control or limit the symptoms of the subject's disease or condition. If the subject's condition does improve, at the discretion of the physician, the composition may be administered continuously, or alternatively, the dose of the administered drug may be temporarily reduced or temporarily suspended for a period of time (i.e., a "drug holiday"). The duration of the drug holiday may vary from 2 days to 1 year, including, by way of example only, 2 days, 3 days, 4 days, 5 days, 6 days, 7 days, 10 days, 12 days, 15 days, 20 days, 28 days, 35 days, 50 days, 70 days, 100 days, 120 days, 150 days, 180 days, 200 days, 250 days, 280 days, 300 days, 320 days, 350 days, and 365 days. Dose reductions during drug holidays can be from 10% to 100%, including, by way of example only, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, and 100%.

[0231] When a composition is administered multiple times, each administration can be performed by the same practitioner and / or in the same geographic location, or each administration can be performed by a different practitioner and / or in a different geographic location.

[0232] For human and veterinary treatments, the amount of a particular agent(s) administered may depend on a variety of factors, including the disorder being treated and the severity of the disorder, the activity of the particular agent(s) used, the age, weight, general health, sex and diet of the patient, the time of administration, route of administration and rate of excretion of the particular agent(s) used, duration of treatment, drugs used in combination or incidentally with the particular agent(s) used, the judgment of the prescribing physician or veterinarian, and similar factors known in the medical and veterinary arts. Similarly, the effective concentration of a given composition may depend on a variety of factors, including the age, sex, weight, genetic status and overall health of the patient or subject. EXAMPLES

[0233] Example 1. Discovery and characterization of engineered receptors We engineered chimeric LGIC receptors containing the ligand-binding domain from the α7-nAChR and the chloride-inducing ion pore domain from human GlyR1α and assessed their responsiveness to acetylcholine, nicotine, and several small molecule agonist ligands. We then generated amino acid substitutions in these "parent" chimeric receptors and retested the mutants for responsiveness to these ligands.

[0234] The efficacy (EC 50 Differences in peak intensity (Pmax) and current flow (Imax) were observed, suggesting that the domains contributing to the extracellular domain of the engineered receptors play an influential role in channel properties. Amino acid substitutions in these engineered channels further altered the responsiveness of the channels, in some cases differentially, to different ligands. These results indicate that a toolbox of LGIC receptors with unique channel properties can be engineered, providing a pathway for the development of therapeutic agents that can be used to control neuronal activity in disease.

[0235] material and method Receptor construction: Each parent chimeric receptor was cloned into pcDNA3.1(+) (Invitrogen) using standard molecular biology techniques, using the BamHI and EcoRI sites. Amino acid substitutions were introduced by site-directed mutagenesis.

[0236] Plate reader YFP quench assay: Lenti-X 293T cells (LX293T, Clontech) were maintained in DMEM containing 10% FBS and 1% penicillin / streptomycin (Invitrogen). For plate reader assays, LX293T cells were infected with lentivirus to generate cells stably expressing a mutant YFP (H148Q / I152L) reporter that exhibits enhanced sensitivity to anions 2 days prior to assay, and cells were split at a density of 20,000 cells / well in poly-d-lysine-coated 96-well tissue culture plates (Thermo Scientific). The next day, cells were transiently transfected with 0.1 μg of DNA per well using standard Fugene protocols (Promega). On the day of the assay, cells were washed twice in 1× extracellular solution (1×ECS: 140 mM NaCl, 5 mM KCl, 1 mM MgCl2, 2 mM CaCl2, 10 mM HEPES, 10 mM glucose, pH 7.2, mOsms300). After the final wash, 100 μL of 1×ECS was added to the wells and the plate was incubated at 37° C. for 30 minutes. While the plate was incubating, drugs were diluted to 2× concentration in 1×ECS-NaI (same composition as 1×ECS except that 140 mM NaCl was replaced with 140 mM NaI). Plates were then read on a Flexstation 3 (Molecular Devices). Each well of the plate, 8 wells at a time, is read for 2 minutes using a Flexstation 3 (Molecular Devices) as follows: 1) baseline YFP fluorescence is read for 17 seconds, 2) 100 μL of ligand is added, 3) then the change in YFP fluorescence is measured every 1.3 seconds for the remainder of the time.

[0237] Electrophysiology: For HEK293T studies, cDNAs encoding ion channels were cloned into pcDNA 3.1 using standard recombinant techniques. HEK293T cells (Lenti-X™ 293T cell line from Clontech) were cultured in DMEM supplemented with 10% FBS and 1% Pen / Strep to 40-50% confluence using standard cell culture protocols, transfected with ion channel plasmids at a concentration of 18 μg per 15 cm dish using Fugene 6, and grown for an additional 24 h. Cells were then assayed on medium throughput electrophysiology systems (IonFluxHT and / or Mercury, Fluxion Biosciences) and dose-response relationships can be assessed through a microfluidics-based platform to establish whole-cell configurations. Ensemble plates were filled with extracellular buffer (140 mM NaCl, 5 mM KCl, 2 mM CaCl), as adapted from Lynagh and Lynch. 2、 1 mM MgCl 2、 The cells were primed with intracellular buffer (10 mM HEPES, and 10 mM glucose, pH 7.2 with NaOH, mOsm 310), intracellular buffer (145 mM CsCl, 2 mM CaCl2, 2 mM MgCl2, 10 mM HEPES, and 10 mM EGTA, pH 7.2 with CsOH, mOsm 305), and test compounds (freshly prepared stocks) were diluted in the extracellular buffer. Cells were then released from the plate using Accutase, centrifuged, resuspended in extracellular buffer, and loaded into the ensemble plate. Cells were then subjected to standard protocols for priming, trapping, disruption, and establishment of the whole-cell configuration, and cells were held at -60 mV throughout the recording. After recording a baseline, progressive doses of test compound were applied and dose-response relationships were assessed using IonFlux software. The data are then converted to .csv format, the traces are replotted and QC measurements are applied to reject unstable recordings (i.e., access resistance at baseline and / or Data were analyzed offline using a custom Python script to calculate peak currents and fit the population data using a four-parameter logistic equation as described by the Hill equation:

[0238] In Xenopus oocyte studies, injections of ion channel-encoding cDNA at a final concentration of 0.04 μg / μL were performed using a proprietary automated injection device and receptor expression was examined at least 2 days later. Oocytes were impaled with two electrodes and their membrane potential was maintained at -80 mV throughout the experiment. All recordings were performed at 18 °C and cells were perfused with OR2 medium containing, in mM: NaCl 82.5, KCl 2.5, HEPES 5, CaCl2.2H2O 1.8, MgCl2.6H2O 1, pH 7.4. Recordings proceeded if oocytes had a sufficiently low holding current, in which case they were subsequently subjected to ligand or test compound application (5-10 s wash intervals) with 100 s wash between applications. Currents evoked by acetylcholine or other agonists were recorded using an automated process with a standard two-electrode voltage clamp configuration (TEVC). Data were captured and analyzed using HiQScreen proprietary data acquisition and analysis software running under Matlab (Mathworks Inc.). Acetylcholine was prepared as concentrated stock solutions (10-1M) in water and then diluted in recording medium to obtain the desired test concentrations. Nicotine was diluted in water as a stock solution (10-1M), kept frozen and diluted immediately prior to the experiment at the desired concentrations. Compounds were prepared as stock solutions (10-1M) in OR2 and then diluted in recording medium to obtain the desired test concentrations. A stock solution for Compound-1 was made in OR2 at pH 5 adjusted with HCl. To assess that dilution in the final concentration of this stock solution did not introduce significant changes, the pH of the final solution was confirmed using a colorimetric assay (Galietta LJV et al. 2001. FEBS Letters 499:220-224. Kruger W. et al. (2005). Neuroscience Letters 380:340-345.).

[0239] result To generate LGICs that conduct anion currents following exposure of the human "α7-nAChR" to non-natural small molecule agonists, we engineered fusion proteins that contain the chloride-inducing ion pore domain of the human GlyR α1 subunit fused to the ligand-binding domain of the α7-nAChR. In some fusion proteins, the β1-β2 loop sequence and / or Cys loop sequence of the α7-nAChR were replaced with the corresponding sequences from GlyR α1 (see schematic diagram in FIG. 4). In other fusion proteins, the junction site between the 3' sequence of the extracellular domain and the 5' sequence of the ion pore domain ("pre-M1 linker") was shifted. In still other fusion proteins, the extracellular loop sequence between transmembrane domain 2 and transmembrane domain 3 of the GlyR α1 ion pore domain ("M1-M2 linker") was replaced with the corresponding M1-M3 linker sequence from the α7-nAChR. The response of these engineered chimeric LGICs to a range of doses of the natural ligand, acetylcholine, was assessed by electrophysiology after a 1 s application of acetylcholine. Different ECs for each channel were 50 , Imax values, and desensitization kinetics were observed (Figure 3), which suggested that inclusion in the ligand-binding domain of the channel heterologous sequence corresponding to the extracellular region of the protein contributing to the ion pore domain of the chimera alters the properties of the ion channel.

[0240] To better understand the effects of the heterologous domains that had been inserted into the channel, we assessed the ligand-dependent response profiles of wild-type α7-nAChR and various engineered chimeric LGIC receptors to acetylcholine and the non-natural ligands TC-6987, AZD-0328, and fascinicline / RG3487. Receptors were transiently expressed in HEK291T cells and, after 1 s of drug addition, were monitored using an automated patch-clamp system (Flux The current was measured on a 100-millimeter-wave ion Biosciences (100-millimeter-wave ion Biosciences). Inclusion of the Cys loop sequence increased the potency of all small molecules on the engineered receptor (EC 50 Leftward shift in EC (e.g., SEQ ID NO:35, FIG. 4C vs. SEQ ID NO:16, FIG. 4B). Increasing the length of the heterologous Cys loop sequence increased the EC 50 Modestly shifting the Imax value to the right, but significantly increasing the Imax value (SEQ ID NO: 33, FIG. 4D, vs. SEQ ID NO: 35, FIG. 4C), indicating a modest decrease in efficacy but an increase in overall conductance. Inclusion of both the GlyR α1 Cys loop sequence and the β1-β2 loop sequence in the extracellular domain reduced the sensitivity by about 1 log compared to that observed with the complete Cys loop sequence alone, but further increased the conductance by about 2-fold and slowed the inactivation rate of the channel (SEQ ID NO: 41, FIG. 4E, vs. SEQ ID NO: 33, FIG. 4D). These results were confirmed in a second model system in which the receptor was expressed in Xenopus oocytes and currents were measured with a manual patch clamp system after 10 s application of increasing doses of compound (FIG. 5).

[0241] Overall, SEQ ID NO:33 is nearly as sensitive to acetylcholine, ABT-126, and TC-6987 as wild-type α7-nAChR, and TC-6987 shows partial agonist activity for SEQ ID NO:33 as wild-type. SEQ ID NO:33 is approximately 2-fold less sensitive to nicotine than wild-type, and approximately 3-fold and 10-fold less sensitive to AZD-0328 and fascinicline / RG3487, respectively. SEQ ID NO:41, which further contains the β1-β2 loop domain from GlyR α1, is sensitive to ABT-126, TC-6987, and AZD-0328, but less sensitive to acetylcholine and nicotine, when compared to wild-type α7-nAChR, and the EC values ​​for acetylcholine and nicotine of SEQ ID NO:41 are approximately 2-fold less sensitive to nicotine than wild-type, and approximately 3-fold and 10-fold less sensitive to AZD-0328 and fascinicline / RG3487, respectively. 50 are approximately 4-fold and 7-fold greater than wild type (rightward shift). SEQ ID NO:41 is less sensitive to fascinicline / RG3487 than SEQ ID NO:33, but is still more sensitive to fascinicline / RG3487 than wild type, with an EC 50 is about two times lower (leftward shift) (Figure 5).

[0242] To further tune the responsiveness of the engineered LGIC receptors to natural and non-natural ligands, the binding pocket of each ligand in the α7-nAChR was modeled and the amino acid residues that form the binding pocket were mapped. A library of mutant chimeric LGICs was then generated, each containing a substitution within one or more amino acids of the binding pocket. To screen these mutant LGICs for those with novel response profiles to ligands, an anion reporter assay was developed to assess the function of the channel in a higher throughput format. In this assay, cells expressing a YFP reporter whose fluorescence is quenched in the presence of anions are transfected with DNA encoding the channel of interest. Upon exposure to ligand, the activated channel fluxes anions, resulting in a dose-dependent quenching of YFP that can be detected on a plate reader. Figure 6 shows the response of four engineered chimeric LGIC receptors (SEQ ID NO:29, SEQ ID NO:33, SEQ ID NO:35, SEQ ID NO:41) to increasing concentrations of acetylcholine as measured by quenching of YFP fluorescence over time. These quench plots show the comparability between the electrophysiology and anion reporter approaches. Figure 7 provides quench plots of engineered chimeric LGIC receptors, SEQ ID NO: 33 and SEQ ID NO: 41, to either acetylcholine (ACH) or AZD-0328. The parent chimeras respond differently to similar concentrations of different ligands.

[0243] A library of mutant chimeric LGIC receptors based on the parent chimera SEQ ID NO:33 was screened for responsiveness to acetylcholine and AZD-0328 using an anion reporter plate reader assay. Figure 8 provides a heat map of the percent quenching of YFP fluorescence following stimulation with various doses of either acetylcholine or AZD-0328. Many amino acid substitutions reduced responsiveness to both ligands. (Figure 8A-F, EC 50rightward shift in β-terminal domain) or increased responsiveness to ligands (Fig. 8I, EC 50 We also identified mutants that showed either a leftward shift in response to acetylcholine but a rightward shift in response to AZD-0328 (Figure 8G), or a much more rightward shift compared to the parent chimera but no significant change in response to AZD-0328 (Figure 8H), demonstrating the ability of a single mutation to uncouple responses to ligands.

[0244] EC of different ligands 50 To better characterize the EC50-binding domain, dose-response curves were generated for several mutants of interest (Figure 9). Substitutions L131S, L131T, and S172D in SEQ ID NO:33 significantly increased the EC50-binding domain for acetylcholine compared to that of the non-mutated SEQ ID NO:33. 50 AZD-0328 resulted in a ≥2-log increase in 50 The W77M substitution resulted in only a small increase (less than 1 log, and in some cases less than 0.5 log) in the EC 50 These dose-response curves show that substitutions of certain amino acid residues resulted in significant increases (>2 logs) in the EC of selected ligands from those observed on the parent chimeras. 50 It was found that it can dramatically change

[0245] EC determined by plate reader 50 To confirm this and to form a better understanding of the maximum current flux, the L131S, L131T, S172D, and W77M mutations were assayed using electrophysiology. The L131S substitution significantly increased the EC value of acetylcholine relative to the parent chimeric SEQ ID NO:33. 50 induced a significant rightward shift (approximately 2 log, 80-100 fold) in the EC 50shows that it is simply a two-fold rightward shift (FIG. 10A). Substituting residue 131 with T instead has an even greater effect, with the EC 50 The S172D substitution also resulted in a rightward shift of approximately 2.5 logs for acetylcholine and approximately 1 log for AZD-0328 compared to the parent chimera (Figure 10D). 50 induced a significant rightward shift (approximately 2 log, or 58-fold) in the EC 50 The W77M substitution results in only a two-fold rightward shift in the EC 50 induced a moderate leftward shift (2-fold) in the EC 50 is significantly rightward shifted (>2.5 logs). These results provide electrophysiological confirmation of the decoupling of acetylcholine and non-natural ligand responses by the single point mutation observed by the plate reader.

[0246] Example 2. Evaluating the efficacy of engineered receptors to treat disease in animal models Chimeric LGIC receptors, containing the ligand-binding domain from the α7-nAChR and the chloride-inducing ion pore domain from the human GlyR α1 subunit, are evaluated for their efficacy in providing analgesia in a rat model of neuropathic pain following administration of small molecule ligands.

[0247] material and method AAV Vector Production: Eight expression cassettes are constructed using standard molecular biology techniques. All contain the human synapsin-1 (hSYN) promoter linked to an engineered chimeric receptor containing the ligand binding domain of the α7-nAChR and the Cys loop and ion pore domains of GlyR α1. Their designs are as follows: (a) Chimera 1: No additional changes. (b) Chimera 2:1, but also including the amino acid substitution from FIG. 8H. The transformation renders the engineered receptor less responsive to acetylcholine than either the wild-type receptor or the parent chimeric receptor from which it was derived, but maintains the responsiveness of the receptor to the non-natural ligand AZD-0328. (c) Same as chimera 3:1, but also containing an amino acid substitution from Figure 8A-F that renders the engineered receptor less responsive to both acetylcholine and non-natural ligands than either the wild-type receptor or the parent chimeric receptor from which it was derived. (d) Chimera 4: Similar, but containing the amino acid substitution from FIG. 8I that restores the EC50 of the non-natural ligands AZD-0328 and facinicline to near wild-type receptor levels. (e) Same as chimera 5:1, but also containing the β1-2 loop domain from GlyR α1. (f) Same as chimera 6:2, but also containing the β1-2 loop domain from GlyR α1. (g) Same as chimera 7:3 but also containing the β1-2 loop domain from GlyR α1. (h) Same as chimera 8:4, but also containing the β1-2 loop domain from GlyR α1.

[0248] These cassettes are subcloned into AAV bacmids, purified, and transfected into Sf9 insect cells to produce recombinant baculoviruses, which are then amplified. Sf9 cells are double-infected with the amplified recombinant baculovirus containing the hSYN-α7-nAChR / GlyRα1 cassette and another recombinant baculovirus containing Rep and AAV6 (Y705+731F+T492V) cap genes to produce recombinant AAV vectors. The viral vectors are purified and the viral titers are determined using qPCR, and the purity of the AAV vectors is verified using SDS-PAGE.

[0249] Behavioral experiments and pain models: To produce mechanical hypersensitivity in a model that mimics neuropathic pain states, the Spared Nerve Injury (SNI) model, a validated model of mechanical allodynia, is used (Shields et al., 2003, The Journal of Pain, 4, 465-470). This model is created by cutting the common peroneal and sural nerves and isolating the tibial branch. Mechanical withdrawal thresholds are assessed by placing rats on an elevated wire mesh grid and stimulating the plantar surface of the hind paw with von Frey filaments.

[0250] AAV injection into the spinal cord of rats: A dorsal hemilaminectomy is performed at the level of the lumbar enlargement to expose two segments of the lumbar spinal cord (approximately 1.5-2 mm), after which the dura is incised and reflected. The virus solution is filled into a glass micropipette (pre-filled with mineral oil). The micropipette is connected to a manual microinjector attached to a stereotaxic device. The virus solution is targeted to the dorsal horn (left side). Six injections of 240 nl each are performed in an equidistant linear fashion along the rostral-caudal axis within the exposed area. A 1-min rest period is observed after each injection, then the muscle layer is sutured, the skin is closed with staples, and the animals are allowed to recover using a heating pad before being returned to their home cage. The animals are perfused for histological analysis after the last behavioral test.

[0251] AAV intraganglionic injection into the rat dorsal root ganglion (DRG): Injections are performed using a borosilicate glass capillary (0.78 / 1 mm id / od) connected by polyethylene tubing (0.4 / 0.8 mm id / od) to a syringe, drawn to a fine tip, attached to an infusion pump. The needle is attached to an extension arm of an outwardly swung stereotaxic frame (used to hold and manipulate the needle only). The tube, syringe, and needle are all filled with water. One microliter of air is loaded into the needle, followed by 3 μL of viral vector solution. The needle is filled with this volume separately for each injection. The animals are anesthetized prior to surgery. After an incision along the dorsal midline, the L4 and L5 DRGs are exposed by removing the lateral nodules of the spine. The epineurium overlying the DRGs is opened, and the glass needle is inserted into the ganglion to a depth of 400 μm from the surface of the exposed ganglion. After a 3-minute delay to allow sealing of the tissue around the glass capillary tip, 1.1 μL of viral solution is injected at a rate of 0.2 μL / min. After a further 2-minute delay, the needle is removed. The L4 ganglion is injected first, followed by the L5 ganglion. The muscles overlying the spinal cord are loosely sutured with 5-0 sutures, and the wound is closed. Animals are allowed to recover at 37° C. and receive post-operative analgesia.

[0252] AAV intrathecal injection in rats: The rat is first anesthetized and then positioned vertically, with the head fixed in a stereotaxic frame. An incision is made at the base of the neck to expose the apical sulcus. An incision (1-2 mm) is made in the cisternal membrane to a depth such that cerebrospinal fluid leaks out. A 4 cm 32 G intrathecal catheter is then slowly inserted in the direction of the lumbar spinal cord and the skin is closed by suturing around the catheter. The rat is then left to recover. The rat is then anesthetized and the vector (6 μL) is administered. The catheter is flushed with 6 μL PBS and then removed, and the rat is left to recover.

[0253] result This SNI model is created by cutting the common peroneal and sural nerves of rats and isolating the tibial branch. Using the up-down method of Chaplan and Yaksh, mechanical thresholds are determined before injecting AAV.hSYN-α7-nAChR / GlyRα1 into the spinal cord, DRG, or intrathecal space. Three weeks after unilateral vector injection, animals are tested again to verify that their mechanical withdrawal thresholds remain unchanged. Motor coordination is also tested before and after injection using an accelerating rotarod (Stoelting, USA) with a maximum speed of 33 rpm. The duration that rats spend on the rotarod is recorded, with a cutoff of 300 s. Each rat undergoes three training trials and is examined 2 h later. Animals that received chimera 1 and chimera 5 appear to experience some analgesia even in the absence of synthetic ligand, suggesting that naturally occurring levels of acetylcholine may be activating the chimeric receptor. The remaining animals on study show no changes in mechanical withdrawal or motor coordination due to the infusion of AAV.

[0254] Subsequently, half of the rats within each chimera cohort are administered a single IP injection of AZD-0328 or facinicline and tested for mechanical thresholds using the up-down method 1, 2, 5, 7, and 13 days after IP injection. When tested with high doses of ligand, complete reversal of mechanical hypersensitivity is observed in all rats. When tested with low doses, rats receiving chimeras 1, 2, 4, 5, 6, and 8 experience complete reversal of mechanical hypersensitivity, whereas rats receiving chimeras 3 and 7 (containing substitutions that reduce responsiveness to the non-native ligand but not those that inhibit its effect) experience only partial reversal of hypersensitivity. There is no change on the contralateral side, i.e., AZD-0328 has no measurable effect in the absence of vector. The reversal lasted for at least 2 days. On the third day, when thresholds have returned to baseline post-injury, AZD-0328 is again IP injected and again, a return to non-injury baseline thresholds is observed. The animals were followed for 48 hours and thresholds remained at baseline, then the animals were perfused for histology.

[0255] Example 3. Treatment of patients suffering from chronic pain In a non-limiting example, a patient suffering from chronic radicular pain is treated using the compositions and methods disclosed herein. The patient receives a medicament delivered directly to one or more dorsal root ganglia on day 1. For intraganglionic convection-enhanced delivery (i.e., intraganglionic convection-enhanced delivery to lumbar, cervical, or thoracic DRG), 10 mL of AAV.hSYN-α7-nAChR / GlyRα1 in a volume of 1.0 mL was administered. 13 The patient is treated with a vector genome. In this example, the AAV vector encodes an α7-nAChR / GlyRα1 chimera under the control of the human synapsin-1 (SYN1) promoter for selective neuronal expression. Two weeks after the injection, the patient returns to the clinic for a prescription for AZD-0328. The patient self-administers 0.1 mg / kg of AZD-0328 orally as needed (i.e., during a pain episode).

[0256] Example 4. Treatment of patients suffering from chronic pain In a non-limiting example, a patient suffering from chronic craniofacial pain (e.g., trigeminal neuralgia or temporomandibular joint dysfunction) is treated using the compositions and methods disclosed herein. The patient receives 10 mL of AAV.hSYN-α7-nAChR / GlyRα1 delivered directly to the trigeminal ganglion (i.e., intraganglionic convection-enhanced delivery) in a volume of 0.150 mL on day 1. 13 The patient is treated with a vector genome. In this example, the AAV vector encodes an α7-nAChR / GlyRα1 chimera under the control of the human synapsin-1 (SYN1) promoter for selective neuronal expression. Two weeks after the injection, the patient returns to the clinic for a prescription for AZD-0328. The patient self-administers 0.1 mg / kg of AZD-0328 orally as needed (i.e., during a pain episode).

[0257] Example 5. Treatment of Patients Suffering from Obesity In a non-limiting example, a patient suffering from obesity is treated using the compositions and methods disclosed herein. The patient is administered 10 13The patient is treated with an AAV vector genome of ghrelin-α7-nAChR / GlyRα1 in a volume of 1.0 mL delivered directly to the gastric branch of the vagus nerve (i.e., intraneurally). In this example, the AAV vector encodes an engineered receptor under the control of the human ghrelin promoter for selective neuronal expression. Two weeks after injection, the patient returns to the clinic for a prescription for AZD-0328. The patient self-administers 0.1 mg / kg of AZD-0328 orally daily for excessive weight loss (i.e., appetite suppression).

[0258] Example 6. Treatment of Patients Suffering from Obesity In a non-limiting example, a patient suffering from obesity is treated using the compositions and methods disclosed herein. The patient receives 10 mL of AAV-TRPV1-α7-nAChR / GlyRα1 delivered directly (i.e., intraganglionically) to the dorsal root ganglion that innervates the pancreas on day 1. 13 The patient is treated with a vector genome. In this example, the AAV vector encodes an engineered receptor under the control of the human TRPV1 promoter for selective neuronal expression. Two weeks after injection, the patient returns to the clinic for a prescription for AZD-0328. The patient self-administers 0.1 mg / kg of AZD-0328 orally daily for excessive weight loss.

[0259] Example 7. Treatment of Patients Suffering from Obesity In a non-limiting example, a patient suffering from obesity is treated using the compositions and methods disclosed herein. The patient receives 10 mL of AAV-SIM1-α7-nAChR / GlyRα1 delivered directly to the paraventricular nucleus of the hypothalamus (PVH) (i.e., intracranial convection-enhanced delivery) in a volume of 1.0 mL on day 1. 13The patient is treated with a vector genome. In this example, the AAV vector encodes an engineered channel under the control of the human single mind family BHLH transcription factor 1 (SIM1) promoter for selective neuronal expression in proopiomelanocortin (POMC) neurons and stimulation of the final appetite suppression pathway. Two weeks after injection, the patient returns to the clinic for a prescription for AZD-0328. The patient orally self-administers 0.15 mg / kg of AZD-0328 daily for excessive weight loss (i.e., appetite suppression).

[0260] Example 8. Treatment of Patients Suffering from PTSD In a non-limiting example, a patient suffering from post-traumatic stress disorder (PTSD) is treated using the compositions and methods disclosed herein. The patient receives 10 mL of AAV-hSYN1-α7-nAChR / GlyRα1 delivered directly (i.e., intraganglionally) to the C6 stellate ganglion on day 1. 13 The patient is treated with a vector genome. In this example, the AAV vector encodes an engineered receptor under the control of the human synapsin-1 (hSYN1) promoter for selective neuronal expression. Two weeks after injection, the patient returns to the clinic for a prescription for AZD-0328. The patient self-administers 0.15 mg / kg of AZD-0328 orally daily for PTSD symptoms (i.e., anxiety).

[0261] Example 9. Treatment of patients suffering from depression In a non-limiting example, a patient suffering from treatment-resistant depression (TRD) is treated using the compositions and methods disclosed herein. The patient receives 10 mL of AAV-hSYN1-α7-nAChR / GlyRα1 delivered directly to the vagus nerve (i.e., intraneurally) in a volume of 1.0 mL on day 1. 13The patient is treated with a vector genome. In this example, the AAV vector encodes an engineered receptor under the control of the human synapsin-1 (hSYN1) promoter for selective neuronal expression. Two weeks after injection, the patient returns to the clinic for a prescription for AZD-0328. The patient self-administers 0.1 mg / kg of AZD-0328 orally daily for depressive symptoms.

[0262] Example 10. Treatment of Patients Suffering from GERD In a non-limiting example, a patient suffering from gastroesophageal reflux disease (GERD) is treated using the compositions and methods disclosed herein. The patient receives 10 mL of AAV-hSYN1-α7-nAChR / GlyRα1 or AAV-CAG-α7-nAChR / GlyRα1 in a volume of 1.0 mL delivered directly to the lower esophageal sphincter (LES) vagus nerve and myenteric plexus (i.e., intraneurally) or smooth muscle (intramuscularly), respectively, on day 1. 13 The patient is treated with a vector genome. In this example, the AAV vector encodes an engineered receptor under the control of the human synapsin-1 (hSYN1) promoter for selective neuronal expression or the CAG promoter for expression in LES muscle cells. Two weeks after injection, the patient returns to the clinic for a prescription for AZD-0328. The patient self-administers 0.15 mg / kg AD-0328 orally daily for GERD symptoms (i.e., acid reflux).

[0263] Example 11. Treatment of patients suffering from epilepsy In a non-limiting example, a patient suffering from seizures associated with epilepsy is treated using the compositions and methods disclosed herein. On day 1, the patient receives 10 mL of AAV-CamKIIα-α7-nAChR / GlyRα1 in a volume of 1.0 mL delivered directly (i.e., intracranially) to a predefined seizure focus, such as the motor cortex. 13The patient is treated with a vector genome. In this example, the AAV vector encodes an engineered receptor under the control of the human calcium / calmodulin-dependent protein kinase II alpha (CamKII alpha) promoter for selective neuronal expression in excitatory neurons. Two weeks after injection, the patient returns to the clinic for a prescription for AZD-0328. The patient self-administers 0.1 mg / kg of AZD-0328 orally daily for epilepsy symptoms (i.e., seizures).

[0264] Example 12. Treatment of patients suffering from movement disorders In a non-limiting example, a patient suffering from a movement disorder (e.g., Parkinson's tremor) is treated using the compositions and methods disclosed herein. The patient receives 10 mL of AAV-CamKIIα-α7-nAChR / GlyRα1 in a volume of 1.0 mL delivered directly to the subthalamic nucleus (i.e., intracranial STN) on day 1. 13 In this example, the AAV vector is engineered for selective neuronal expression in excitatory neurons. The gene encoding the engineered receptor under the control of the human calcium / calmodulin-dependent protein kinase II alpha (CamKIIα) promoter for AZD-0328 expression is then administered to the patient. Two weeks after injection, the patient returns to the clinic for a prescription for AZD-0328. The patient self-administers 0.1 mg / kg of AZD-0328 orally daily for movement disorder symptoms (i.e., tremors).

[0265] The foregoing merely illustrates the principles of the present disclosure. It should be understood that those skilled in the art will be able to devise various arrangements that embody the principles of the present disclosure and are within its spirit and scope, although not expressly described or shown herein. Furthermore, all examples and conditional language recited herein are intended primarily to aid the reader in understanding the principles of the present disclosure and the concepts that the inventors have contributed to the advancement of the art, and should be interpreted as not being limited to such specifically recited examples and conditions. Furthermore, all statements herein reciting the principles, aspects, and embodiments of the present disclosure, as well as specific examples thereof, are intended to encompass both their structural and functional equivalents. Moreover, such equivalents are intended to include both currently known equivalents and equivalents that will be developed in the future, i.e., any elements developed to perform the same function, regardless of structure. Thus, the scope of the present disclosure is not intended to be limited to the exemplary embodiments shown and described herein. Rather, the scope and spirit of the present disclosure is embodied by the appended claims.

Claims

1. An engineered receptor, said engineered receptor being a chimeric ligand-gated ion channel (LGIC) receptor; (a) a ligand-binding domain derived from a first wild-type Cys-loop LGIC receptor; (b) a Cys loop domain from a second wild-type Cys loop LGIC receptor; and (c) an ion pore domain derived from the second wild-type Cys-loop LGIC receptor.

2. 2. The engineered receptor of claim 1, wherein the receptor further comprises a β1-2 loop domain from the second wild-type Cys-loop LGIC receptor.

3. 3. The engineered receptor of claim 1 or 2, wherein the first and second wild-type Cys-loop LGIC receptors are different.

4. 4. The engineered receptor of any one of claims 1 to 3, wherein the first wild-type Cys-loop LGIC receptor is a human α7 nicotinic acetylcholine receptor (α7-nAChR, SEQ ID NO: 4).

5. 5. The engineered receptor of claim 3 or 4, wherein the second wild-type Cys-loop LGIC receptor is the human glycine receptor α1 subunit (GlyRα1, SEQ ID NO:2).

6. 6. The engineered receptor of claim 5, wherein the Cys loop domain comprises amino acids 166-180 of SEQ ID NO:

2.

7. 6. The engineered receptor of claim 5, wherein the Cys loop domain comprises amino acids 166-172 of SEQ ID NO:

2.

8. 6. The engineered receptor of claim 5, wherein the β1-2 loop domain comprises amino acids 81-84 of SEQ ID NO:

2.

9. 9. The engineered receptor of any one of claims 1 to 8, wherein the ligand binding domain comprises one or more amino acid substitutions of residues corresponding to residues in the α7-nAChR selected from the group consisting of: W77, Y94, R101, W108, Y115, T128, N129, V130, L131, Q139, L141, Y151, S170, W171, S172, S188, Y190, Y210, C212, C213, and Y217.

10. 10. The engineered receptor of claim 9, wherein the one or more amino acid substitutions are loss-of-function mutations that reduce the potency of acetylcholine on the receptor while substantially maintaining the potency of a non-natural ligand on the receptor.

11. 11. The engineered receptor of claim 10, wherein the substitution is selected from substitutions corresponding to L131S, L131T, L131D, or S172D of the α7-nAChR.

12. 11. The engineered receptor of claim 10, wherein the non-natural ligand is selected from AZD-0328, TC6987, ABT-126, and facinicline / RG3487.

13. 10. The engineered receptor of claim 9, wherein the one or more amino acid substitutions are gain-of-function mutations that increase the potency of acetylcholine on the receptor.

14. 14. The engineered receptor of claim 13, wherein the substitutions are selected from substitutions corresponding to L131N, L141W, S170G, S170A, S170L, S170I, S170V, S170P, S170F, S170M, S170T, S170C, S172T, S172C, S188I, S188V, S188F, S188M, S188Q, S188T, S188P, or S188W of the α7-nAChR.

15. A polynucleotide encoding the engineered receptor of any one of claims 1 to 14.

16. A vector comprising the polynucleotide of claim 15.

17. 17. The vector of claim 16, wherein the vector is a viral vector selected from the group consisting of an adenoviral vector, a retroviral vector, an adeno-associated viral (AAV) vector, and a herpes simplex type 1 viral vector (HSV-1).

18. The viral vector of claim 17, wherein the AAV vector is AAV5 or a variant thereof, AAV6 or a variant thereof, or AAV9 or a variant thereof.

19. A pharmaceutical composition comprising the polynucleotide of claim 15 or the vector of any one of claims 16 to 18 and a pharma- ceutically acceptable vehicle.

20. 1. A method of ameliorating neuropathy in a subject in need thereof, comprising: Administering to the subject a polynucleotide encoding an engineered ligand-gated ion channel (LGIC) receptor according to any one of claims 1 to 15; administering to the subject a binding agent that acts as an agonist of the engineered LGIC receptor.

21. 21. The method of claim 20, wherein the polynucleotide is administered to the subject by a non-viral method.

22. 22. The method of claim 21, wherein the non-viral method is lipofection, nanoparticle delivery, particle bombardment, electroporation, sonication, or microinjection.

23. 21. The method of claim 20, wherein the polynucleotide is delivered to the subject in a viral vector.

24. 24. The method of claim 23, wherein the viral vector is an adenoviral vector, a retroviral vector, an adeno-associated viral (AAV) vector, or a herpes simplex type 1 viral vector (HSV-1).

25. 25. The method of claim 24, wherein the AAV vector is AAV5 or a variant thereof, AAV6 or a variant thereof, or AAV9 or a variant thereof.

26. 26. The method of any one of claims 20 to 25, wherein the engineered receptor is operably linked to a promoter active in excitable cells.

27. 27. The method of claim 26, wherein the excitable cell is a neuron or a muscle cell.

28. 28. The method of claim 27, wherein the neuron is a dorsal root ganglion, a motor neuron, an excitatory neuron, an inhibitory neuron, or a sensory neuron.

29. 29. The method of any one of claims 20-28, wherein the subject suffers from pain, a seizure disorder, a movement disorder, an eating disorder, a spinal cord injury, neurogenic bladder, a spastic disorder, or pruritus.

30. 29. The method of any one of claims 20-28, wherein the subject suffers from Alzheimer's disease, Parkinson's disease, post-traumatic stress disorder (PTSD), gastroesophageal reflux disease (GERD), addiction, anxiety, depression, memory loss, dementia, sleep apnea, stroke, narcolepsy, urinary incontinence, essential tremor, movement disorder, or atrial fibrillation.

31. The method of any one of claims 20 to 30, wherein the binding agent is selected from the group consisting of AZD0328, ABT-126, TC6987, or facinicline / RG3487.

32. 32. The method of any one of claims 20-31, wherein the polynucleotide is administered subcutaneously, orally, intrathecally, topically, intravenously, intraganglionally, intraneurally, intracranially, intraspinally, or intracisternally.

33. The method of any one of claims 20 to 31, wherein the binding agent is administered orally, subcutaneously, topically, or intravenously.

34. The method of any one of claims 20 to 33, wherein the subject is a human.